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Abstract
This doctoral thesis outlines a body of research within the field of mathematical oncology
that focusses on the inclusion of microenvironmental factors in mathematical models for
solid tumour behaviour. These models primarily address tumour angiogenesis signalling,
tumour metabolism and inducing apoptosis via novel treatment combinations.
After a brief introduction in Chapter 1, background material pertinent to cancer biology
and treatment is provided in Chapter 2. This chapter details tumour angiogenesis, tumour
metabolism and various cancer treatments. This is followed in Chapter 3 by a survey of
mathematical models that directly influence my work including summaries of models for
relevant tumour entities such as angiogenic growth factors, interstitial fluid pressure, tu-
mour metabolism and acidosis. The progression of topics in these two preliminary chapters
emulate the ordering of the original research presented in Chapters 4–6.
Chapter 4 presents an angiogenic growth factor (AGF) model used to study the impact
of transport processes on tumour angiogenic behaviour. The study focusses on a coupled
system of diffusion-convection-reaction equations that establish the role of convection in
determining relative concentrations of proangiogenic and antiangiogenic growth factors,
and hence the angiogenic behaviour, in solid tumours. The effect of various cancer treat-
ments, such as chemotherapy and antiangiogenic drugs, that can alter tumour properties
are considered through parameter analyses. The angiogenesis that results from angiogenic
stimulation provides tumours with an oxygen and nutrient supply required for metabolism.
Chapter 5 quantifies the benefit of metabolic symbiosis on tumour ATP production.
A diffusion-reaction model of cell metabolism in the hypoxic tissue surrounding a leaky
tumour blood vessel is developed that includes both lactate and glucose fuelled respiration
along with glycolysis. We can then study the energetic effects of cancer cells’ metabolic
behaviour, such as the Warburg effect and metabolic symbiosis. A model coupling these
metabolic behaviours with acidosis is also analyzed that includes the effects of extracel-
lular buffers. These models can be used to investigate metabolic inhibitor treatments by
knocking out specific model parameters and buffering therapies.
While treatment effects are considered in the previous chapters via parameter alter-
ation, Chapter 6 explicitly models concentrations of molecular inhibitors and chemotherapy
nanoparticles. These treatments are coupled to a model for apoptotic protein expression to
evaluate strategies for counteracting chemoresistance in triple-negative breast cancer. The
protein model is then used to predict cell viability, which indicates the efficacy of schedules
for treatment combinations. The model prediction of post-chemotherapy inhibitor outper-
forming pre-chemotherapy and simultaneous application is verified by further experiments.
Finally, a summary of the contributions to the field of mathematical oncology and
suggested future directions are indicated in the final chapter.
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Chapter 1
Introduction
This doctoral thesis outlines my body of research within the field of mathematical on-
cology, an area that utilizes mathematical tools to address problems in cancer research.
The overarching goal is to develop mathematical models that provide insight into cancer
processes with a focus on cancer treatment, which fosters collaboration with clinicians and
leads to meaningful contributions in the medical community. Repeated calls to bridge
the gap between the fields of experimental and mathematical oncology [6, 7] have been
met with many success collaborative efforts and my research has been strongly enriched
and occasionally guided by direct collaboration with biologists and clinicians [8]. Mathe-
matical oncology encompasses the modelling of many cancer processes, including genetic
mutational events, tumour growth, cell signalling, among many others; for an overview, see
[9]. These models can occur on multiple length scales, ranging from molecular modelling
all the way up to tissue modelling, and can even address problems on multiple scales,
referred to as multiscale models [10]. These models can be developed within numerous
mathematical frameworks ranging from continuous partial differential equations (PDEs)
to discrete models [11], and can be combinations of these methodologies, termed hybrid
models [12]. The models that I use will be formulated as PDEs on the microscale (single
blood vessel) or on the macroscale (whole tumour) and then analyzed in steady state, thus
reducing their complexity to ordinary differential equations (ODEs) in Chapters 4 and 5,
or be formulated as strictly time-dependent ODEs in Chapter 6.
From a public health perspective, encouraging non-medical scientists to research cancer,
and indeed other diseases, is becoming a favourable and increasingly common phenomenon
amongst mathematicians, computer scientists, physicists, statisticians, chemists and, un-
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surprisingly, biologists. This serves as a boon to cancer research as cancer continues to
be a global threat that is one of the leading causes of death in both the developed and
developing world, causing an estimated 7.6 millions deaths in 2008 [13]. In Canada the
incidence rate for all cancers has increased by 0.9% per year in males and 0.8% in females,
however, the mortality rates dropped 0.3% for males and 0.2% for females over the same
time period [14]. Some of the seemingly bloated rates of incidence can be explained by im-
proved screening methods and diagnosis, while the decrease in mortality can be attributed
to improved treatments and earlier detection [14]. Mathematical oncology has much to
contribute to the further improvement of cancer treatments, including the optimization of
treatment scheduling and dosages, especially in the complex scenarios encountered when
considering combinations of multiple treatment modalities. This can be achieved by pre-
dicting tumour progression, cell signalling, metabolic and angiogenic behaviours as well as
cancer cell evolution, all of which can be addressed with mathematical models and have
crucial bearing on the efficacy of cancer treatments.
My research focusses on the incorporation of microenvironmental factors unique to
cancerous tissues into mathematical models that govern tumour behaviour. To facilitate
the discussion of these medically motivated models, a brief background of cancer biology
and treatment is provided in Chapter 2. This contains pertinent information on tumour
angiogenesis, tumour metabolism and various therapies. This is followed by a survey of
mathematical models that directly influence my work in Chapter 3. This chapter contains
summaries of models for relevant tumour entities such as angiogenic growth factors, in-
terstitial fluid pressure, tumour metabolism and acidosis. The progression through these
two preliminary background chapters mirror the sequence of original research content in
Chapters 4–6.
Chapter 4 presents an angiogenic growth factor (AGF) model to study the impact of
transport processes on tumour angiogenic behaviour. The study focusses on a coupled
system of diffusion-convection-reaction equations that elucidate the role of convective fluid
flow on local imbalances of proangiogenic and antiangiogenic factors in solid tumours.
These cell signalling factors promote or suppress angiogenesis and hence have a significant
influence on determining a tumour’s oxygen and nutrient supply. The effect of various
cancer treatments, such as chemotherapy and antiangiogenic drugs, that can alter tumour
properties are considered through parameter analyses.
Chapter 5 investigates a diffusion-reaction model of cell metabolism in the hypoxic
tissue surrounding a leaky tumour blood vessel. The model includes both lactate and glu-
2
cose fuelled respiration along with glycolysis, to study the effects of cancer cells’ metabolic
behaviour, such as the Warburg effect and metabolic symbiosis, on ATP production. A
model coupling metabolic behaviour and acidosis is also analyzed that includes the effects
of extracellular buffer and blood vessel properties. These models can be used to investigate
metabolic inhibitor treatments by knocking out specific model parameters.
While effects of treatment are included in the previous models by altering model pa-
rameters, Chapter 6 explicitly studies drug concentrations in a data-driven study of com-
binations of molecular inhibitors and chemotherapy nanoparticles. A model for apoptotic
protein expression is coupled to models for nanoparticle release in an acidic microenviron-
ment and cellular treatment concentrations to investigate counteracting chemoresistance
in triple-negative breast cancer. These protein expressions are then used in a cell viability
model in an attempt to predict the optimal scheduling of nanoparticles in combination
with a molecular inhibitor. The model prediction of post-chemotherapy inhibitor per-
forming better than pre-chemotherapy or simultaneous application is verified by further
experiments.
The major contributions to the field of mathematical oncology include the following,
contained in Chapters 4, 5 and 6 respectively:
(i) Establishing the role of convective transport in angiogenesis signalling: This model
is used to classify angiogenic tumour behaviours and to predict the effects of various treat-
ments via physiological parameter changes. This finding is generalizable to other cell
signalling pathways in tumours.
(ii) Metabolism model that includes lactate-fuelled and glucose-fuelled respiration along
with oxygen-repressible glycolysis: This was the first model to spatially consider the opti-
mal ATP production in a tumour on the microscale and could be used to analyze metabolic
inhibitors.
(iii) The optimal sequence of chemotherapy nanoparticles and molecular inhibitors:
Utilizing nanoparticle release models in conjunction with protein expression models can
yield cell viability estimates for treatment optimization. This contribution has the most
significant medical and clinical relevance.
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Chapter 2
Biological and Medical Background
2.1 Cancer
Cancer is the result of genetic mutations that accumulate through the generations of a cell’s
progeny. These mutations lead to abnormal cells, typically characterized by unregulated
proliferation, that are detrimental to an organism’s survival. A cell population is considered
cancerous when these mutations lead to their uncontrolled proliferation and intrusion into
nearby tissues. In humans these cancer cells can interfere with the normal functioning
of the body and if left untreated can metastasize to other tissues and lead to death.
While some forms of cancer do not form a solid mass, such as leukaemia (cancer of the
blood/bone marrow), our focus will be on solid tumours that possess most or all of the
following capabilities: avoidance of apoptosis (the natural cell death trigger), self-sufficient
growth signalling, antigrowth signal insensitivity and unlimited replicative potential [15].
Along with these traits, solid tumours promote angiogenesis, the growth of new vessels from
pre-existing vessels. They facilitate this by upregulating the production of proangiogenic
growth factors and developing insensitivity to antiangiogenic growth factors, leading to
tumour vasculature [16] (see Section 2.1.1). In light of recent evidence it has become
increasingly clear that cancer cells also reprogram their energy metabolism pathways and
can evade the immune system [17]. Most lethal is their invasive nature, a result of decreased
cell-cell adhesion due to disruption of the normal production of integrins that tether cells to
the extracellular matrix (ECM). In addition, they can often degrade the surrounding ECM
in order to facilitate their movement within the tissue. The invasiveness of cancer cells poses
4
a threat to the viability of normal cell populations as they become crowded and attempt
to create space by triggering their own death or those of surrounding normal cells. The
normal cells are also deprived of oxygen and nutrients as these invaders use their resources
to fuel their movements and proliferation. This invasion is often not limited to those tissues
that are directly adjacent to the tumour. Tumour cells often metastasize, making their
way into blood vessels or the lymphatic system, using the vasculature for transport to
other parts of the body. This process is very complex and includes the original event of
entering the vasculature, the process of eventually extravasating into tissue, adapting to
this new microenvironment and finally the development of another cancer cell colony that
could lead to a secondary tumour. Pioneering attempts by cancer cells commonly fail, but
the ones that do succeed will themselves have the potential to colonize further.
Each of these cancer cell traits must be taken into consideration when attempting
to treat a tumour (and when attempting to model their behaviour). Their ability to
avoid apoptosis and senescence implies that natural cell death is relatively rare and must
therefore be triggered (directly or indirectly) by an agent. Their accelerated proliferation
can be exploited by using drugs that target rapidly dividing cells. The promotion of
angiogenesis can be countered by antiangiogenic agents that target endothelial cells or
inhibit proangiogenic factors. The invasive nature of cancer implies that in many tissues,
the surrounding area must also be treated in case cancer cells have migrated to these areas.
While metastasis continues to be the most consistent indicator of negative prognosis, this
is countered primarily by expedient treatment and early detection efforts.
2.1.1 Tumour angiogenesis
Ever since the extremely important connection between angiogenesis and tumour growth
was established in [16], the field of oncology has been revitalized by the advent of antian-
giogenic treatments. When a tumour begins to form, the survival of the cell colony is
completely dependent on the diffusion of oxygen and nutrients in its immediate vicinity.
However, after it reaches a certain size, approximately 2–3 mm in diameter, the center of
this cell cluster can no longer be sustained by the inadequate amount of oxygen attain-
able via simple diffusion, a condition known as hypoxia. In response to this, the effected
cells begin to release hypoxia-inducible factors (HIFs). These HIFs are responsible for
triggering the production of proangiogenic factors in nearby cells, most prominently (and
heavily-studied) among them being those in the vascular endothelial growth factor (VEGF)
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family. These factors initiate signalling cascades that begin the complex process of tumour
vascularization. Typically there is a balance between the action of proangiogenic and
antiangiogenic factors which leads to vessel maintenance in normal tissues. However, the
increased proangiogenic factor production in tumours disrupts the delicate balance between
angiogenic inducers and inhibitors [18].
These processes are very effective in causing blood vessels to sprout from nearby ex-
isting vasculature, however, the development of the vessels is hasty and unregulated. The
balance between proangiogenic and antiangiogenic factors is disrupted to the point that
vessel construction and network structure are sacrificed. Tumour vasculature is often highly
tortuous and inefficiently assembled, with the vessels typically exhibiting large fenestra-
tions and poor pericyte coverage (pericytes are cells that wrap around endothelial cells
and regulate blood flow among many other vessel processes) [19]. These factors lead to
both spatially and temporally heterogeneous blood flow. The vessel leakiness results in
compromised nutrient and oxygen delivery and contributes to high interstitial fluid pres-
sure (IFP). The cancer cells that originally triggered the angiogenic switch rarely see the
benefit of their efforts since these incoming vessels usually penetrate only the tumour rim,
leaving the bulk of the tumour with an inadequate oxygen supply. As a result, regions
near the center of a tumour often develop into a necrotic core and the hypoxic cells that
surround this core maintain constant angiogenic signalling. As the tumour grows, the very
dense blood vessels and tumour cells become compacted leading to restricted blood flow
and collapsed blood vessels.
2.1.2 Cell metabolism
Cell metabolism can be broadly lumped into two categories, those that are catabolic, break-
ing down molecules to derive energy, and those that are anabolic, constructing molecules
using this energy. Anabolic processes, such as cellular proliferation and motility, are pri-
marily fuelled by adenosine triphosphate (ATP) whilst catabolic processes, such as gly-
colysis and cellular respiration, are primarily employed to manufacture ATP. Thus ATP
is the fundamental carrier of chemical energy in cells. In what follows we will focus on
catabolism, specifically the consumption of glucose and the subsequent generation of ATP
molecules. While anabolism is certainly central to cancer research as it is responsible for
cell growth, division and movement, the models that comprise the bulk of this thesis are
concerned with processes that occur on a much faster time scale than tumour growth, and
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Figure 2.1: A simplified view of glycolysis. The top row contains the molecules required
for the ten constitutive steps of glycolysis that convert glucose to pyruvate; see C.5 for the
intermediary steps and enzymes. Glycolysis yields two ATP and one NADH. If respiration
cannot proceed due to hypoxia, or glucose upregulation then the pyruvate is converted to
lactate by lactate dehydrogenase (LDH). Once the ATP is consumed the net reaction is:
glucose→2 lactate+2H+.
thus we generally assume static tumour tissues. As such we will only consider anabolism
via the inclusion of ATP hydrolysis in the cytosol.
Before relating how genetic mutations and the tumour microenvironment affect cancer
cell metabolism, we will present a highly simplified view of normal cell respiration includ-
ing glycolysis, the citric acid cycle (CAC) and the electron transport chain (ETC). As
mentioned above, the primary goal of these processes is to produce ATP, either directly
via substrate-level phosphorylation or indirectly via the reduction of cofactors, specifically
nicotinamide adenine dinucleotide (NAD) and coenzyme Q10 (Q), that will be used by the
ETC to fuel ATP synthesis.
In normal adequately oxygenated tissues the primary source of ATP is the process of
cellular respiration. The complete conversion of glucose to carbon dioxide and water has
an ideal yield of approximately 29 ATP [20] (my calculations, which are the result of the
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reactions contained in C.4, purport that this theoretical yield is an overestimate). The
preliminary stage of cellular respiration is glycolysis, the conversion of glucose to pyruvate.
This process consists of ten enzyme-catalysed steps (given in C.5) and directly produces two
ATP and two reduced NAD (NADH). In hypoxic conditions this pyruvate is converted into
lactate by the enzyme lactate dehydrogenase (LDH) to regenerate the essential oxidized
cofactor NAD+. This process, including ATP hydrolysis, which regenerates adenosine
diphosphate (ADP) and phosphate (Pi), is shown in Figure 2.1. The net reaction for
glycolysis is then: glucose→2 lactate+2 H+.
In oxygenated conditions the pyruvate is transported across the inner mitochondrial
matrix and the malate-aspartate shuttle enables the NADH in the cytosol to reduce a
NAD+ in the mitochondrion. The pyruvate is decarboxylated and then enters the citric
acid cycle. The citric acid cycle directly generates 1 more ATP per pyruvate (2 per glucose).
One pyruvate molecule’s pathway can also produce four NADH and one reduced Q (QH2).
A pictorial summary of this process is provided in Figure 2.2 and the details are found in
C.5.
The primary energy payoff is a result of cofactor oxidization that enables the electron
transport chain (ETC) to establish a proton gradient across the inner mitochondrial matrix.
Ten H+ are deposited in the intermembrane space per NADH, and 6 per QH2. ATP
synthase then utilizes the electrochemical gradient across the mitochondrial matrix to
drive the phosphorylation of ADP at a cost ratio of 10 H+ for 3 ATP [21]. The simplified
version of the reactions involved with the ETC are given in C.5 and the net effect on
intermembrane space protons is shown in Figure 2.3.
The summary given above is a highly simplified version of metabolic biochemistry. A
more in-depth view of the reactions is given in C.4 where the impacts of transport across
the cell membrane and the inner mitochondrial membrane are detailed along with summary
reactions of the above processes.
2.1.3 Tumour metabolism and acidosis
The metabolic scenario described above corresponds to the case of a tissue that has ac-
cess to sufficient nutrients and oxygen. There are a number of factors, including increased
metabolic requirements to support uncontrolled proliferation, tumour blood vessel proper-
ties and acidosis that compound to create a much altered metabolic landscape in tumours.
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Figure 2.2: The components of cellular respiration excluding the electron transport chain
are presented here. The first step is the conversion of glucose to pyruvate via glycolysis
followed by transport of the pyruvate into the mitochondrion. The pyruvate is decarboxy-
lated to acetyl-CoA, reducing a NAD and fuelling the CAC. The CAC intermediaries are
denoted with their first letter. One full ‘revolution’ of the CAC directly produces three
more NADH, one ATP and one reduced Q (QH2).
The inefficient structure of the tumour vasculature network is directly responsible for high
interstitial fluid pressure and the lack of oxygen and nutrients that most tumours expe-
rience. In addition to releasing HIFs that trigger tumour angiogenesis, tumour cells can
also alter their metabolic pathways. Typically, in the presence of sufficient oxygen, cells
prefer to use respiration to produce energy. However, in the tumour microenvironment
there are typically regions experiencing hypoxia or anoxia, leaving them unable to perform
aerobic respiration. Instead, they must rely on the consumption of glucose via the process
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Figure 2.3: Ten H+ are deposited in the intermembrane space per NADH, and 6 per QH2.
ATP synthase then utilizes the electrochemical gradient across the mitochondrial matrix
to drive the phosphorylation of ADP at a ratio of 10 H+ per 3 ATP [21]. ATP generated
in the mitochondrion can be consumed by cellular processes in the cytosol. The acidic
statuses of mitochondrion components are also shown.
of glycolysis for their energy needs. The drawback of utilizing predominantly glycolysis
is the resulting acidification of the microenvironment. The net byproducts produced by
this metabolism are more acidic than those from respiration. The issue is compounded
by the fact that even in the presence of sufficient oxygen, cancer cells continue to rely on
glycolysis as their primary metabolism. There is still no consensus as to the cause of this
phenomenon, known as the Warburg effect [22], although by not requiring oxygen, it could
give tumour cells a proliferative advantage [23]. The resulting acidosis from upregulated
glycolysis is considered to be a key factor in the invasiveness and metastatic activity of
cancer cells as they try to escape the toxic microenvironment [24].
Some very interesting experimental results, reported in [5] show that cancer cell metabolism
and acidosis may be more complicated than originally suspected. They took measurements
of pH and oxygen concentration around single microvessels, the first time this had been
done, to give average radial profiles of these quantities. Perhaps surprisingly, there was
a plateau observed in the pH measurements, located approximately 100 to 170 µm away
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Figure 2.4: The average pH profile surrounding a single microvessel [5]. The smooth curve
is a simple functional fit to the data.
from the vessel as can be seen in Figure 2.4. It was surmised to be a consequence of the
tumour cells performing respiration even in anoxic conditions or a lack of glucose prevent-
ing glycolysis. An alternative explanation of this is provided by a mathematical model [25]
and will be revisited in Sections 3.4.2 and Chapter 5.
There is also an emerging metabolic story in tumours of a symbiosis existing between
lactate-producing glycolytic cells and lactate-consuming respiratory cells whereby lactate
is converted back into pyruvate via LDH and fed into respiration. This has been observed
since the 80s [26] but rekindled interest due to successful cancer treatment that blocked lac-
tate transport [27]. The phenomenon of metabolic symbiosis (and the effects of metabolic
inhibition) will also be investigated in Chaper 5.
2.2 Cancer treatments
Prior to the seminal work of Folkman [16], and the subsequent development and integration
of antiangiogenic therapy into mainstream clinical use, the focus in oncology had always
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been on surgical techniques and cytotoxic therapies aimed at directly removing or killing
cancer cells. Here, I will omit discussions of two very important and common treatment
strategies, surgery and radiotherapy, and focus on those that will be the topic of the
mathematical modelling to follow: chemotherapy, antiangiogenic agents and molecular
inhibitors. Drug delivery vehicles such as nanoparticles, and treatment combinations will
also be discussed.
2.2.1 Chemotherapy
Chemotherapy involves the administration of drugs that directly kill cancer cells. Unfor-
tunately, this cytotoxicity is rarely specific to tumour cells alone leading to the death of
normal cells as well. Most often, these drugs damage the DNA or inhibit microtubule
formation which kills rapidly dividing cells. This results in a wide array of side effects that
limit both the size of the dosage and the frequency of administrations. Initially, chemother-
apy agents were used primarily on those tumours that were beyond the physical limitations
of the surgical and radiotherapy techniques of the time. However, they are now frequently
used, targeting many different cellular pathways. For example, one of the more commonly
used agents, doxorubicin, discovered and shown to have anti-tumour effects by DiMarco
et al. [28], induces apoptosis by essentially wedging itself between the two DNA strands
(intercalation) inhibiting transcription and replication. The chemotherapy drug that will
be of most interest to us here, is cisplatin, a platinum-containing drug that is capable of
binding to DNA bases and can cause crosslinking of DNA strands [29]. When the cell
attempts to repair this DNA damage, apoptosis is triggered once it is deemed impossible.
This cell-killing mechanism is widely effective and thus used in the treatment of testicular,
ovarian, cervical, lung and breast cancer among others [30, 31, 32].
The combination of chemotherapy agents with other treatments presented a major leap
forward in oncology, starting with adjuvant therapy, the administration of chemotherapy
agents after surgery to kill the remaining cells. The next step was combination chemother-
apy which employed different cytotoxic agents administered concurrently. These met with
success in certain forms of leukaemia and lymphoma and these types of drug cocktails are
still researched extensively today. Today, chemotherapy is often combined with antiangio-
genic agents, that target tumour vasculature, and molecular inhibitors, that can prevent
chemoresistance, leading to questions of optimal scheduling; the latter case will be ad-
dressed in Chapter 6. Also of concern in chemotherapy research is the efficient delivery of
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chemotherapy agents and their ability to preferentially target cancer cells. These concerns
will be described shortly when drug delivery vehicles are introduced.
2.2.2 Antiangiogenic agents
In recent years the focus of cancer treatments has shifted, with the realization that tumours
are dependent on angiogenesis for sustained growth and metastasis, to the development of
antiangiogenic treatments. Originally, the rationale was that destroying all tumour vascu-
lature would starve the tumour of essential nutrients and oxygen leading to tumour cell
death. When endothelial cell killing drugs such as combretastatin were first injected into
a tumour, the antiangiogenic effects were deemed to be significant and fast-acting [33], yet
the majority of tumour cells remained unaffected. This outcome is due to a number of
factors but most importantly, many types of cancer cells can survive under hypoxic condi-
tions until vasculature is re-established. Not only does the tumour survive, it also leaves
the source of angiogenic signalling intact ensuring the recurrence of tumour angiogenesis.
Moreover, with no functioning vasculature in the tumour, the delivery of chemotherapy
drugs to the tumour is highly compromised, severely reducing treatment efficacy [34]. An
alternative to this approach, coined vascular normalization [35], involves applying enough
antiangiogenic drugs to prune underdeveloped or unnecessary vessels and remodel the net-
work. This would theoretically lead to a more regular blood vessel structure that could
provide a means of effectively delivering chemotherapy drugs in a more homogeneous fash-
ion to the tumour. While this could also lead to the improved delivery of oxygen and
nutrients to the tumour, this effect would hopefully be inconsequential. Some successes
have been documented [36], but the main limitation remains: this state of normalized vas-
culature lasts for a brief period of time, referred to as the normalization window, followed
by either a return to an irregular, dense system or, on the other hand, an overkill of the
endothelial cells.
While the efficacy of antiangiogenic treatment strategies remains far from established,
there have been a number of different angiogenic mechanisms successfully exploited for
antiangiogenic treatments. There are many types of drugs which target endothelial cell
proliferation in various ways, some similar to regular chemotherapy drugs. While not
specifically antiangiogenic, standard chemotherapy agents have been shown to have an-
tiangiogenic effects even before they begin to kill tumour cells [37]. There are a few that
do attack endothelial cells directly such as combretastatin, angiostatin and endostatin.
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Combretastatin disrupts the cytoskeletal structure of the endothelial cells causing them to
change into a balloon-shape resulting in vasculature breakdown [38]. Others inhibit the
migration or adhesion of endothelial cells. The other key area of antiangiogenic therapy
are those that indirectly target the endothelial cells by instead targeting various signalling
integrins and factors.
Naturally, due to its large role in tumour angiogenesis and consistent overexpression
by cancer cells, VEGF is a prime target of antiangiogenic therapy. The two most com-
mon ways to prevent the angiogenic action of VEGF are by blocking its receptors or
directly inhibiting it. In the former case, a small molecule which blocks tyrosine kinase
receptors is administered, preventing the binding of VEGF. Two of these drugs are now
commercially available, sunitinib (Sutent) and sorafenib (Nexavar) while there are a hand-
ful more in clinical trials. The side effects of these treatments are rarely serious but due
to their nonspecific receptor targeting there is a wide array of possible side effects. Factor
inhibiting agents were the first type of anti-VEGF drug developed and the monoclonal an-
tibody bevacizumab was the first anti-angiogenesis drug to be successfully combined with
chemotherapy in a Phase III trial [39] and has now been used in various clinical scenarios
[40]. Bevacizumab recognizes all of the VEGF isoforms and has widespread clinical appli-
cations. The most serious side effects include the impairment of wound healing and the
suspension of the body’s natural blood vessel maintenance which has made the research
focus turn toward drug localization. Large fenestrations in the tumour vasculature lead
to some natural targeting of the areas around the tumour but drug delivery vehicles (see
Section 2.3) will improve targeting capabilities. Both forms of anti-VEGF treatments are
now primarily used in combination with chemotherapy drugs or radiotherapy.
Other forms of antiangiogenic treatment have been proposed, some even the result
of mathematical models that show a specific mechanism to be a worthwhile target. For
instance, the blockade of the coupling between VEGFR-2 and its co-receptor NRP1 was
shown to be a good strategy in [41] yet such an inhibitor has not yet been developed.
Various aspects of antiangiogenic drug treatments will be investigated in Chapter 4
including the augmentation of antiangiogenic factors and the inhibition of proangiogenic
factors.
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2.2.3 Molecular inhibitors
With ever-increasing knowledge of cell signalling pathways, automated molecular discovery
algorithms and the emergence of systems biology, the list of potential cellular targets and
corresponding potential cancer treatments grows by the day. However, there is still hope
that the very potent cytotoxic agents already developed can be made to be more effective
by overcoming their main drawbacks: side effects and resistance. The side effects can
be reduced by improved targeting and delivery techniques which will be described below.
Chemoresistance on the other hand can be counteracted by targeting specific molecules
of signalling networks that elicit an anti-apoptotic response [42]. Here, we will discuss a
specific instance of this phenomenon that will be the focus of the study in Chapter 6.
In previous studies, a chemotherapy drug described above, cisplatin, has been shown
to upregulate PI3K signalling, which can reduce the cytotoxic effects of cisplatin and thus
cause the cells to display chemoresistance [43]. This suggests the application of a PI3K
inhibitor in combination with cisplatin could increase the anti-tumour effect. The question
of the scheduling of molecular inhibitors with chemotherapy is the primary concern of
Chapter 6.
2.2.4 Other treatments
While some of the most popular forms of treatment have been outlined, there are many oth-
ers which will not be included in the mathematical models to follow but those with potential
for significant clinical benefits could be considered in future modelling attempts. Various
hormonal therapies have gained prominence across genders since breast and prostate can-
cers rely heavily on specific hormones for tumour growth. Immunotherapy is a treatment
that relies on the patient’s immune system to fight the cancer. This can be achieved by
giving monoclonal antibodies that can identify antigens specific to the tumour cells. In
fact, the antiangiogenic drug bevacizumab can be thought of as a form of immunother-
apy against tumour vasculature. The developing field of radioimmunotherapy which uses
radioactively conjugated antibodies to target tumour antigens holds promise in treating
radio-sensitive tumours (such as lymphomas [44]). Along with gene therapy and photo-
dynamic therapy, there are countless other biological mechanisms that are targeted by
current cancer treatments and as more viable targets are found, additional molecules will
be fashioned to exploit them.
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Figure 2.5: Comparing the levels of folate receptors on the cell membrane of normal tissues
with medium or high grade tumours. Adapted from [48] using data from [49].
2.3 Drug delivery vehicles
By administering drugs in nanoparticles, many advantages over direct administrations of
free agents have been observed [45]. Improved tumour cell specificity can be achieved by
natural and engineered tumour targeting, longer circulation times are obtained by avoiding
the immune system and slowly eroding layers lead to sustained drug release.
Natural tumour targeting is exhibited by most nanoparticles larger than 100 nm since
the typical pore size in normal blood vessels is approximately 50 nm while the size of
tumour vasculature pores can be upwards of 500 nm. Due to their size, the nanoparticles
cannot escape the tight gap junctions of normal blood vessels leading to their extravasation
primarily in the tumour vicinity. Once they exit the blood vessel, they are trapped in the
tumour tissue. This increases the efficiency of the contained agents and decreases the
severity of side effects in the normal tissue. Exploitation of this natural targeting process,
known as the enhanced permeability and retention (EPR) effect and coined in [46], is a
critical consideration for reducing side effects and successful delivery of therapeutics to
tumours [47].
In addition to this natural targeting, nanoparticles also enable bioengineered attempts
at increasing cancer cell targeting capabilities. Most commonly, a ligand is attached to the
nanoparticle surface whose corresponding receptor is overexpressed on the cancer cell mem-
brane. The prime example of this technique is folate targeting since folate receptors are
overexpressed on the cell membrane of many different cancers. Due to the comparatively
16
Figure 2.6: Approximate sizes of nanocell and nanoparticle core in relation to normal and
tumour pores. Data from [53].
low concentration of folate receptors on most types of healthy cells, this was identified as a
possible marker that could be targeted, see Figure 2.5. By attaching folic acid to both lipo-
somal [50] and polymer nanoparticle surfaces, these nanoparticles would be preferentially
taken up by the tumour cells, leaving normal cells mostly unaffected [51].Many other cell
surface receptors have been exploited for cancer treatment targeting. Tumour vasculature
has also been targeted, commonly using the αvβ3 integrin as a target for antiangiogenic
therapies [52].
The immune system is a large obstacle to overcome for successful drug delivery. As soon
as a foreign substance is detected in our bloodstream, our immune system tags them for
removal (opsonization) and then macrophages remove them. Therefore, the drug delivery
system must attempt to avoid this natural process. By attaching certain polymers to the
surface of the nanoparticle envelope, the tagging proteins are prevented from binding to
the nanoparticle. A concern that must be kept in mind is that in order to successfully
target cancer cells via receptor-ligand binding, the density of these polymers cannot be so
high as to interfere with this process.
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Nanoparticles are typically either lipid-based or polymer-based. Lipid-based nanopar-
ticles can be lumped into two categories based on the number of phospholipid layers they
contain: single-layered micelles and double-layered liposomes. Micelles are good for carry-
ing hydrophobic agents and are relatively straightforward to create. However, they have
relatively short release times since after injection they are rapidly dissolved to below the
minimum micelle concentration. Liposomes have the advantage of being able to carry
both hydrophobic and hydrophilic drug in a single delivery vehicle and have longer circu-
lation times due to the increased stability of the structure. They can also fuse with other
lipid bilayers such as the cell membrane, aiding in drug delivery. The main disadvantage of
these lipid-based vehicles is their surfaces are not easily modifiable for targeting or immune
system avoidance [45].
Polymer-based nanoparticles, usually forming a nanocapsule or nanosphere, are typi-
cally upwards of 100 nm in diameter in order to take advantage of the EPR effect. The
major advantage of polymer-based nanoparticles over lipid-based nanoparticles is their sta-
ble surface structure. This allows for various surface modifications that can dissuade the
immune system and preferentially target cancer cells as described above. However, as we
shall discuss below, a combination of lipid and polymer-based delivery may be advanta-
geous.
Nanocells
Pioneered by Shiladitya Sengupta at the labs of MIT, nanocells are delivery vehicles that
have the ability to trap different agents in separate layers of lipids and polymers. Nanocells
can target cancer cells, in much the same way as nanoparticles, by attaching ligands cor-
responding to overexpressed receptors to their surface. They are approximately 150 nm in
diameter, allowing them to take advantage of the EPR effect. Initial trials were reported
in [53] and used a nanoparticle core (nanocore) loaded with doxorubicin (chemotherapy)
inside of a lipid envelope containing the antiangiogenic drug combretastatin. The nanopar-
ticles were heterogeneous in size, so they were filtered and only those between 80–120 nm
were covered in lipids to form nanocells; see Figure 2.6 for the comparative average (de-
sired) sizes of the nanoparticle and the nanocell complete with lipid layer. This delivery
vehicle enables the controlled temporal release of two separate drugs in a single administra-
tion. First, the outer lipid-bound antiangiogenic agents are released and destroy or prune
the surrounding vasculature. The chemotherapy nanoparticles are now captured inside the
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Figure 2.7: The antiangiogenic agent in nanocells leads to tumour vasculature normaliza-
tion and the trapping of chemotherapy agents in the tumour [55].
tumour, liberating cytotoxic agents as they erode (this process is illustrated in Figure 2.7).
This research area has ‘taken off’ with many centers investigating the concept of a nanocell
with recent attempts at improving folate-targeted nanocells reported in [54].
2.4 Treatment strategies and combinations
The maximum-tolerated dose (MTD) method was a popular treatment technique amongst
oncologists during the 1950’s and 60’s. Since typical chemotherapy drugs have serious side
effects due to their toxicity to normal cells as well as cancer cells, there is an upper limit
on the drug dosage that can be administered to an individual in a single administration
without risking the patient’s life. This amount is referred to as the MTD and anything
above this amount is potentially lethal. The MTD requires a break of weeks between
administrations allowing the patient to recover from the treatment and effected healthy
cells to repair. Unfortunately this also gives the cancer cells time to reproduce. While this
method has fallen out of favour, the MTD is still often explored during experiments and
considered at certain points during a patient’s treatment.
The metronomic technique, coined in [56], is different from MTD in both the scheduling
and dosage of treatments. Dosages much lower than the MTD are used and thus less
recovery time is needed between treatments. These treatments are applied more frequently,
even daily and have been shown to cause less side effects and improved tumour response.
This technique has been shown to provide increased antiangiogenic effects (reviewed in
[57]) since the tumour vasculature does not have time to repair during breaks in treatment
[58]. These two extremes of cancer treatment scheduling can be viewed as a spectrum with
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continuous low dose at one end of the spectrum and an infrequent MTD at the opposite
end.
A more complicated question than individual drug dosing is how to schedule the treat-
ments of multiple methodologies to optimize the anti-tumour effect. My Master’s thesis
[59] focussed primarily on the optimal scheduling of antiangiogenic drugs and chemother-
apy, using a mathematical model to predict the benefits of tumour vessel normalization.
Here, we will not look at this specific combination but instead at a combination of cisplatin-
nanoparticles and the molecular inhibitor described above (PI3K inhibitor) that has been
demonstrated to aid in overcoming chemoresistance.
2.5 Summary
The understanding of cancer biology has expanded exponentially over the past couple of
decades; historically one of the largest threats to life with no known cure, advanced treat-
ment techniques greatly improve chances of survival. The discovery of the importance of
tumour angiogenesis led to the development of antiangiogenic treatments which in combi-
nation with traditional chemotherapy agents have improved clinical outcomes. Improved
targeting and increased circulation time of these agents have been achieved due to drug
delivery vehicles such as nanoparticles. The surface of nanoparticles can be manipulated to
target specific cancer cell receptors and to degrade in a controlled way. The recent advent
of nanocells that have the aforementioned advantages along with the ability to carry mul-
tiple agents could be the next leap forward for efficient delivery and tumour eradication.
The diagrammatic summary contained in Figure 2.8 and explained below will outline the
topics that will be of importance in this thesis. These areas span a wide breadth of cancer
research but still comprise only a minute niche of the field.
A diagram containing the most relevant interactions and causal relationships between
tumour microenvironmental factors, treatment effects, treatment targets and tumour be-
haviour is presented in Figure 2.8. The entries contained in the leftmost column, with
the exception of cell survival, are not explicitly included in the models that follow but
are the tumour responses to the tumour traits and microenvironmental conditions listed
in the second column. These omitted phenomena include tumour invasion in response
to hypoxic or acidic conditions, metastases enabled by tumour blood vessels and cellular
proliferation fuelled by metabolism. The tumour properties in the second column include
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Figure 2.8: Interactions and relationships between the major components of cancer bi-
ology and treatments that are the focus of the models contained in this thesis. The
leftmost column are tumour responses to microenvironmental factors that, with the ex-
ception of cell survival, are not the focus of the models to follow. Tumour properties
are linked as follows: Hypoxia leads to AGF production that initiates angiogenesis; an-
giogenesis provides oxygen to the tumour; this angiogenesis also provides nutrients for
cell metabolism, which produces energy for angiogenesis and cell proliferation. Tumour
metabolism is predominantly glycolysis which acidifies the environment; this acidity can
impede metabolic enzymes. Cancer cells can also avoid apoptosis by ignoring apoptotic
signals. These properties affect the outcome of cancer therapies. Hypoxia decreases the
efficacy of chemotherapy and radiotherapy; angiogenesis enables drug delivery while the
leaky walls of tumour vessels lead to convection of drugs and AGFs; acidity causes rapid
drug release from delivery vehicles; pro-survival signalling also increases chemoresistance.
These properties can be exploited by therapies: angiogenesis is targeted by antiangiogenic
agents, metabolic inhibitors can halt ATP production, buffer therapies could normalize
acidity, and molecular inhibitors can overcome chemoresistance.
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the most substantial links between them. Hypoxic microenvironmental conditions lead to
AGF production (via HIFs) that initiates angiogenesis. The resulting angiogenesis provides
oxygen to some cells but hypoxic populations typically remain at all times. Angiogenesis
also provides nutrients for cell metabolism, which produces energy for angiogenesis, cell
proliferation and many other cellular processes. Tumour metabolism relies predominantly
on glycolysis, a process which acidifies the environment. The resulting acidosis can re-
duce enzyme functionality and further alter metabolic pathways (e.g. increased reliance
on glutaminolysis). In addition to these interconnected properties cancer cells can also
avoid apoptosis by ignoring anti-growth signals and producing pro-survival signals. This
cell survival is typically the result of genetic mutations (as is much of the altered cell
metabolism).
The aforementioned tumour characteristics also affect the outcome of cancer therapies
and are shown in Figure 2.8 under ‘Treatment effects’. Hypoxia decreases the efficacy of
chemotherapy (since these cells proliferate less) and radiotherapy. Angiogenesis enables
drug delivery and the blood vessel structure enables the EPR effect. These leaky walls
of tumour vessels lead to elevated interstitial fluid pressure. The resulting pressure gra-
dient leads to convective flow that can dramatically impair drug delivery and alter AGF
concentrations. Acidity promotes more rapid drug release from delivery vehicles due to
accelerated erosion. Upregulated pro-survival signalling, and other cellular adaptations,
result in decreased chemotherapy efficacy, known as chemoresistance. However, all of these
properties can be exploited as shown in the rightmost column under ‘Treatment targets’.
Tumour angiogenesis suggests the application of antiangiogenic agents to eradicate vessels
or normalize the vessels. Metabolic inhibitors could be applied to impede glycolysis or
respiration while buffer therapies could normalize acidity, thus reducing invasion. Finally,
molecular inhibitors could be applied to encourage cell apoptosis to occur upon adminis-
tration of cytotoxic agents.
Our attention will now turn to modelling the entities that affect the tumour microenvi-
ronment and cancer treatments described above. Previous models will be reviewed in the
next chapter in order to lay the foundation for the mathematical models contained in the
original research discussed in Chapters 4–6.
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Chapter 3
Mathematical Modelling Background
The development of mathematical models that accurately predict tumour growth has been
an ongoing field of research for over fifty years. The first models were simple ordinary
differential equations (ODEs) typically borrowed from ecology. The parameters in the
models were estimated from limited experimental data. The evolution of these model sys-
tems exhibits ever-increasing complexity as more aspects of the tumour microenvironment
and the effects of cancer treatments are included. Mathematical models can be simplified
by assuming spatial homogeneity and symmetry, strict time-dependence, which does not
take into account spatial effects, or steady state. These models are now complemented by
ones with more complex formalisms that include tumour heterogeneity, a defining charac-
teristic that determines, among many others, local growth rates [60], metabolic behaviours
and treatment response. For continuous spatio-temporal models, we use partial differen-
tial equations (PDEs) that have enabled modellers to simulate heterogeneity by adding
tumour vasculature, growth factor concentrations, and drug distributions [59]. Tumour
metabolic behaviour and the resulting acidosis have also been modelled, whereby the tu-
mour growth and invasive capability are linked by the development of hypoxia resistant
and acidity resistant populations of cancer cells [24, 61]. Efforts continue to develop spa-
tial models that include accurate tumour vasculature and concentrations of metabolites,
signalling factors and various treatment types. Developing a model of this type has been
the focus of my previous work while the focus of this thesis is the development of three
interconnected mathematical models spanning the processes of angiogenesis, metabolism
and chemoresistance.
The predominant mathematical oncology models that have guided my work will be pre-
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sented in this chapter. First, a mathematical model of interstitial fluid pressure and velocity
developed by Jain et al. [62] will be considered on both the microscale (∼ 10−4 m=100 µm)
and the macroscale (∼ 10−2 m=1 cm). This model is critical to developing models for the
convective transport of solutes including AGFs. General solute transport equations includ-
ing convection, diffusion and ion migration are also developed on these spatial scales. We
will then formulate specific applications of these equations. The first application, modelling
of angiogenic growth factors (AGFs), will be outlined, where diffusion-reaction equations
are used to predict angiogenic activity. This model will be extended in Chapter 4 to in-
clude the well-established and prevalent convective transport in solid tumours. We will
then turn our attention to models of tumour metabolism including the work of Casciari et
al. [3, 4], which links metabolism and acidity on the macroscale and Molavian et al. [25],
which does this on the microscale. Other models of cell metabolism that contribute to the
development of functional forms for metabolite consumption, e.g. [63, 64, 65] will also be
touched upon. These will all contribute to the modelling contained in Chapter 5, which
consider metabolite consumption on the microscale and their effect on acidosis. The novel
nanoparticle release, protein expression and cell viability model contained in Chapter 6
remain independent of the mathematical background given below.
3.1 Interstitial fluid pressure
Based on studies of fluid and molecule movement in tumours through interstitial space [66]
and through the blood vessel wall [19], a series of papers developed models for fluid and
macromolecule transport ([67, 68, 69, 70]) and were used to explain various phenomenon
such as the heterogenous distribution of monoclonal antibodies (mAbs) in tumours [62].
The fluid transport models are rigorously derived in [71] and a simplified formulation
will be outlined here for predicting IFP. This will be followed in the next section by its
effect on macromolecule distribution. This will be needed to formulate the PDEs for
macromolecules, such as AGFs and large metabolites.
3.1.1 Microscopic pressure
We adapt the derivation from [71] to calculate the pressure profile in the interstitial matrix
surrounding a single blood vessel. The radial distance under consideration is restricted to
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some value Ω known as the penetration depth; small enough to ensure limited interactions
with neighbouring vessels but large enough to ensure that this local pressure profile, p,
approaches the average macroscopic pressure p∗ at this distance. We assume this vessel
is a rigid cylinder of constant radius ω with negligible changes in the local axial pressure
gradient. It is also assumed that this vessel experiences constant vascular pressure pv
(mmHg), the vessel wall has constant hydraulic conductivity Lp (cm/mmHg-s) while the
blood plasma has constant osmotic pressure piv and the osmotic reflection coefficient for
plasma proteins is σv (the fraction of solute filtered through a membrane if there is zero
concentration difference with high filtration rate). This vessel is surrounded by tissue which
is treated as a homogeneous poroelastic medium with constant hydraulic conductivity K
(cm2/mmHg-s) and osmotic pressure pii.
We consider the interstitial fluid on a length scale such that the assumption of it being a
continuous entity is appropriate. From the conservation of mass equation, once can derive
the formula
∂ρ
∂t
= −∇ · J
where J is the mass flux and ρ is the density of the fluid. The flux of the fluid is given by
J = ρv where v is the interstitial fluid velocity. This give a differential equation
∂ρ
∂t
+∇ · (ρv) = 0,
referred to as the continuity equation for fluids. Expanding the second term using the
product rule gives:
∂ρ
∂t
+∇ρ · v = −ρ∇ · v. (3.1)
For incompressible flow, it is assumed that ρ is constant within an infinitesimal volume
dV that moves at the velocity v of the fluid. This is equivalent to assuming that the
material derivative of the fluid, denoted Dρ/Dt, and given by
Dρ
Dt
=
∂ρ
∂t
+∇ρ · v,
is equal to zero. This expression can be identified as the left-hand side of (3.1). Putting
this together with the fact that Dρ/Dt = 0 for incompressible flow, we must have
∇ · v = 0. (3.2)
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It should be noted that (3.2) can also be reached by making a stronger assumption: that
the fluid itself is homogeneous and incompressible, and thus of constant density. This
would mean ∂ρ
∂t
= 0 and ∇ρ = 0 in (3.1) giving (3.2) without discussion of the material
derivative. The relationship between these two derivations can be summarized by noting
that homogeneous, incompressible fluids always lead to an incompressible flow while those
fluids undergoing incompressible flow are not necessarily incompressible.
For the geometry we are currently considering, a rigid cylinder with axial and angular
symmetry, the interstitial fluid velocity (IFV) in the interstitial space is given by v =
(u(r), 0, 0). Thus, (3.2) becomes
d
dr
(ru) = 0.
where u is interstitial fluid velocity in the radial direction. The IFV of this fluid is related
to the IFP by Darcy’s Law in a porous medium [72]:
u = −Kdp
dr
. (3.3)
Substituting this into the continuity equation gives
d
dr
(
r
dp
dr
)
= 0. (3.4)
Before moving on, we should note that the above derivation of (3.4) corresponds to
incompressible fluid flow, however it ignores the fact that tissue is in fact comprised of
multiple non-fluid phases, most notably the extracellular matrix and various cell types,
whose behaviours are not strictly fluid and are better treated as deformable solids. Many
physical models of tumour tissues consider biphasic [73] or even triphasic (separate com-
partment for vasculature) [74]. These problems can be addressed using mixture theory,
which fundamentally assumes that the phases simultaneously exist at each point in space,
among other simplifying assumptions which make the equations tractable (e.g. complete
saturation, small deformations, etc.). However, despite the complexity invoked by consid-
ering multiple phases, if one assumes that the fluid exchange between phases is small [75],
that the fluid is experiencing incompressible flow and that the solid is incompressible, then
one once again obtains (3.2), see Appendix A for a brief derivation.
For the boundary condition at the vessel wall, we must balance the IFV with the fluid
velocity across the vessel wall Jf/S, where Jf is the flux across the vessel wall and S is
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the surface area of the vessel wall. This fluid flux was observed to be proportional to the
difference between the hydrostatic pressure change, ∆p = pv− p, and the osmotic pressure
change, ∆pi = piv − pii, across the vessel wall by Starling [76]. This was later altered to
account for the vessel permeability of those molecules that contribute to maintaining the
osmotic pressure difference, predominantly albumin, via the osmotic reflection coefficient
σv, which is set to one if the vessel wall is completely impermeable to plasma proteins, and
approaches zero as the vessel becomes leakier [77]. Thus, the net fluid loss from a single
vessel, Jf (mL/s), is then given by Starling’s Law
Jf = LpS[pv − p− σv(piv − pii)]. (3.5)
This gives us the boundary condition,
−Kdp
dr
= Lp(pe − p) at r = ω (3.6)
where pe is the effective pressure, pe = pv − σv(piv − pii). The other boundary condition
ensures that the macroscopic pressure is reached as we move far away from the vessel
p = p∗ at r = Ω. (3.7)
With these boundary conditions, (3.4) can be solved for p from which the IFV u can be
obtained via Darcy’s Law (3.3). Before solving we will nondimensionalize the problem as
described below.
Nondimensionalizing (3.4) and the corresponding boundary conditions by setting p =
pep˜ and r = ωr˜ and rescaling p
∗ = pep˜∗ and Ω = ωr˜0 gives the identical nondimensional
equivalent of (3.4) and the boundary conditions
dp˜
dr
= −α(1− p˜) at r˜ = 1
p˜ = p˜∗ at r˜ = r˜0,
where the nondimensional parameter α is given by α = Lpω/K. Solving (3.4) yields the
solution p˜(r˜) = A ln r˜ + B where A and B are constants. Using the boundary conditions
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to solve for the constants yields
A = −α
(
1− p˜∗
1 + α ln r˜0
)
and B =
p˜∗ + α ln r˜0
1 + α ln r˜0
.
With some algebraic manipulation, once can find that
p˜(r˜) =
α(1− p˜∗)
1 + α ln(r˜0)
ln
(
r˜0
r˜
)
+ p˜∗. (3.8)
Applying Darcy’s Law, and nondimensionalizing the IFV by the characteristic velocity of
Kpe/ω gives
u˜(r˜) =
α(1− p˜∗)
1 + α ln(r˜0)
1
r˜
. (3.9)
This implies that the fluid velocity at the vessel wall is
u˜(1) =
α(1− p˜∗)
1 + α ln(Ω)
.
3.1.2 Macroscopic pressure
Similar to the derivation above, we will now consider an entire spherical tumour of radius R
embedded in a host tissue, both of which are considered to be homogeneous and poroelastic
media. The average flow across the vessel wall is again given by Starling’s Law (3.5) where
now the parameters correspond to average values in the entirety of the tissue rather than
corresponding to any one specific vessel. In normal tissues, the excess fluid flux by normal
vessels Jf would be counteracted by absorption by the lymphatic system. However, in
tumours the fluid can either leak toward the core of the tumour, or toward the periphery
[62]. Inward flow would lead to increased IFP until the effective pressure, pe = pv−σv(piv−
pii), is reached at which point Jf = 0. Outward flow would lead to excess fluid entering
the interstitium. The interstitial velocity of this fluid, u, is related to the IFP by Darcy’s
Law (3.3) where now r is the macroscopic distance from the tumour core.
Considering the conservation of mass between the fluid filtered from the vessels with
the fluid moving toward the periphery gives
1
r2
d(r2u)
dr
=
Jf
V
. (3.10)
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Substituting equations Darcy’s Law (3.3) and Starling’s Law (3.5) into (3.10) yields
1
r2
d
dr
(
r2
dp
dr
)
= −Lp
K
S
V
[pv − p− σv(piv − pii)], (3.11)
which is typically rewritten as
1
r2
d
dr
(
r2
dp
dr
)
= −α
2
R2
(pe − p), (3.12)
where
α = R
√
LpS
KV
is a nondimensional parameter that measures the ratio of the flow resistance in the intersti-
tial space to the resistance in the microvessel wall. With appropriate boundary conditions
(3.12) can also be solved analytically. Below we will present a different derivation than that
typically found in the literature [67, 2] since the nondimensionalization implicitly assumes
the same effective pressure in both tumour and host tissues, involves a far-field bound-
ary condition that fixes the pressure at some value or shifts the solutions by this far-field
pressure. Here, we assume far-field zero flux conditions and include the generalization to
nonzero effective pressures in the host tissue for the embedded tumour case.
Isolated
Considering the case of an isolated tumour, we can nondimensionalize (3.12) by setting
p = pep˜ and r = Rr˜, which gives
1
r˜2
d
dr˜
(
r˜2
dp˜
dr˜
)
= −α2(1− p˜). (3.13)
To achieve spherical symmetry at the tumour core a no-flux boundary condition is enforced
dp˜
dr˜
∣∣∣∣
r˜=0
= 0. (3.14)
Note that the form of (3.13) is very similar to the diffusion-reaction equations that will be
considered below for AGF concentrations (3.35) discussed in Section 3.3, so the derivation
to follow will be referred to later.
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To solve this system we will consider a Dirichlet boundary condition, where at the
tumour boundary, we set the pressure to the pressure found in the host tissue, p˜h and
hence take p˜(1) = p˜h.
The nondimensional equation for the equation (3.13) can be transformed into a modified
Bessel function in z(u) of order n = 1/2 via the substitutions u = αr˜, z =
√
r˜(p− 1) [78].
This modified Bessel function is
u2
d2z
du2
+ u
dz
du
− z
(
1
4
+ u2
)
= 0,
which has the general solution
z(u) = C1I1/2(u) + C2K1/2(u),
where In and Kn are the modified Bessel functions of the first and second kind, respectively.
For n = 1/2, these functions reduce to the elementary functions:
I1/2(u) =
√
2
piu
sinh(u), K1/2(u) =
√
pi
2u
e−u.
Thus, reverting back to our original variables, the solution of (3.35) is of the form
p˜(r˜) = A
sinh(αr˜)
r˜
+B
e−αr˜
r˜
+ 1, 0 ≤ r˜ ≤ 1, (3.15)
where the constants A and B will be determined by enforcing boundary conditions.
Considering boundary conditions, the symmetry condition at the tumour core (3.14)
can only hold if B = 0 eliminating the second term in the general solution. Enforcing the
tumour boundary condition gives A = (p˜h − 1)/ sinh(α) and so the solution is
p˜(r˜) = 1− 1− p˜h
sinh(α)
sinh(αr˜)
r˜
.
If p˜h is set to zero, then the solution typically found in the literature (e.g. [2]) is recaptured.
Applying Darcy’s Law and nondimensionalizing u by again setting u = Kpeu˜/R gives
u˜(r˜) =
1− p˜h
sinh(α)
(
αr˜ cosh(αr˜)− sinh(αr˜)
r˜2
)
.
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Embedded
We now consider the case of a tumour embedded in host tissue. This boils down to the
consideration of an infinite spatial domain instead of the finite one considered for the
isolated case, where the various parameters change value at the tumour boundary. We
differentiate between tumour and host tissue parameters with subscripts (or superscripts
for effective pressures) t and h, i.e.
α =
{
αt, 0 ≤ r ≤ R,
αh, r > R.
We will once again nondimensionalize (3.12) by setting p = pte p˜ and r = Rr˜, to obtain
the equation
1
r˜2
d
dr˜
(
r˜2
dp˜
dr˜
)
=
{
α2t (p˜− 1), 0 ≤ r˜ ≤ 1,
α2h(p˜− pˆe), 1 < r˜ <∞,
(3.16)
where pˆe = p
h
e/p
t
e.
The boundary conditions for this case, in addition to the symmetry condition (3.14),
are:
p˜|r˜=1− = p˜|r˜=1+ ,
−Ktdp˜
dr˜
∣∣∣∣
r˜=1−
= −Khdp˜
dr˜
∣∣∣∣
r˜=1+
,
lim
r˜→∞
dp˜
dr˜
= 0.
Performing an analogous procedure to the one outlined above, the nondimensional equa-
tion for the system (3.16) can once again be transformed into a modified Bessel function.
Thus, reverting back to our original variables, solutions to (3.35) are of the form
p˜(r) =

At
sinh(αt r˜)
r˜
+Bt
e−αt r˜
r˜
+ 1, 0 ≤ r˜ ≤ 1,
Ah
sinh(αh r˜)
r˜
+Bh
e−αh r˜
r˜
+ pˆe, 1 < r˜ <∞,
(3.17)
where the constants Ae and Be, e = t, h will be determined by enforcing the boundary
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conditions above.
The tumour core and far-field conditions immediately yield Bt = 0 and Ah = 0 re-
spectively. Enforcing the conditions at the tumour boundary yields two equations for the
unknowns At and Bh, which can be solved to give
At =
(pˆe − 1)(1 + αh)
(1 + αh −K) sinh(αt) +Kαt cosh(αt) ,
Bh =
(pˆe − 1)K[sinh(αt)− αt cosh(αt)]eαh
(1 + αh −K) sinh(αt) +Kαt cosh(αt) ,
where the relative hydraulic permeability K is given by Kt/Kh; for simplicity we typically
assume K ≈ 1. This gives the analytical solution,
p˜(r˜) =

1− (1− pˆe)(1 + αh)
φ+ θ
sinh(αtr˜)
r˜
, 0 ≤ r˜ ≤ 1
pˆe +
(1− pˆe)θ
φ+ θ
e−αh(r˜−1)
r˜
, r˜ > 1
(3.18)
where θ = K[αt cosh(αt) − sinh(αt)] and φ = (1 + αh) sinh(αt). A typical solution in
the literature corresponds to the case where pˆe = 0, i.e. p
t
e  phe . The nondimensional
interstitial fluid velocity is then given by
u˜(r˜) =

(1− pˆe)(αh + 1)
φ+ θ
[αtr˜ cosh(αtr˜)− sinh(αtr˜)]
r˜2
, 0 ≤ r˜ ≤ 1
(1− pˆe)θ
K(φ+ θ)
(αhr + 1)e
−αh(r˜−1)
r˜2
, r˜ > 1.
(3.19)
The nondimensional pressure and velocity profiles are given in Figure 3.1. As the pa-
rameter αt increases, the pressure reduction at the tumour rim becomes more drastic, it
also leads to higher IFP inside the tumour. Equivalently, as αt increases, the interstitial
fluid velocity reaches a higher and sharper peak at the tumour rim. Note that the pa-
rameter choices for αt inside the tumour of 2, 6, and 14 correspond roughly to parameters
associated with normal tissue, normalized tumour tissue, and nonnormalized tumour tis-
sue, respectively [2]; the choice for αh outside the tumour remains a constant value of 2 in
Figures 3.1a and 3.1b [2].
These analytical solutions were first presented in [62] but were not experimentally
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(a) Nondimensional interstitial fluid pressure.
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Figure 3.1: The effect of changing the parameter α on IFP and IFV in an embedded
tumour. These analytical solutions are given in (3.18) and (3.18) respectively and are from
a model developed and analytically solved by Baxter and Jain [62, 67].
confirmed until direct measurements of interstitial fluid pressure were made in [79]. It
was found that indeed the isolated tumour solution fit the IFP data of various tumours,
including mammary adenocarcinoma using the parameter values of α2 = 1210 and pe =
10.2 mmHg [79, Figure 8], which was in good agreement with the estimated parameters
from [62].
3.2 General solute transport equations
Considering the conservation of mass equation for concentrations of a solute in solution X,
results in the continuity equation,
∂X
∂t
= −∇ · JX + PX (3.20)
where JX is the flux of the solute and PX is the production rate (related to source and
sink densities). This solute flux through the interstitium is governed by some combination
of transport processes, including diffusion, convection and charge migration, each of which
we will address below. Letting Jd be the diffusive flux, Jc be the convective flux and Ji
be the charge migratory flux, we seek an expression for JX of the form JX = Jd + Jc + Ji,
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where depending on the relative contributions of each process, in specific scenarios one or
more of these fluxes can be omitted for simplicity.
Diffusion is driven by thermal energy which results in the random movement of molecules.
The macroscopic effect of this random movement is the movement of molecules down their
concentration gradient, i.e. in the direction of −∇X. This can be intuitively understood
as the movement from areas of higher concentration to those of lower concentrations. The
diffusive flux is assumed to be proportional to −∇X, known as Fick’s Law, with propor-
tionality constant, called the diffusion coefficient DX . In a biological context this constant
is more accurately referred to as the interstitial effective diffusion coefficient and we will
typically assume that it is constant throughout each tissue.
Convection is the transport of molecules in the direction of a bulk fluid flow. In tissue
this flow is typically due to leaky blood vessels. The convective flux is proportional to
the product of the concentration and the interstitial fluid velocity u with proportionality
constant rX known as the retardation factor, the ratio of solute velocity to fluid velocity.
Thus the convective flux is given by Jc = rXu, where analytical solutions for the IFV u have
already been derived in cylindrical (microscopic) and spherical (macroscopic) geometries
above.
Finally, the flux due to the electric potential φ is proportional to the product of the
concentration and the ion migration velocity vX . The derivation of a functional form for
vX is more in depth so we will address this in the next section. Taking all of the previous
form for fluxes into consideration this gives the total interstitial flux as
JX = −DX∇X + (rXu+ vX)X. (3.21)
We will now address vX before explicitly writing down the corresponding microscopic and
macroscopic tumour equations.
3.2.1 Charge migration
For charged particles, we must calculate a form for the velocity vX , here we will adapt a
derivation from [3] to include convection and diffusion.
The force F (N) exerted on a unit charge within an electric field E (N/C) is given by
F = qE where q ≈ 1.602 × 10−19 C is the elementary charge. The force exerted on an
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ion with valence zX is then FX = qXE, where qX = zXq is the charge of the particle.
The velocity of ion migration is then this force divided by a frictional coefficient fX (kg/s)
giving
vX =
qX
fX
E;
fX (kg/s) is sometimes called the Stokes drag coefficient and is related to the commonly
used parameter electrical mobility µX = qX/fX . Before simplifying this expression, note
that the ionic current, Jion associated with this velocity is
Jion =
qXX
fX
E,
which is Ohm’s Law with conductivity σ = qXX/fX .
Assuming a quasi-steady state, there is no magnetic contribution to the electric field
and E = −∇φ where φ (V) is the electric potential, which gives
vX = −qX
fX
∇φ.
The Stokes-Einstein equation gives the relationship between the diffusion coefficient DX
and the drag coefficient fX (for low Reynolds number) as
DX =
kBT
fX
,
where kB ≈ 1.380× 10−23 J/K and T (K) is the absolute temperature. Thus,
vX = −DX qX
kBT
∇φ,
or using different universal constants
vX = −DX zXF
RT
∇φ,
since Faraday’s constant, F = qNA ≈ 96485C/mol and the gas constant R = kBNA ≈ 8.314
J/K/mol, where the Avogadro constant NA ≈ 6.022 × 1023 /mol, share the same ratio as
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q/kB. The flux granted by the ionic current is then
Jion = −DX zXF
RT
X∇φ. (3.22)
If a system is comprised of multiple species X with charges zX , then the charge density of
the system is
Q = F
∑
X
zXX,
while the total charge flux is
I = F
∑
X
zXJX
where JX is given in (3.21). When Q = 0 this represents electroneutrality in the system;
this is a commonly justified modelling assumption. A stronger simplifying assumption, is
the condition that there is no net current, equivalent to I = 0, gives
∑
X
zX
(
−DX∇X + rXuX −DXXzXF
RT
∇φ
)
= 0,
or
∇φ = RT
F
∑
X zX(−DX∇X + rXuX)∑
X DXz
2
XX
.
This expression for the electric field can now be substituted back into (3.22) and subse-
quently into (4.2) to give
∂X
∂t
= −∇ ·
(
rXuX −DX
(
∇X + zXX
∑
Y zY (−DY∇Y + rY uY )∑
Y DY z
2
Y Y
))
. (3.23)
If transport is diffusion-dominated, implying the contribution of convection is relatively
negligible, we can write
∂X
∂t
= −DX
(
∇2X − zX∇ ·
(
X
S1,1
S2,0
))
, (3.24)
where Si,j =
∑
X Dxz
i
X∇jX, and we define ∇0X = X. Distributing the divergence over
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the ionic flux gives the tractable form
∂X
∂t
= −DX
(
∇2X − zXS1,1
S2,0
(
X
(
S1,2
S1,1
− S2,1
S2,0
)
+∇X
))
. (3.25)
This previous equation, or the more general (3.23), could be adapted for microscopic and
macroscopic applications, but to simplify the equations in what follows, we will limit the
discussion to uncharged particles and thus take vX = 0 (since zX = 0).
3.2.2 Microscopic solute transport
Making similar assumptions on the blood vessel and interstitial space as was done when
deriving equations for microscopic pressure in Section 3.1.1, we arrive at the equation
∂X
∂t
=
DX
r
∂
∂r
(
r
∂X
∂r
)
− 1
r
∂
∂r
r(rXu+ vX)X + PX . (3.26)
Further, noting that the fluid is assumed to be incompressible, (3.26) simplifies to
∂X
∂t
=
DX
r
∂
∂r
(
r
∂X
∂r
)
− rXu∂X
∂r
+ PX , (3.27)
for an uncharged molecule; the case of vX > 0 would require the use of (3.25).
Following the process above, we determine the vessel boundary condition by considering
the transport of solute molecules Js due to extravasation from blood vessels. There are
many variations on the formula for this transport, such as the Kedem-Katchalsky equation
[77], but the most useful to us is written as a sum of its diffusive and convective parts.
This diffusion is proportional to the difference between the plasma concentration VX and
the interstitial concentration X, and convection is proportional to the fluid leakage Jf in
(3.5). Known as the Patlak equation [80], it gives the rate of solute transport as,
Js = µXS(VX −X) PeX
ePeX − 1 + Jf (1− σX)VX , (3.28)
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where PeX is the Peclet number defined by
PeX =
Jf (1− σX)
µXS
,
µX is the vascular permeability coefficient and σX is the osmotic reflection coefficient for
the solute. For large molecules the first term can be ignored since they do not diffuse
very much, instead their primary means of movement is convection while the opposite is
true for small molecules dominated by diffusion. Now, balancing the solute extravasation
from blood vessels in (3.28) with the solute moving in the interstitial space (3.21) gives the
boundary condition at the vessel wall for a microscopic model:
rfuX −DX dX
dr
= µ(VX −X) PeX
ePeX − 1 +
Jf
S
(1− σX)VX at r = ω. (3.29)
We also require the concentrations to reach a steady state as we move away from the vessel
and take
dX
dr
= 0 at r = Ω, (3.30)
where Ω is the penetration depth [71], a distance far enough from the microvessel to
justify the assumption that the system has reached steady state but close enough to ensure
minimal contributions from other nearby vessels.
3.2.3 Macroscopic solute transport
As in the above discussion on interstitial fluid pressure, this can be readily expanded into a
macroscopic convection-diffusion equation for the entire tumour by taking the blood vessels
as an averaged source term giving,
∂X
∂t
=
DX
r2
∂
∂r
(
r2
∂X
∂r
)
− 1
r2
∂
∂r
[r2(rXu+ vX)X] + PX +
Js
V
. (3.31)
Once again assuming that interstitial fluid is incompressible and the particle is uncharged
yields
∂X
∂t
=
D
r2
∂
∂r
(
r2
∂X
∂r
)
− rXu∂X
∂r
+ PX +
Js
V
. (3.32)
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The boundary conditions ensure continuity of concentrations and equality of fluxes at the
tumour boundary. The above equation can be useful when considering the extravasation
of drug delivery vehicles from tumour vasculature and the release of the agents contained
therein and could be easily expanded to a non-radially symmetric case.
3.3 Angiogenic growth factor model
This section will outline a model developed by Ramanujan et al. [1] that considers the con-
centrations of proangiogenic and antiangiogenic growth factors in a solid spherical tumour
of radius R. This will be followed by consideration of measures of angiogenic activity, es-
sentially functions that summarize whether angiogenic activity is being locally stimulated
or suppressed. The notation used in this section is consistent with the simplified notation
used in my work [81], i.e. instead of cfe to denote the concentration of factor f (proangio-
genic: +, antiangiogenic: -) in environment e (malignant: m, host: h) [1], we will use fj
for concentration of factor j (proangiogenic: p, antiangiogenic a) where it is understood
that for 0 < r < R we are inside the tumour and for R > 0 we are in the host tissue;
when necessary tumour (t) and host (h) parameters are differentiated with the appropriate
superscript.
Following [1] for this preliminary modelling, let fj denote the concentration of factor
j where the factor can either be considered to be proangiogenic (j = p) or antiangiogenic
(j = a). This tumour is assumed to be a homogeneous sphere of radius R. Proangiogenic
growth factors are those responsible for encouraging and stimulating angiogenesis while
antiangiogenic growth factors are those that discourage or counteract vascularization. The
factors are assumed to be produced at constant rates gj, degrade exponentially at rates kj
and diffuse with diffusion constants Dj, j = p, a, all of which can differ between tumour
(superscript t) and host (superscript h) tissues. These assumptions lead to the PDEs
∂fj
∂t
= Dj∇2fj − kjfj + gj, j = p, a. (3.33)
Now by making a pseudo-steady-state assumption, it is assumed that local changes in factor
concentration are relatively small, i.e. ∂fj/∂t = 0, compared to the cellular responses such
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as proliferation. Assuming spherical symmetry, solutions of the equation
Dj
1
r2
∂
∂r
(
r2
∂fj
∂r
)
− kjfj + gj = 0 (3.34)
with suitable boundary conditions can be derived. First we nondimensionalize (3.34),
which is not only a useful process for parameter reduction in this case, but also crucial
to subsequently defining angiogenic activity. This can be achieved by setting r = Rr˜,
fj = f
s
j f˜j, and by defining the rescaled parameters κj =
√
kjR2/Dj and γj = gjR
2/Djf
s
j
where
f sj := lim
r→∞
fj(r) =
ghj
khj
is the steady state factor concentration in host tissue. This process yields the equations
1
r˜2
d
dr˜
(
r˜2
df˜j
dr˜
)
− (κj)2f˜j + γj = 0. (3.35)
Note that the derivatives are no longer denoted as partial derivatives to reinforce that the
concentration f˜j is a function of the single variable r˜ with no time dependence and that
γhj = (κ
h
j )
2. To be explicit about the spatial dependence and since the solutions to follow
require their consideration, we could rewrite (3.35) as
1
r˜2
d
dr˜
(
r˜2
df˜j
dr˜
)
=
{
(κtj)
2f˜j − γtj, 0 ≤ r˜ ≤ 1,
(κhj )
2(f˜j − 1), 1 < r˜ <∞.
(3.36)
Solutions to (3.35) with appropriate boundary conditions can be found and the details are
presented below since only partial ([82]) or erroneous ([1, 59]) solutions in this context exist
in the literature. The solution process is very similar to the process whereby the analytical
pressure solution in an embedded tumour geometry was derived above in Section 3.1.2.
The nondimensional equation for the system (3.35) can be transformed into a modified
Bessel function in z(u) of order n = 1/2 via the substitutions u = κj r˜, z =
√
r˜(f˜j − γj/κ2j)
[78]. This modified Bessel function is
u2
d2z
du2
+ u
dz
du
− z
(
1
4
+ u2
)
= 0,
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Figure 3.2: The nondimensional concentrations of antiangiogenic, f˜a, and proangiogenic,
f˜p, growth factors [1]. At the tumour core f˜p > f˜a, at the rim (r˜ = 1) f˜p < f˜a and in the
host tissue they are approximately equal.
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which has the general solution
z(u) = C1I1/2(u) + C2K1/2(u),
where In and Kn are the modified Bessel functions of the first and second kind, respectively.
For n = 1/2, these functions reduce to the elementary functions:
I1/2(u) =
√
2
piu
sinh(u), K1/2(u) =
√
pi
2u
e−u.
Thus, reverting back to our original variables, solutions to (3.35) are of the form
f˜j(r) =

Atj
sinh(κtj r˜)
r˜
+Btj
e−κ
t
j r˜
r˜
+ Ωj, 0 ≤ r˜ ≤ 1,
Ahj
sinh(κhj r˜)
r˜
+Bhj
e−κ
h
j r˜
r˜
+ 1, 1 < r˜ <∞,
(3.37)
where Ωj = γ
t
j/(κ
t
j)
2 and the constants Aej and B
e
j (j = p, a; e = t, h) will be determined
by enforcing boundary conditions.
Considering boundary conditions, we require symmetry at the tumour core, continuity
of concentrations and fluxes at that the tumour boundary, and the concentrations approach
steady state value as we move into the host tissue. These correspond to the following
conditions:
df˜j
dr˜
∣∣∣∣∣
r˜=0
= 0,
f˜j
∣∣∣
r˜=1−
= f˜j
∣∣∣
r˜=1+
,
−Dtj
df˜j
dr˜
∣∣∣∣∣
r˜=1−
= −Dhj
df˜j
dr˜
∣∣∣∣∣
r˜=1+
,
lim
r˜→∞
df˜j
dr˜
= 0.
The first (tumour core) and last (far-field) conditions immediately yield Btj = 0 and
Ahj = 0. This gives the factor concentrations fj(0) = A
m
j κ
m
j + Ωj at the tumour core and
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f˜j = 1 as r˜ →∞. Enforcing the conditions at the tumour boundary yields two equations
for the unknowns Atj and B
h
j , which can be solved to give
Atj =
(1− Ωj)(1 + κhj )
(1 + κhj − βj) sinh(κtj) + βjκtj cosh(κtj)
,
Bhj =
(1− Ωj)βj[sinh(κtj)− κtj cosh(κtj)]eκ
h
j
(1 + κhj − βj) sinh(κtj) + βjκtj cosh(κtj)
,
where βj = D
t
j/D
h
j . Thus, the final solution is given by
f˜j =

Ωj −
(Ωj − 1)(κhj + 1)
θj + φj
sinh(κtj r˜)
r˜
, 0 ≤ r˜ ≤ 1
1 +
(Ωj − 1)θj
θj + φj
e−κ
h
j (r˜−1)
r˜
, 1 < r˜ <∞,
(3.38)
where θj = βj[κ
t
j cosh(κ
t
j)− sinh(κtj)] and φj = (1+κhj ) sinh(κtj). This solution is analogous
to the solution form of IFP in an embedded tumour (3.16). A plot of the solutions using
the parameters from [1], given in Table B.1 for your reference, is shown in Figure 3.2.
Angiogenic growth factor models have been used in my previous work [59], where it is
assumed that these angiogenic factors slide along the tumour cell density gradient toward
the periphery. The equation for these factors was given by
∂fj
∂t
= Dj∇2fj − kjfj + gj + Pjn+ γj∇ · (fj∇n), (3.39)
where n is tumour cell density and Pj is the rate of production by tumour cells. The
last term is a proxy for the omission of a model for interstitial fluid pressure which is
typically required in order to add convective transport. This directed movement term is
a convenient addition to the equation but could be made more precise by adding a true
convection term as will be done in Chapter 4. However, this modelling will not be coupled
to tumour growth in what follows.
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Figure 3.3: Areas of angiogenic suppression near the tumour core (r = 0) fall below the
dashed line while areas of stimulation near the rim (r = 1) are above the line. The measure
a depicted here corresponds to the AGF concentrations from Figure 3.2 [1].
3.3.1 Angiogenic activity
The balance between proangiogenic and antiangiogenic factors is the primary determinant
of whether angiogenesis is suppressed or initiated. This was represented in [82] by the
parameter a defined by
a =

f˜p
f˜a
− 1 f˜p > f˜a
1− f˜a
f˜p
f˜p < f˜a
(3.40)
where f˜p and f˜a correspond to the nondimensional concentrations of proangiogenic and
antiangiogenic factors respectively. This definition makes a an indicator of angiogenic
activity where a > 0 corresponds to angiogenesis being initiated, a = 0 when angiogenesis is
stable and a < 0 implies vessels are regressing. This measure of angiogenic activity has been
incorporated into blood vessel development models based on the previous observations [82].
A typical scenario of an angiogenic activity radial profile displaying angiogenic repression
at the tumour core and angiogenic stimulation around the rim is shown in Figure 3.3.
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3.4 Models for cancer cell metabolism and pH
We will now briefly review a model developed for tumour cell metabolism and acidity in an
entire tumour [3] before showing how this model was adapted to model metabolic and acid-
ity on the microscale. This will be followed by a more general discussion of consumption
rates for glucose, oxygen and other metabolites that are present in the literature. Finally,
we will present many of the estimated parameters for diffusion coefficients, vessel concen-
trations and metabolic parameters for cancerous tissues that appear in the literature.
3.4.1 Macroscopic tumour model
Following a model developed by Casciari et al. [3], a model to describe the concentrations
of the major players in the metabolic pathways of respiration and glycolysis, along with a
pH buffering system, will be outlined here.
Respiration requires oxygen (O2) and glucose (C6H12O6) molecules to produce a total
of approximately 29 ATP molecules [20], with carbon dioxide (CO2) and water (H2O) as
the only byproducts. Denoting glucose by G, the simplified chemical reaction is
G + 6O2 → 6CO2 + 6H2O. (3.41)
In hypoxic and anoxic conditions, cells must partially or exclusively rely on metabolic
pathways, such as glycolysis, that do not require oxygen. In glycolysis, a single glucose
molecule yields 2 ATP with the byproducts of the anion lactate (C3H5O
−
3 ) and a single
hydrogen ion (H+). Denoting lactate by L−, we consider the net reaction to be
G→ 2L− + 2H+. (3.42)
The accumulation of these hydrogen ions in a solid tumour is one of the primary causes
of tumour acidosis, quantified by the usual measure of acidity, pH. The precise definition
and measurement techniques of pH will not be addressed here, and are rarely discussed in
mathematical models that consider tumour acidosis, e.g. [3], [83]. Suffice it to say, in the
tumour microenvironment we will calculate pH with the approximate relationship
pH = − log10(H), (3.43)
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where H denotes the concentration of hydrogen ions measured in mol/L, a unit which we
will denote with M, the commonly used molar concentration. A seemingly pedantic point
of clarification in this approximation is that we must normalize H with a standard state H0
(M). This eliminates the units of concentration allowing the application of the logarithm
to this dimensionless value. In practice, this standard state is always set to H0 = 1 M thus
recovering the approximation above, although other non-arbitrary choices for this state
could yield more biochemically relevant measures of acidity.
In addition to the chemical species in the metabolic pathways in (3.41) and (3.42), they
included the primary biological buffering system due to bicarbonate, whereby bicarbonate
(HCO−3 ) neutralizes a hydrogen ion by combining into carbonic acid (H2CO3) which rapidly
disassociates into water and carbon dioxide. This reaction is reversible and summarized
by
CO2 + H2O
kf
GGGGGBF G
kr
HCO−3 + H
+, (3.44)
where kf and kr are the forward and reverse rate (taken to be kr = 58 /mM/s and
kf = 7.4×10−7 /s [84]). In order to ensure charge neutrality, chloride ions (Cl−) and sodium
cations (Na+) must be included in the model, however, they do not play an active role in the
production or consumption rates of the other molecules, so they are considered extraneous
and are not explicitly considered in what follows. The presence of water molecules in (3.41)
and (3.44) is also non-consequential to the modelling since they comprise the bulk of the
fluid in the cytosol and interstitial fluid.
We denote the concentrations of H+, lactate−, bicarbonate−, CO2, glucose and oxygen
in the extracellular space by X = H, L, B, C, G, O, respectively, and in the intracellular
space by X∗; their consumption rates are denoted by QX , and when appropriate their
production rate is denoted by PX = −QX . These extracellular concentrations are modelled
by conservation equations of the form
∂X
∂t
+∇ · JX +QX = 0,
where JX is the flux of species X. Assuming this flux is given by Fick’s law JX = −DX∇X,
where DX is the constant diffusion coefficient, gives
∂X
∂t
−DX∇2X +QX = 0. (3.45)
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Steady state solutions in a spherical tumour are sought and so (3.45) becomes
DX
1
r2
∂
∂r
(
r2
∂X
∂t
)
= QX . (3.46)
The boundary condition to ensure symmetry at the tumour core is:
dX
dr
∣∣∣∣
r=0
= 0
while at the tumour rim, we must have equality of the flux inside the tumour and outside.
Inside the tumour,we have JX = −DXdX/dr while just outside the flux will be assumed
to be a linear function of the concentration difference between the medium outside the
tumour Xo and at the tumour rim X(R
−) giving the boundary condition
DX
dX
dr
= µX
(
Xo −X(R−)
)
.
The consumption rates of glucose and oxygen are empirically formulated and will be
addressed below but relationships between the production rates of the molecules involved
in cell metabolism can be gleamed. Since CO2 and H
+ are present in the buffering reaction
along with a metabolic pathway, it will be convenient to denote the production of CO2
by respiration alone by PY and the production of H
+ by glycolysis alone by PZ . It is
immediately clear from reaction 3.41 that PY = QO and from 3.42 that PZ = −QL.
Considering both reactions, it can be observed that the consumption of glucose is given by
QG =
1
6
PY +
1
2
PZ . Putting these three observations together yields, QL =
1
3
QO − 2QG, a
relation between the three production rates that are not explicitly involved in the buffering
reaction 3.44.
The following production rates follow from the metabolic and buffering reactions above:
PC = kr(BH + (1− )B∗H∗)− kf (C + (1− )C∗) +QO, (3.47)
PB = kf (C + (1− )C∗)− kr(BH + (1− )B∗H∗), (3.48)
PH = kf (C + (1− )C∗)− kr(BH + (1− )B∗H∗)−QL, (3.49)
where  denotes the volume fraction of extracellular space and 1− is the volume fraction of
the intracellular space. The only species that will be assumed to have the same extracellular
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and intracellular concentrations, are oxygen and CO2 which can freely diffuse across the
cell membrane whereas the others have to rely on the action of cell membrane transporters
and other forms of active transport.
We now present a modified argument (modified from [3]) for eliminating the product
B∗H∗ in (3.47)-(3.49) to obtain a system with extracellular concentrations only. We utilize
the assumption C = C∗ to perform this crucial simplification of the model. We use XC to
denote the left hand side of (3.46) for CO2, the total mass transport in the radial direction
per unit volume of tumour. Considering only the extracellular transport, the following
equation must be satisfied
βXC = −kfC + krBH
where β is the fraction of transport that occurs outside the cells. Since it has already been
assumed that C = C∗, this implies that β =  and therefore,
XC = −kfC + krBH. (3.50)
Now, considering just the intracellular production of CO2, we must also have
γXC = QO − kf (1− )C∗ + kr(1− )B∗H∗
where γ = 1 −  is the fraction of transport that occurs through the cells and once again
C = C∗. This gives
XC =
QO
1−  − kfC + krB
∗H∗. (3.51)
Equating (3.50) and (3.51) yields
B∗H∗ = BH − QO
kr(1− ) (3.52)
which upon substituting into (3.47)-(3.49) yields
PC = krBH − kfC, (3.53)
PB = kfC − krBH +QO, (3.54)
PH = kfC − krBH −QL +QO. (3.55)
The issue of what functional forms to utilize for glucose and oxygen consumption was
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broached in [4] and applied in [3] in tandem with the buffering model described above.
They suggest a simple form for glucose and oxygen production rates given by
QO =
(
AO +
BO
G
)(
O
kO +O
)
QG =
(
AG +
BG
O
)(
G
kG +G
)
.
They also present a more complicated version that incorporates the decreasing consumption
of oxygen and glucose in the presence of hydrogen ions due to the acidic breakdown of
proteins critical to metabolism:
QO =
(
AO +
BO
GHn
)(
O
kO +O
)
QG =
(
AG +
BG
O
)
1
Hm
(
G
kG +G
)
where n and m are phenomenological constants. Other possible functional forms for these
consumption rates will be addressed below.
3.4.2 Microvessel model
Microvessel scale models of coupled glucose and oxygen concentrations exist in the litera-
ture [85], but do not analyze the implications for tumour acidity. Of note, they proposed
oxygen and glucose consumption rates of the form:
QO = KO
OG
(kO +O)(kG +G)
QG = KG
OG
(kO +O)(kG +G)
−KGly G
kGly +G
where KO and KG are the maximum consumption rates than can be achieved by respiration
while KGly is the maximum rate of glycolysis. These consumption rates will make an
appearance in the next section where we discuss the development of these functional forms.
In [25], a mathematical model was developed to describe the concentrations of various
molecules important to cell metabolism in order to study pH profiles in a two-dimensional
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region outside of a single microvessel. This corresponds with the experimental setup used
in [5], a transparent dorsal window chamber implanted in a mouse. This was partly under-
taken to explain the observed pH plateau in [5] and to incorporate the role of an alternative
metabolic pathway, glutaminolysis.
Diffusion-reaction equations were used to describe concentrations of the major players
in respiration and glycolysis: H+, Cl−, Na+, lactate−, bicarbonate−, CO2, glucose and
oxygen, given by (3.45) where the consumption rate of species X, QX , is a function of the
other chemical species (provided in Table B.4, detailed below). We are not concerned with
the time evolution of these concentrations, and so assume that all species have reached
steady state by setting ∂X/∂t = 0. Thus, we must solve the equations:
Di
d2X
dr2
= QX , (3.56)
similar to (3.46) except now we are using a Cartesian Laplacian rather than a spherical one.
Since we are considering a single micro vessel rather than an entire tumour, the boundary
conditions must change as well. The boundary condition at the vessel wall must ensure
that the diffusive flux in the interstitial space outside of the vessel is equal to the fluid flux
across the vessel wall:
−DX dX
dr
= µX(VX −X). (3.57)
We also use a far field assumption that as r grows large the system approaches steady
state.
The production rates of bicarbonate, hydrogen ions and carbon dioxide are from [3]
and are given in (3.53)-(3.55). The glucose and oxygen consumption rates for this model
are given by QG = KGG/(G + kG)f1(O) and QO = RQGO/(O + kO)f2(O) respectively,
where 0 ≤ R ≤ 6 is the ratio of respiration to glycolysis and the functions f1 and f2 are
given by
fi(O) = 1− aiO0.02 exp(−100(O − 0.01)4), i = 1, 2,
where a1 = 2/3 and a2 = 1/2. These consumption rates are depicted in (the inset) of
Figure 3.4. These forms of the consumption rates assume that respiration is the dominant
metabolism near the vessel (in well-oxygenated regions), glycolysis and oxygen are both
reduced at intermediary distances (in hypoxic regions) and glycolysis is dominant distant
from the vessel (in anoxic regions).
First, the coupled system of oxygen and glucose can be solved. Using these we can then
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Figure 3.4: Profiles of pH (red) and oxygen concentration (blue) in the tissue surrounding
a single microvessel with the base case of parameters [25]. Inset: glucose and oxygen
consumption rates.
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solve for the system governing bicarbonate, carbon dioxide and hydrogen ions. Finally,
acidity is determined using the relation pH=− log10(H). As can be seen in Figure 3.4
these assumptions produce a pH plateau experimentally observed in [5] (see Figure 2.4).
We delay a discussion of any results gleamed from this paper as they will be expanded
upon in Chapter 5. Here, in order to build upon previous work, we will outline the
nondimensionalization and numerical methods used to solve the system outlined above.
Nondimensionalizing X by setting x = X/VX and formally nondimensionalizing space
by dividing the spatial variable r by a characteristic length 1µm (but not changing its
notation), gives the equations
d2x
dr2
= Qx, (3.58)
where Qx = QX/(DXVX) and the boundary conditions are
− dx˜
dr
= µx(1− x), at r = ω (3.59)
where µx = µX l/DX and
dx
dr
= 0, at r = Ω. (3.60)
Nondimensionalization is a useful process for computational and analytical reasons. When
attempting to understand model behaviour and performing sensitivity analyses, it is usu-
ally enlightening and convenient to consider nondimensional groups of parameters rather
than individual parameters. Additionally, computational and numerical methods could be
rescued from errors by scaling variables by a characteristic value.
3.4.3 Metabolite consumption rates
The most straightforward place to start our discussion about proposing functional forms
for consumption rates is with consideration of the oxygen consumption rate, In models
that do not include lactate-fuelled respiration, oxygen is consumed at six times the rate
of glucose-fuelled respiration, i.e. QO = 6kO, see (C.34). Assuming for now that there is
sufficient glucose to ensure that this rate is not glucose-limited, i.e. independent of G, then
a reasonable starting point, would be to require that (i) QO = 0 when O = 0 and (ii) QO is
bounded and approaches some constant value, say BO, as O grows large. The simplest form
for this rate would be some constant rate QO = BO for O > 0. This supposition forms the
basis of the Krogh model [86] whose work with Erlang helped form the foundation for the
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disciplinary nature of the field of mathematical biology. This model is limited by the fact
that once all the oxygen is consumed the solutions dip into negative concentration values
unless the spatial domain is truncated when O = 0, or if the consumption rate is piecewise
defined so that no consumption occurs once the oxygen supply is depleted. The simplest
form for a continuous function that satisfies the aforementioned conditions is given by a
Michaelis-Menten formulation, which has been rigorously formulated for certain enzyme
kinetics, and is given by
kO(O) = BO
O
O +KO
,
where KO is the concentration at which the consumption is half the maximum rate, i.e.
kO(KO) = BO/2. This was first proposed and analyzed in the context of oxygen consump-
tion by Blum [87]; he also analyzed constant (the correct solution in this case was derived
later [88]) and linear consumption rates. The latter will be neglected here due to its un-
bounded nature although it could be used as an approximation to the Michaelis-Menten
rate for small oxygen concentrations (only applicable in hypoxic conditions).
One generalization of a Michaelis-Menten function is the Hill equation,
kO(O) = BO
On
On +KnO
,
where n > 0 is the Hill coefficient which recaptures Michaelis-Menten kinetics when n = 1.
This form can also be derived in a biological context to describe cooperative (or noncoop-
erative) binding, but here we mention it only because of its sigmoidal properties. A sample
of these functions is shown in Figure 3.5 showing that as n increases, the function exhibits
more switch-like behaviour. Using these functions with larger values of n than unity can
have numerical advantages for low concentrations as their derivatives are equal to 1/KnO as
the concentration approaches zero. So for large n, the derivative at the origin approaches
zero.
The Michaelis-Menten formulation formed the basis of more complicated versions that
included dependencies on other species concentrations. For instance, if the rate is limited
by glucose availability then the maximal rate BO should also show some dependance on
G. An appropriate form for kO that continues to satisfy the minimal requirements above
was proposed by Kirkpatrick et al. [85] and is given by
kO(O,G) = BO
G
G+ ΓG
O
O +KO
.
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Figure 3.5: Michaelis-Menten function (n = 1) and Hill functions (n = 2, 10) of concen-
tration C with maximum rate p and half-maximal concentration k. As the exponent n
increases the function becomes more switch-like.
In [4], a seemingly opposite approach was taken with the maximal rate approaching a
constant as G increases, but approaching infinity as G approaches zero
kO(O,G) = BO
(
1 +
AO
G
)
O
O +KO
.
This functional form captures the so-called Crabtree effect, which is the observation that
oxygen consumption will actually decrease as glucose increases, as cells tend to rely more
on glycolysis in hyperglycaemic conditions. However this form certainly does not hold for
small glucose values, as the rate rapidly increases. When they attempted to implement
this form numerically, they had to modify the expression for low glucose values, so that
when G < 0.27 mM,
kO(O,G) = αO(1− βOG2) G
2
G2 + Γ2G
O2
O2 +K2O
,
forced to use both a Hill coefficient of 2, and bounding the maximal rate. While more
complicated forms for oxygen consumption certainly exist, we will hold off their discussion
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since they must be broached in tandem with glucose, lactate or pyruvate consumption
rates.
Similarly for our discussion of glucose consumption QG, as a starting point for proposing
a functional form, we require as a bare minimum that QG = 0 when G = 0 and that QG is
bounded and preferably approaches some constant value, say BG, as G grows large. The
simplest form for this is once again given by a Michealis-Menten formulation,
QG(G) = BG
G
G+KG
.
This formalism for glucose consumption has been used in previous tumour spheroid models
[65, 63, 89] that similarly consider diffusion-reaction equations albeit in a larger spherical
tissue with boundary conditions appropriate for that scenario. Unfortunately this form
does not account for the Pasteur effect, i.e. the decreased glucose consumption as oxygen
increases, or conversely the increased glucose consumption as oxygen decreases. The lat-
ter interpretation can be understood by the cell’s adaptation to the lower ATP yield of
glycolysis experienced by hypoxic cells. This could be achieved by making the maximal
achievable consumption rate, previously denoted by BG, a decreasing function of O. This
one again was attempted in [4] by introducing a variable maximum rate which we will
denote by BG(O), which gives a consumption rate of
QG(G,O) = BG(O)QG(G) = BG
(
1 +
AG
O
)
G
G+KG
,
where BG is the consumption rate at high oxygen concentrations and AG determines the
inhibitory sensitivity to oxygen. This expression cannot be applied globally since BG(O)→
∞ as O → 0, so in [3] they modify the expression and use BG(O) = BG(1 − AOO2) and
similarly switch to a Hill coefficient of 2 for O < 0.01 mM. In [25], a complicated form of
BG(O) was proposed, namely,
BG(O) = 1− 23O0.02 exp(−100(O − 0.01)4).
Its main drawbacks are the introduction of many parameters, a very sharp upward spike for
low oxygen values and lower glucose consumption values for hypoxic conditions. However, it
is a bounded functional form that can be easily interpreted as a maximal rate. This glucose
consumption rate was coupled to oxygen consumption with the form QO = RQGO/(O +
55
kO)f(O), where 0 ≤ R ≤ 6 is the ratio of respiration to glycolysis [25] and the functions f
is very similar to the form of BG(O) given above and is given
f(O) = 1− 1
2
O0.02 exp(−100(O − 0.01)4).
These forms of the consumption rates ensure that respiration is the dominant metabolism
near the vessel (in well-oxygenated regions), glycolysis and respiration are both active yet
reduced at intermediary distances (in hypoxic regions) and glycolysis is dominant distant
from the vessel (in anoxic regions). The consumption rates above include a total of 14
parameters and manage to produce a pH plateau.
Another tactic for proposing glucose consumption rates is to formally separate the
two processes of respiration (in the presence of oxygen) and glycolysis (ending in lactate
production) by proposing functions for the glycolytic rate kG and the respiration rate kO
and taking their sum, giving QG = kO + kG. This is the approach taken in [85], where
QG = BO
G
G+ ΓG
O
O +KO
+BG
G
G+KG
.
This is also the approach taken in [90], discussed below, where the phenomenon of metabolic
symbiosis was included in their model. The lactate produced by glycolytic cells can be con-
sumed during respiration by cells with access to oxygen. This is captured via a competition
term, where lactate inhibits glucose consumption via respiration and vice versa,
QG = BO
αGG
αGG+ αLL+ ΓG
+BG
G
G+KG
.
In addition to glucose and oxygen, lactate consumption is also a key consideration since
it can be used as fuel for cells performing respiration. In [65], the transmembrane transport
of glucose, oxygen and lactate are given by Michaelis-Menten rates QX,m (the m subscript
denotes transmembrane rates),
QX,m = BX
X
X +KX
and serve as the maxima for the corresponding metabolic rates. The model is more com-
plicated than this but was criticized in [63] for a lack of lactate production when lactate
concentrations drop to zero in normoxic conditions. To remedy this Bertuzzi et al. formu-
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lated a series of models originating in [63], and being revised in[89] that propose forms for
glucose, lactate and pyruvate consumption
QG = BG
G
KG +G
,
QP = −2QG +BP P
Kp + P
O
KO +O
+ φ,
QL = −φ− h(L− L∗),
where BP is the maximal rate of oxidative phosphorylation, φ is the rate of interconversion
between lactate and pyruvate, and h is the rate constant for lactate transmembrane trans-
port which is proportional to the difference between extracellular and intracellular con-
centration (L− L∗). This uses the facts that pyruvate is produced at twice the glycolytic
rate, consumed in the presence of oxygen, and that pyruvate and lactate are reversibly
interchanged by the enzyme lactate dehydrogenase (LDH). They derive their oxygen con-
sumption based on the intracellular equations for pyruvate and lactate which ends up
being the solution to a quadratic equation. This approach differs from those above be-
cause they consider glycolysis and respiration to be inextricably linked processes, instead
of two distinct fates of glucose. This requires the introduction of pyruvate, but since its
intracellular concentration can be found in steady state, it is readily eliminated. However,
their functional form for QG leaves something to be desired since hypoxic conditions are
often prevalent in tumours and cells compensate for the lowered rate of respiration (and
thus ATP production) by dramatically increasing their glycolytic flux. This approach also
leads to a very complicated function form for QO which will not be reproduced here.
A key step was taken by Mendoza-Juez et al. [90] when they explicitly included the
symbiotic nature of glycolytic and respiration fuelled cells (without including pyruvate).
They used ODEs of the form dX/dt = −QX where their functional forms for glucose and
lactate consumption by respiration assume that glucose inhibits lactate consumption and
vice versa and are given by
QG = BO
αGG
αGG+ αLL+N∗
+BG
G
G+G∗
QL = BL
αLL
αGG+ αLL+M∗
− 2BG G
G+G∗
,
where BX , X = O,L,G have been redefined from [90] for simplicity and comparison, by
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BO = βoPo, BG = βgPg, BL = βLPo to absorb the aerobic and glycolytic cell population
proportions, denoted by Po and Pg respectively. Equations that govern these population
proportions are omitted but it should be noted that they switch metabolism when lactate
reaches a threshold level L∗. These equations were extended to include oxygen concen-
trations and spatial effects (by including diffusion), but were not investigated [90]. These
proposed rates are
QG = BO
αGG
αGG+ αLL+ ΓG
O
O +KO
+BG
G
G+KG
,
QL = BL
αLL
αGG+ αLL+ ΓL
O
O +KO
− 2BG G
G+KG
,
QO = 6BO
αGG
αGG+ αLL+ ΓG
O
O +KO
+ 3BL
αLL
αGG+ αLL+ ΓL
O
O +KO
.
As summarized above, the issue of what functional forms to utilize for glucose and
oxygen consumption was broached in [4] and applied in [3] in tandem with a bicarbonate
buffering model. In [4] they suggest a simple form for glucose and oxygen production rates
given by
QO =
(
AO +
BO
G
)(
O
O +KO
)
QG =
(
AG +
BG
O
)(
G
G+KG
)
.
The choice of modification from standard Michaelis-Menten kinetics is to compensate for
a Pasteur-like and Crabtree-like effect explained above. They also present a more compli-
cated version that incorporates the decreasing consumption of oxygen and glucose in the
presence of hydrogen ions due to the acidic breakdown of proteins critical to metabolism:
QO =
(
AO +
BO
GHn
)(
O
O +KO
)
QG =
(
AG +
BG
O
)
1
Hm
(
G
G+KG
)
where n and m are phenomenological constants, and the choice of the pH dependencies
are based on experimental observations. An equivalently generalized model could raise O
and G to some powers in these consumption rates as well (as they were forced to do for
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low concentrations).
3.4.4 Parameter estimation
Diffusion coefficients
There is no single study that has measured the apparent diffusion coefficients of all of the
molecules of interest, which include but are not limited to glucose, lactate, oxygen, carbon
dioxide, bicarbonate and hydronium, in the same type of tissue. In fact, our references for
these parameter values have not measured any more than two of the diffusion parameters of
interest. In general, these apparent diffusion coefficients may exhibit spatial-dependence
due to changes in temperature, tissue properties and molecular concentrations but for
simplicity, we will assume that they are constant in the tissue surrounding a blood vessel.
As a starting point, we will consider these diffusion coefficients in water and then move to
measurements in various normal and tumour tissues to observe their changes.
A detailed study on the estimation of the diffusion coefficients of dissolved carbon diox-
ide and bicarbonate was performed by R. Zeebe [91]; we will only use the functional fit to
his simulation results, namely, DwX = D
0
X [(T/TX)−1]pX , where the applicable temperature
range is 273 < T < 373 and the parameters are given in Table 3.1. These functions give a
reasonable fit to carbon dioxide diffusion coefficients [92, 93, 94], and bicarbonate diffusion
coefficients [94, 95] in the literature. We will fix the temperature at a value slightly higher
than body temperature (≈310 K) due to hyperthermia exhibited by many solid tumours
[96]. Temperature differences can even differentiate between malignant and benign growths
with malignant tumours, exhibiting a temperature more than 0.7 K higher than normal
tissue [97]. We will take T=311 K which would yield DC=2745 µm
2/s and DB=1495 µm
2/s
in water. Approximate diffusion coefficients of other molecules in water are given in Table
3.2.
X D0X (µm
2/s) TX pX
C 14 683.6 217.2056 1.9970
B 7015.8 204.0282 2.3942
Table 3.1: Parameter values for calculating diffusion coefficients of bicarbonate and carbon
dioxide in water, adapted from [91].
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Most mathematical models of tumour metabolism that include diffusive transport use
values calculated in various tissues; some common choices are listed in Table 3.3. However,
the self-consistency of these values is rather suspect. In some cases, the diffusion coefficients
of uncharged molecules are not even inversely related to their molecular mass, i.e. some
particle A with lower molecular weight than particle B (MA < MB) is assumed to have a
lower diffusion coefficient than particle B (DA < DB). Here, we will ensure this does not
occur by first taking a very loose assumption, by simply ensuring that MA < MB implies
DA > DB.
X MX (g/mol) D
w
X (µm
2/s) Reference
G 180.16 940 [98]
925 [99], used in [100, 89]
L 89.07 1230 [101]
1200 [75] used in [102, 89]
O 32.00 3240 interpolated [103]
B 61.02 1495 [91]
C 44.01 2745 [91]
H 1.01 >10 000 extrapolated [95]
Table 3.2: Molecular masses and diffusion coefficients DwX of molecules in water.
Diffusion coefficients vary depending on the tissue under study but the ratio between
the diffusion coefficients of different species remains relatively constant. For two neutral
molecules, A and B, with molecular weights MA and MB respectively, their diffusion coef-
ficients satisfy the (very) approximate relation
DX
DY
=
(
MY
MX
)n
where n = 1/2 in water and n ≈ 3/4 for molecules in 37◦ tissue [75] (specifically DX =
17780/M
3/4
X µm
2/s, 32 < M < 69000, [75]). The latter is used to estimate the lactate
diffusion coefficient in [3] from the glucose diffusion coefficient measured in [105].
Vessel concentrations
Typical ranges for normal lactate, glucose and oxygen concentration in the blood are VL:
0.5–2 mM, VG: 4–6 mM, and VO: 0.04–0.08 mM. The range of glucose to include extreme
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hyperglycaemic and hypoglycaemic conditions that could arise locally in a tumour would
encompass VG: 1–10 mM; similarly, for oxygen, including severely hypoxic conditions would
allow VO: 0.01–0.08 mM.
As an example of tumour blood vessel concentrations, the experiments performed by [5]
represent the first micrometer scale measurements of the partial pressure of oxygen (pO2)
and interstitial pH adjacent to tumour blood vessels. We will focus on their measurements
of average pO2 provided as functions of distance from a single blood vessel. In their exper-
iment the individual measurements were taken from multiple blood vessels in 7 tumours.
When averaged, these measurements were only considered up to a distance D/3 from the
vessel, where D is the distance to the nearest neighbouring vessel, in order to ensure that
the contribution was predominantly from the local effects of a single vessel. The corre-
sponding average pO2 profile gives even more information, specifically that certainly the
oxygen concentration drops to zero well before the penetration depth, in fact here near
anoxic conditions are encountered less than 200 µm away from the vessels, and the average
partial pressure of oxygen in the tumour vessel is 13.5 mmHg [5]. Henry’s Law relates this
partial pressure, pO2, to the molar concentration, O, via the solubility coefficient, SO, i.e.
O = SOpO2. At 37
◦ C the solubility of oxygen of DS-carcinosarcoma in the rat kidney is
SO = 1.05× 10−3 mM/mmHg [117]; this yields VO ≈ 1.43× 10−2 mM.
Metabolic parameters
Parameters determining Michaelis-Menten consumption rates and half-maximal concen-
trations have been estimated in a number of tissues. Some representative values and their
previous model usage are summarized in Table 3.4.
3.5 Summary
The mathematical models presented in this chapter will form the basis on which the models
to follow will be built. The general solute transport equation derived in Section 3.2 are
utilized in the models that consider the concentrations of specific entities in tumours. The
models for interstitial fluid pressure and velocity, along with those that govern angiogenic
growth factor concentrations in Sections 3.1.2 and 3.3 respectively will both be utilized to
formulate the system in Chapter 4. Similarly the metabolic models developed in Section
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3.4, especially the microscale model, and the consumption rates discussed have influenced
the symbiosis model and the metabolism-acidity model presented in Chapter 5.
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X DX (µm
2/s) Medium
G
11.5 V79-171B tumour spheroid [104]∗
23–55 human cell spheroids [105], upper bound used in [106]
42.1 EMT6/Ro tumour spheroid [104]∗, used in [107]
105 EMT6/Ro tumour spheroid [105], used in [64, 25]∗∗,[108, 109, 65, 63, 89]
126/139 rat brain (with/without glucose infusion) [110]
150 9L rat brain tumours[99]
362 Swabb relation [75]
500 EMT6/Ro tumour spheroid [111], used in [85] (they cited [75])
560 used in [112]
700, 770 blood plasma [113], [114]
L
59 used in [107]
176 rat brain [110]
177 molecular weight correlation with DG [105] [3], used in [65, 63, 89]
350 used in [102]
608 Swabb relation [75]
820, 887 blood plasma [114], [113]
900 [112]
O
1321 Swabb relation [75]
1460 EMT6/Ro tumour spheroid [115] (25◦ C), used in [25]
1500 used in [85]
1650 used in [107]
1690 V79-171B tumour spheroid [116]
1750 DS-carcinosarcoma (rat kidney) [117], used in [108, 109]
1820 EMT6/Ro tumour spheroid [116] (37◦ C), used in [3, 65, 64, 63, 89]
1980 [112]
2000 [118] used in [119, 120, 106, 121]
B
22 mammalian corneal epithelium (310 K) [122]
140 100% hemolysate [123]
150 mammalian corneal stroma (310 K) [122]
C 340 100% hemolysate [123]
H
190 mammalian corneal epithelium (310 K) [122]
1180 mammalian corneal stroma (310 K) [122]
Table 3.3: Apparent diffusion coefficients reported in the literature for various molecules
in tissues. Those for bicarbonate, carbon dioxide and hydrogen ions are sparsely reported
whereas those for metabolites have been frequently measured in tumour tissues.
* value calculated using molecular weight correlation with inulin.
**value rounded to 110 as in the abstract of [105]
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Parameter Value Reference
KO 2×10−4 used in [25]
KO 4.640×10−3 mM [3], used in [64, 65, 63, 89]
KG 4.0×10−2 mM [4] cites [99], used in [3, 64, 65, 63, 89]
KG 5.0×10−2 mM used in [25]
KG 0.58 mM 9L rat brain tumours[99], cited by [4]
βO 1.43916×10−2 mM/s [3], used in [64]
βG 0.04 mM/s [3], used in [64]
Table 3.4: Parameters used in metabolic models.
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Chapter 4
The Effect of Convective Transport
on Angiogenic Activity
In this chapter, the effect of convective transport on angiogenic factors concentrations
and consequently the overall angiogenic behaviour is investigated. The majority of results
presented here are reported in [81]. This work shows that altering physiological parameters
of a tumour, such as hydraulic conductivity of the tissue, vessel permeability and vascular
pressure, all of which alter macromolecule transport, can alter the spatial distribution of
angiogenic growth factors (AGF) concentrations. The imbalance between proangiogenic
and antiangiogenic factors can subsequently suppress or initiate angiogenesis in a tumour.
While the process of tumour angiogenesis and interstitial fluid pressure were outlined in
Chapter 2 and models for AGFs and interstitial fluid pressure (IFP) were given in Chapter
3, we will first give a brief introduction for the modelling to follow.
4.1 Introduction
The process of angiogenesis, the development of new blood vessels from preexisting vascu-
lature, is governed by the net balance between proangiogenic and antiangiogenic growth
factors [124]. Multiple regulatory factors are involved in this process, including the vascu-
lar endothelial growth factor (VEGF) family and its receptors, the fibroblast growth factor
(FGF) family, angiostatin, and endostatin [124]. During tumour progression, this delicate
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balance is heavily skewed in favour of angiogenesis at the tumour rim, resulting in an
abnormal tumour vasculature and microenvironment [35, 125]. The tumour core remains
relatively devoid of nutrient-providing blood vessels and thus maintain highly upregulated
AGF production.
The tumour vascular network in solid tumours is spatially and temporally heteroge-
neous, resulting in a harsh microenvironment characterized by hypoxia, acidosis, and el-
evated interstitial fluid pressure. While all three of these traits play critical roles in the
activity and upregulation of angiogenic growth factors, the relationships between these
features and tumour angiogenesis are complex and not fully understood. The most promi-
nent and widely studied AGF is VEGF, a potent proangiogenic agent that is independently
upregulated by both hypoxia and acidosis [126]. While angiogenesis is commonly triggered
as a result of hypoxia, it is also the case that acidic pH induces the production of several
other angiogenic molecules including basic FGF [127] and nitric oxide [128]. Although the
effects of hypoxia and acidosis on angiogenic factors have been investigated experimentally,
the effects of elevated IFP are less clearly understood. Here, we seek to explore the effect
of IFP gradients on proangiogenic and antiangiogenic factor concentrations, with a focus
on extrapolating a tumour’s spatial angiogenic tendency induced by the local imbalance of
these factor concentrations.
Two compounding factors that contribute to elevated IFP in solid tumours are the
increased permeability of blood vessels and the absence of functional lymphatics [125, 129].
It has been hypothesized that the normalization of tumour vessels, by the application of
antiangiogenic therapies such as antibodies inhibiting VEGF or blocking VEGFR-2, would
lead to lowered tumour IFP [35, 130]. Baxter and Jain [67] developed a mathematical
model to study the transport of fluid and macromolecules in tumours. Recently, Jain et al.
[2] revisited their model to investigate the effect of vascular normalization by antiangiogenic
therapy on IFP, as well as to determine the parameters that could lead to a reduction of
IFP.
In other work, Ramanujan et al. [1] used a mathematical framework to study the local
imbalance of pro- and antiangiogenic factors. Their model contained production, diffusion,
and degradation of these factors, and was used to explain focal necrosis and dormancy
in tumours. The details of their work is contained in Section 3.3. Here, we expand and
generalize their model to include the effect of interstitial convection on proangiogenic and
antiangiogenic factor concentrations, which is supported by the fact that convection can
contribute significantly to the transport of molecules of the typical size of AGFs (see
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Table 4.1). It has also been noted that convection plays an important role, not only
in determining local concentrations, but also in the functionality and activity of AGFs,
particularly VEGF [131]. This effect is added via a convection term in the equations that
govern the concentrations of AGFs (see following section). The mathematical model is then
used to study the changes in a tumours angiogenic behaviour as a result of altering tissue
or blood vessel properties (e.g. hydraulic conductivity of tissue, hydraulic permeability of
vessels).
Molecule Angiogenic category Size (kDa) Reference
VEGF165 dimer Proangiogenic 45 [132]
FGF family Proangiogenic 17–34 [133]
TSP-1 Antiangiogenic 140 [134]
Angiostatin Antiangiogenic 38 [135]
Endostatin Antiangiogenic 20 [136]
Table 4.1: Molecular weights of common proangiogenic and antiangiogenic growth factors.
4.2 Mathematical model
4.2.1 Angiogenic growth factor model
We first assume that angiogenic growth factors can be considered to initiate either proan-
giogenic (stimulatory) or antiangiogenic (inhibitory) activity [1, 78]. Although some of
these factors may behave in either a proangiogenic or antiangiogenic manner depending
on the state of the system, we consider this effect to be negligible. While different cellular
mechanisms and signaling cascades activated by specific (and possibly multiple) factors
have greater effects on the level of angiogenic activity than others, we simply consider the
pro- and antiangiogenic factor concentrations to be representative of the angiogenic ef-
fect enabled by these two categories. The proangiogenic (p) and antiangiogenic (a) factor
concentrations will be denoted by fp and fa (µg/mm
3), respectively. These factors are as-
sumed to diffuse with constant diffusion coefficients Dj (mm
2/s), j = p, a, to degrade under
first-order kinetics with constant deactivation rates kj (s
−1) and to be produced indepen-
dently with constant production rates gj (µg/mm
3/s). Since the aforementioned diffusion,
deactivation, and production parameters are used to describe entire families of factors with
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Parameter Units Host Tumour Normalized
R mm – 4 4
K mm2/s/mm Hg 2.5×10−5 2.5×10−5 2.5×10−5
Angiogenic growth factors
Dp mm
2/s 4.0×10−5 5.5×10−5 5.5×10−5
Da mm
2/s 3.25×10−5 4.0×10−5 4.0×10−5
kp s
−1 2.0×10−4 1.99×10−4 1.99×10−4
ka s
−1 1.5×10−4 1.1×10−4 1.1×10−4
gp µg/mm
3/s 2.0×10−4 12.0×10−4 12.0×10−4
ga µg/mm
3/s 1.5 ×10−4 7.0×10−4 7.0×10−4
k˜p – 80 57.9 57.9
k˜a – 73.8 44 44
g˜p – 80 349 349
g˜a – 73.8 280 280
K˜p – 12.5 9.1 9.1
K˜a – 15.4 12.5 12.5
Interstitial fluid pressure
Lp mm/s/mm Hg 3.6×10−7 1.86×10−5 3.7×10−6
Φ = S/V mm22/mm3 17.4 16.5 15.2
pv mmHg 20 20 20
σ – 0.91 8.7×10−5 2.1×10−3
piv mmHg 20 19.8 19.2
pii mmHg 10 17.3 15.1
pe mmHg 10.9 20 20
α – 2 14 6
Table 4.2: AGF model parameters primarily from [1] and [2]. See Tables B.1 and B.2 for
further information.
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varying molecular weights and kinetic rates, they are assumed to be representative of their
respective angiogenic categories. However, each of these parameters can differ in host and
tumour tissue, both of which are assumed to be homogeneous and isotropic, so that when
appropriate, we will distinguish between these values with superscripts for host (h) and
tumour (t) tissues, explicitly, e.g.
Dj =
{
Dtj, 0 ≤ r ≤ R,
Dhj , r > R.
As indicated earlier, we also include the convection of these factors since interstitial fluid ve-
locity (IFV) in the tumour plays a role in determining the concentration of macromolecules
including AGFs in the tumour. Assuming the velocity of these molecules is equal to the in-
terstitial fluid velocity u (mm/s) [75] (this is equivalent to setting the retardation coefficient
to 1), we arrive at the equation
∂fj
∂t
= Dj∇2fj − kjfj + gj −∇ · (ufj), j = p, a, (4.1)
where the IFV, u, is given by Darcy’s Law u = −K∇p, where K (mm2/s/mm Hg) is the
hydraulic conductivity of the interstitium and p (mm Hg) is the IFP [62, 137]. The IFP is
modelled utilizing Starling’s Law; see Section 3.1.2 for the derivation, specifically (3.12).
In addition, the analytical pressure solutions are given in Equation(3.18) and plotted in
Figure 3.1a for a tumour embedded in host tissue.
By adding convection to this equation, we can study larger tumours since the model
was previously restricted to those where convection was not a factor (usually those tumours
with radii less than 2 mm). It is worthwhile reemphasizing that interstitial convection also
plays a vital role in the activity of AGFs and the process of tumour angiogenesis [131].
Convective effects have been incorporated in previous models of drug distribution and
other macromolecules in tumours [62, 67], and thus it seems natural to include it in this
case. The parameters for the diffusion, production, and degradation of AGFs inside the
host and tumour tissues are those assumed based on the conditions stated in Ramanujan
et al. [1] and these are presented in Table 4.2.
To facilitate solving (4.1), we assume that the tumour is a sphere of radius R (mm),
and since the dynamics of growth factor distribution occur on a much faster time scale
than tumour growth, we consider the system to be in quasi-steady-state. This results in
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the equation
Dj
r2
d
dr
(
r2
dfj
dr
)
− kjfj + gj + K
r2
d
dr
(
r2
dp
dr
fj
)
= 0. (4.2)
Equation (3.34) can be nondimensionalized by setting r˜ = r/R and f˜j = fj/f
s
j where
f sj = g
h
j /k
h
j is the steady-state AGF concentration in host tissue. Dividing by Dj elim-
inates the diffusion coefficient and gives the nondimensional parameters k˜j = kjR
2/Dj,
g˜j = gjR
2/(Djf
s
j ) and K˜j = Kpe/Dj where pe (mm Hg) is the effective pressure used to
nondimensionalize the equation for pressure (the nondimensional pressure is defined to be
p˜ = p/pe, refer to Equation (3.13)). This nondimensionalization yields the equation
1
r˜2
d
dr˜
(
r˜2
df˜j
dr˜
)
− k˜j f˜j + g˜j + K˜j
r˜2
d
dr˜
(
r˜2
dp˜
dr˜
f˜j
)
= 0. (4.3)
This step is essential to the model since the nondimensional quantities are used to define
a measure of angiogenic activity below in (4.4).
The nondimensional parameters in the tumour and host tissues are shown in the context
of the model geometry in Figure 4.1 with tumour parameters shown inside the spherical
tumour and host parameters outside. Note that in the host tissue, the normalization by
the steady state factor concentrations simplifies the degradation rate so that g˜hj = k˜
h
j . The
system has been reduced to a system with seven nondimensional parameters.
In the absence of the convection term, that is, eliminating the last term in (4.3), an
analytical solution can be obtained with appropriate boundary conditions [1] (see Section
3.3). However, in this work, we also consider the scenario where diffusion and convection
could play a significant role in factor transport, and hence we rely on numerical integration
schemes to solve (4.3).
4.2.2 Angiogenic activity
While we are interested in the qualitative effects of IFP on AGF concentrations, we are not
specifically interested in the quantitative concentrations of these two factor groups. The
relationship between the proangiogenic and antiangiogenic forces is of greater importance,
since the balance between these factors is the determinant of whether angiogenesis will
be locally suppressed or initiated. Following Stoll et al. [82], we introduce a measure of
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Figure 4.1: The nondimensional parameters in the tumour and host tissues are shown in the
context of the model geometry. Tumour parameters are shown inside the spherical tumour
while host parameters are shown outside. These parameters include the nondimensional-
ized production, degradation and transport parameters for AGFs and the nondimensional
pressure parameter.
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angiogenic activity a defined by
a =

f˜p
f˜a
− 1, if f˜p ≥ f˜a,
1− f˜a
f˜p
, if f˜p < f˜a,
(4.4)
where a > 0 corresponds to angiogenesis being initiated, a = 0 indicates a stable vascu-
lature network, and a < 0 implies that no angiogenesis is taking place, and vessels could
be regressing. These scenarios are depicted in Figure 4.2 where the scale of AGFs can be
tilted toward suppression or initiation of angiogeniesis. While other forms of this function
for a are viable, we choose this form due to its symmetry and the apparent inclusion of
the balance between these nondimensionalized factor concentrations.
A typical angiogenic activity scenario in a solid tumour maintains angiogenic repression
at the tumour core where heightened levels of angiogenic inhibitors override the effect of
elevated proangiogenic factor production. They also exhibit angiogenic stimulation near
the tumour boundary where the angiogenic balance leans toward a proangiogenic tendency.
This typically leads to the development of both an oxygen-deprived core consisting of
hypoxic and necrotic cells along with a heavily vascularized and rapidly proliferating outer
rim [138].
We use the angiogenic activity measure a to classify the model output into one of
three cases: focal suppression, global suppression, and global angiogenesis [1]. The typical
focally suppressive behaviour described above is characterized by a transition from negative
to positive values of a as we move from the core to the rim part of the tumour. Global
suppression and angiogenesis are defined by a < 0 and a > 0, respectively, everywhere
inside the tumour (i.e., for all r ∈ [0, R]).
4.2.3 Parameters
Parameters governing AGF production, degradation and diffusion are taken from [1] while
those that govern the pressure and therefore convection in the model are taken from [2,
Table 3]; these are all given in Table 4.2. Those that differ between host (superscript h)
and tumour (superscript t) tissues along with those for tumours whose vascular structure
has been normalized using antiangiogenic agents are given in separate columns. While
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Figure 4.2: The balance between proangiogenic and antiangiogenic factors can be perturbed
by the removal or addition of proangiogenic or antiangiogenic factors. If the angiogenic
switch is thrown, the balance is tipped toward proanigiogenic factors, this corresponds to
a > 0. If vessels are regressing, the balance is tipped toward antiangiogenic factors and
a < 0. In normal tissues and normalized tumour tissues, the scale is balanced and a = 0.
the original table in [2]has a range for the vascular pressure pv, we have set a base value
of pv = 20 mmHg for all tissues. This value is close to the mean value for the range of
parameters in both normal and tumour tissues. Similarly, the ranges for surface area of
blood vessel wall per unit volume Φ := S/V are replaced with values near the mean.
4.2.4 Solution method
We assume that the tumour is embedded in normal host tissue (e.g., in an organ) and
consider the following boundary conditions. We ensure spherical symmetry at the core by
imposing
dfj
dr
∣∣∣∣
r=0
= 0, and
dp
dr
∣∣∣∣
r=0
= 0
and enforce continuity of factor concentrations and fluxes at the tumour boundary by
setting
fj(R
−) = fj(R+), and −Dtj
dfj
dr
+ ufj
∣∣∣∣
r=R−
= −Dhj
dfj
dr
+ ufj
∣∣∣∣
r=R+
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along with continuity of IFP and IFV by setting
p(R−) = p(R+), and u(R−) = u(R+).
The latter condition is equivalent to
−Khdp
dr
∣∣∣∣
r=R−
= −Ktdp
dr
∣∣∣∣
r=R+
,
where typically Kh = Kt (based on [2, Table 3]). We also require that factor concentrations
and the pressure reach steady state as we move away from the tumour and so impose
lim
r→∞
dfj
dr
= 0, lim
r→∞
dp
dr
= 0.
This ensures that the factor concentration reaches steady state f sj and that p(r) → 0 for
large r (achieved by setting phe = 0).
The analytical solution for nondimensionalized pressure, p˜, can be obtained by solving
(3.13). This along with the solution for nondimensional IFV, u˜ = uR/(Ktpe), was derived
by Jain et al. [67] (see Section 3.1.2). The radial profile for p˜ is then used to numerically
solve for the factor concentrations in (4.3). Due to the non-linearity of (4.3), we could no
longer rely on the analytical technique shown in 3.3, instead we had to develop a numerical
scheme to approximate their solutions. The corresponding matrix inversion problem was
performed using a second-order finite difference scheme in MATLAB [139].
4.3 Results
Interstitial pressure and velocity profiles are obtained from solving (3.13); these profiles
can be viewed in Figures 3.1a and 3.1b, respectively. Most notably, as the parameter αt
increases, the pressure reduction at the tumour rim becomes more drastic and the IFP
inside the tumour increases. Equivalently, as αt increases, the interstitial fluid velocity
reaches a higher and sharper peak at the tumour rim while remaining zero at the core.
We solve (4.3), with the boundary conditions given in the previous section and the ana-
lytical pressure profiles, to determine AGF concentrations and subsequently the imbalance
factor in (4.4). First, we compare the results of our model with those of the model without
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Figure 4.3: Comparing 4.3a nondimensionalized proangiogenic (solid) and antiangiogenic
(dashed) growth factor concentrations and 4.3b angiogenic activity for the model without
convection (u = 0) and with convection (αt = 14, αh = 2). With the addition of convection,
the area of angiogenic stimulation is larger and more pronounced
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Figure 4.4: Effect of varying the vascular hydraulic permeability, Lp (mm/s/mm Hg), in
the tumour tissue on 4.4a AGF concentrations and 4.4b angiogenic activity. The values
of αt=2, 6, 14 correspond to Lp=3.6×10−7, 3.7×10−6, 1.86×10−5 mm/s/mm Hg. The
parameter for host tissue was fixed at αh = 2. This changes the shape of the resulting
pressure profile and thus the interstitial fluid velocity.
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convection [1]; the only difference between the curves corresponding to no convection in
Figure 4.3a and the original results of [1] is that we consider a tumour radius of 4mm
(up from 2.5mm) in order to remain consistent with the parameter estimates from [2] that
are used for the pressure model. For our model with convection, the angiogenic activity
still reaches a maximum at the tumour boundary, and the region of angiogenic suppres-
sion persists at the tumour core. However, we now observe a higher peak of angiogenic
tendency at the rim and a larger area of angiogenic stimulation, see Figure 4.3b. This is
due to the larger difference between the proangiogenic and antiangiogenic growth factor
concentrations near the boundary, a result of these factors being pushed out of the tumour
core into the surrounding normal tissue as can be seen in Figure 4.3a. However, as we will
see, the transition from a system without convection to a system with convection is not
straightforward.
By changing the values of αt, we can see the effect of varying only the contribution
of the pressure profile on the model. This can be achieved by modifying Lp, Φ, or R.
However, we wish to consider a fixed tumour radius and surface to volume ratio, so we
will consider changes in αt to correspond to changes in the values of Lp only. Note that
we cannot analyze the contribution of IFP alone by modifying K since this would also
change the value of the nondimensional convection parameter in (4.3). Similarly, we can
look at the contribution of the nondimensional convection parameter alone by modifying
pe. Finally, we will consider the effect of changing the hydraulic conductivity K which
simultaneously decreases αt and increases K˜j affecting the pressure profile and the rate of
convection.
We consider first the effects of varying only the pressure parameter αt (for fixed αh = 2),
which, as stated above, we will assume is achieved by changing Lp, leaving the rest of the
parameters fixed as in Table 4.2. As can be seen in Figures 4.4a and 4.4b, the results
suggest that altering the pressure parameter leads to different angiogenic behaviour in the
tumour. Indeed, the region of angiogenic suppression (a < 0) at the core is not conserved
for all values of αt between the cases of negligible convection (αt ≈ 0) and non-normalized
tumour tissue (αt = 14). Thus, the behaviour is more complicated than that observed by
modifying the convection parameter via pe or both pressure and convection parameters via
K (see Figures 4.5a and 4.5b and the Discussion below). For values of αt close to zero,
there is a region of angiogenic suppression (a < 0) at the core and stimulation (a > 0) at
the rim (similar to the no convection case in Figure 4.3b). For midrange values of αt the
tumour can experience global angiogenesis (i.e., a > 0 for all r ∈ [0, R]). That is, instead
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of the proangiogenic and antiangiogenic concentrations balancing inside the tumour, the
antiangiogenic factor concentration lies entirely below that of the proangiogenic factor
concentration. Considering αt = 2, this assumes that the tumour tissue has the same
value of Lp as normal tissue. Indeed, the angiogenic activity in this case remains constant
inside the tumour due to a consistent difference between the two factor concentrations
leading to global angiogenesis. For the parameters corresponding to normalized tumour
tissue (αt = 6), we see an intermediate behaviour where global angiogenesis occurs, but
the activity at the core is much lower than at the tumour rim. For high values of αt
(e.g., αt = 14), the core once again becomes a region of suppression but with higher levels
of angiogenic activity occurring close to the tumour rim as previously observed in the
convection case in Figure 4.3b. While different angiogenic profiles are obtained, it remains
true that the angiogenic activity at the tumour rim increases with αt.
As expected, fixing αt = 14 and increasing pe, thereby increasing the convection of
factors leads to higher concentrations outside the tumour (see Figure 4.5b) and larger
concentration differences at the rim. This coincides with an increase of angiogenic activity
at the tumour rim. For the parameters considered and a reasonable range of pe, the tumour
exhibits only focal suppression. Other activities can be achieved but require a modification
of the AGF parameters (see the sensitivity analysis in Figures 4.6a–4.6c).
Finally, we consider varying K, an increase in this parameter value leads to decreased
αt and αh along with increased values of the convection parameters K˜j. This essentially
compounds the effects observed in Figures 4.4a, 4.4b and 4.5a leading to elevated levels of
angiogenesis inside the tumour (from decreasing αt) and at the tumour rim (from increasing
pe); refer to Figure 4.5b.
Following Ramanujan et al. [1], we performed a sensitivity analysis on AGF production;
see Figures 4.6a–4.6c. We generalize their results by fixing one of the parameters of interest
(αt, pe, and K) and analyze results over a large range of tumour production values (g˜
t
p and
g˜ta). Focal suppression occurs between lines of the same colour, global suppression occurs
above this region (high g˜ta, low g˜
t
p), and global angiogenesis occurs above (low g˜
t
a, high
g˜tp). The results indicate that focal suppression is observed only for a narrow sliver of the
parameter space. This is realistic since one would assume that the behaviour is sensitive
to the balance of these factors production rates. As expected, the behaviour is not as
sensitive to varying the host production parameters as it is to tumour production (results
are not shown).
Figure 4.6a shows how this sensitivity changes when varying αt. As αt increases, the
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giogenic activity a.
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region of focal suppression widens from a very narrow region to encompass more of the
parameter space above and below this region. For different values of pe, we notice little
movement in the boundary between focal suppression and global angiogenesis while the
boundary between focal suppression and global suppression increases with pe (see Figure
4.6b). Finally, for K, we see a combination of these effects; the region where focal suppres-
sion and peripheral stimulation occur is widening and drifting towards the top left corner
of Figure 4.6c (high g˜ta, low g˜
t
p). Parameter values that correspond to focal suppression
switch to values corresponding to globally angiogenic behaviour when the convection term
is added. Also shown in these graphs are the precise points in parameter space correspond-
ing to the tumour production values g˜tp = 349 and g˜
t
p = 279; this will be discussed further
in the following section.
4.4 Discussion
αt g˜
t
p = 349 (no treatment) g˜
t
p = 279
2 Global angiogenesis Global suppression
6 Global angiogenesis Focal suppression
14 Focal suppression Focal suppression
Table 4.3: Angiogenic activity resulting from cytotoxic therapy (see Figure 4.7a).
We have presented a mathematical model to study the effects of interstitial convection
on proangiogenic and antiangiogenic factor concentrations in tumour and surrounding host
tissue, and from this determined the overall angiogenic activity of the tumour. The re-
sulting AGF concentration profiles agree qualitatively with experimental observations that
show the highest concentrations in the core of the tumour, decreasing as one approaches
the tumour rim [126]. Also, the resulting angiogenic behaviours, including suppression at
the tumour core and maximal angiogenic stimulation near the tumour rim, correspond with
experimental observations such as tumour perfusion [140]. The imbalance between proan-
giogenic and antiangiogenic factors provides an empirical explanation for observed angio-
genic activity and could be correlated with resulting tumour necrosis or growth. While the
precise effects of IFP and factor convection on the angiogenic activity of tumours have not
been experimentally verified, our results indicate that an IFP gradient could significantly
influence suppression and stimulation of angiogenesis in a tumour.
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Figure 4.6: Sensitivity to AGF production parameters where focal suppression occurs be-
tween lines of the same color, global suppression occurs above this region (high g˜ta, low g˜
t
p)
and global angiogenesis occurs above (low g˜ta, high g˜
t
p). The black square denotes parame-
ters from Table 4.2 used for the tumour angiogenic factor production (g˜tp = 349) while the
black circle indicates the lowered proangiogenic factor production used for chemotherapy
(g˜tp = 279); resulting angiogenic activity profiles are shown in Figure 4.7a.
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While not explicitly included, the effect of antiangiogenic treatments can be ascertained
in this model since it has been shown that the value of αt decreases when the vasculature
is normalized due to the application of, for instance, anti-VEGFR-2 [130]. The value of αt
can decrease through any combination of decreasing Φ, Lp, or R, all of which could occur
as a result of antiangiogenic therapy. Φ decreases as blood vessels are destroyed and/or
remodelled due to the administration of an antiangiogenic drugs (in this case, there is
less area of vessel wall per unit of tumour volume). The radius R decreases indirectly;
as tumour vessels regress, tumour cells are deprived of oxygen and consequently become
hypoxic or necrotic. Moreover, the vessel permeability Lp could decrease due to judicious
application of antiangiogenic agents (vessel normalization, [35]). The pressure parameter
αt could also be decreased by increasing the hydraulic conductivity K, an effect that would
be somewhat counterbalanced by the corresponding increase in the convection parameter
(refer to Figure 4.5b). However, K could be increased by administering enzymes that
degrade the extracellular matrix (ECM), which subsequently decreases the flow resistance
in the interstitium [137]. Overall, strategies that lead to the reduction of the parameter αt
result in decreased IFP, which influences tumour angiogenesis activity. As shown in Figure
4.4b and discussed in the previous section, the changes in the interstitial fluid velocity from
decreasing αt reduces the angiogenic activity at the rim and produces a more constant level
of angiogenic activity inside the tumour. On the other hand, one could also consider the
administration of antiangiogenic agents by decreasing the concentration of proangiogenic
factors through an increase of their degradation (or deactivation) constant (see Figure
4.7b). This increase in deactivation should take into account that most antiangiogenic
treatments only affect a single factor or a family of growth factors.
One can consider the effect of cytotoxic therapies by noting that the application of
either chemotherapy or radiotherapy reduces the number of tumour cells leading to less
proangiogenic factor production (Figure 4.7a); this is achieved by lowering the parameter
g˜tp. We considered the reduction of this production rate and the movement through param-
eter space is shown in the sensitivity diagrams (Figures 4.6a–4.6c). In Figure 4.7a, we can
observe that the resulting angiogenic behaviour depends on the value of αt as summarized
in Table 4.3. The effect of cytotoxic therapies either on tumour cells or blood vessels could
also reduce the pressure due to increased interstitial space; this could be included in our
model by, for instance, increasing K (Figure 4.5b). The effects of cytotoxic treatments
could also be included by reducing the tumour radius R. Combinations of antiangiogenic
therapy and chemotherapy could be considered by performing the aforementioned param-
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Figure 4.7: The effects of treatment on angiogenic behaviour of tumours.
eter changes simultaneously; these changes compound the effects leading to even further
reduced angiogenic tendency.
Decreasing the IFP prior to or simultaneously with other therapies is an important
concern in cancer treatment since the flow of interstitial fluid out of the tumour prevents
drugs from penetrating the tumour bulk. While the various effects of antiangiogenic treat-
ments (decreasing Φ, Lp, or R) or ECM-degrading enzymes (increasing K) all reduce αt
and hence pressure, there are other independent mechanisms that could also elicit reduc-
tions in pressure. For instance, reducing pe would reduce IFP. This could be achieved by
reducing the vascular pressure pv, which can be readily accomplished by decreasing the
resistance of blood. Clinically, decreasing the viscosity of the blood or normalizing the tu-
mour vasculature would accomplish the goal of less resistance [137]. The effects of changing
pe are shown in Figure 4.5a as decreasing the effective pressure leads to diminishing levels
of angiogenic activity at the rim.
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4.5 Conclusions
By taking into consideration the different angiogenic behaviours exhibited by modifying
any of the key parameters involved in the pressure model, we can establish an alternate
(or more likely, complementary) mechanism for these changes. Whereas it was previously
hypothesized [1] that the production, degradation, and diffusion of the AGFs were primar-
ily responsible for the overall angiogenic behaviour, we have exhibited that changes in the
tumour tissue physiology could also elicit these changes. The interplay between the two
groups of parameters, those related to AGF properties that determine AGF concentrations
and those corresponding to the tumour physiology that determine interstitial fluid pres-
sure, should be further investigated with more detailed modelling and experimental work.
We emphasize that it was never the goal of this work to quantitatively predict concen-
trations of specific AGFs or to model the process of angiogenesis but rather to emphasize
the importance of tumour tissue properties and macromolecule convection on angiogenic
behaviour.
One should note that there are limitations to our mathematical model, many of which
have been mentioned during the model development. These include the existence of two
distinct groups of AGFs, the specific functional form of our angiogenic activity measure and
the distributed fluid source terms. Most prominent among these various assumptions are
those of spherical symmetry and homogeneity of tissues and environment [1]. The other
main limitation is the assumption of constant parameter values both inside the tumour
and in the host tissue, or even the constant values assumed across this boundary. These
assumptions make the modelling and computation tractable especially since physiological
parameters as functions of radial distance are uncommon in the literature. However, our
computational approach can readily be extended to include aspects of the heterogeneous
tumour microenvironment upon availability of relevant experimental data. Finally, we
propose that an experimental study measuring both interstitial fluid pressure and quanti-
ties associated with AGF concentrations or angiogenic activity (such as vessel density or
perfusion) would help to validate our qualitative model predictions.
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Chapter 5
Microvessel Models for Cell
Metabolism and pH
This chapter analyzes microvessel models for cell metabolism and pH. Cell metabolism in a
tumour is enabled by angiogenesis that brings the oxygen, glucose, and other metabolites
necessary to cell survival. First, we will propose a model for metabolic symbiosis that
includes glucose, lactate and oxygen concentrations in a tissue that utilizes glucose-fuelled
and lactate-fuelled respiration along with glycolysis. The ATP production in tissue un-
der various metabolic inhibitor treatments are considered and the importance of glycolysis
shutdown is emphasized. A simpler version of this metabolic model that includes oxygen-
fuelled respiration and glycolysis is coupled to a cellular buffering model that requires the
addition of carbon dioxide, bicarbonate and H+ to the model. The effects of hypoxia and
cell permeability are observed in this context. We also show results for adding convec-
tive transport, which show that unlike the macroscopic model considered in the previous
chapter, this is a diffusion-dominated system.
5.1 Introduction
The extensive metabolic requirements for cancer cell proliferation coupled with the harsh
microenvironment in solid tumours culminates in a highly adaptive and complex network
for cellular energy production. The genetically altered metabolic behaviour of cancer cells
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has led to a number of emerging metabolic paradigms, in addition to those that are uni-
versally exhibited in both cancerous and normal cells. We will investigate this complex
metabolic behaviour by formulating a minimal mathematical model that includes the es-
sential metabolites of glucose, lactate and oxygen in the tissue surrounding a microvessel.
This model will enable the quantification of various behaviours, such as the symbiotic
relationship that exists between lactate-producing glycolytic cells and lactate-consuming
respiratory cells, and the analysis of metabolic dependence on various physiological con-
ditions such as hypoxia and induced metabolic inhibition. Metabolic inhibition including
glycolytic inhibitors among many others targets could be very important for cancer treat-
ment since an ATP deficit can induce apoptosis [141]. The key consideration for addressing
this problem with mathematics is the formulation of nutrient consumption rates that en-
compass the various primary facets of cancer cell metabolism and their corresponding ATP
yields.
In normal well-oxygenated tissues the primary source of ATP is the process of cellular
respiration. The complete conversion of glucose to carbon dioxide and water has an ideal
yield of at most 29 ATP [20] (although the reactions contained in C.4 suggest a yield as
low as 24.25). The preliminary stage of cellular respiration is glycolysis, the conversion
of glucose to pyruvate; this process directly produces 2 ATP. In hypoxic conditions this
pyruvate is preferentially converted into lactate via the enzyme lactate dehydrogenase
(LDH) to regenerate the essential cofactor NAD+. In oxygenated conditions this pyruvate
is transported across the inner mitochondrial matrix where it is decarboxylated and enters
the citric acid cycle; the citric acid cycle directly generates 2 more ATP per glucose. The
primary energy payoff is a result of cofactor oxidization that enables the electron transport
chain to establish a proton gradient across the inner mitochondrial matrix. ATP synthase
utilizes this electrochemical gradient to drive the phosphorylation of approximately 25
additional ATP per glucose molecule.
The aforementioned universal traits that cancer cells and normal cells share include
cellular responses to various levels of oxygen, lactate or glucose. Examples include a
Crabtree-like effect and a Pasteur-like effect [4]. The Crabtree-like effect is when oxygen
consumption decreases as glucose concentration increases. This can be explained by an
increasing reliance on glycolysis for ATP when hyperglycaemic conditions are encountered.
The Pasteur-like effect is decreased glucose consumption as oxygen increases. This is due
primarily to the inhibition of various metabolic steps by the presence of elevated ATP and
other intermediaries. However, cancer cells are unique in that they preferentially utilize
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Figure 5.1: The spatial relationship between the cell populations in the model. When the
glucose and oxygen concentrations are highest near the vessel wall, the cells preferentially
utilize glucose-fuelled respiration. When the oxygen supply is depleted far from the vessel,
the cells rely on glycolysis. The glycolytic cells produce large quantities of lactate which are
consumed by cells at intermediary distances. These cells are participating in a behaviour
that we will refer to as metabolic symbiosis.
glycolysis, even in the presence of oxygen, coined aerobic glycolysis. This phenomenon
is generally referred to as the Warburg effect whereby cells rely primarily on glycolysis
even in the presence of sufficient oxygen to perform respiration [22]. There is a perceived
inefficiency of this metabolic strategy, namely the dramatically reduced ATP yield, just
2 per glucose instead of 29, however, it has the benefits of faster ATP production and
it is likely that much of this glucose is being consumed for proliferative [23] (e.g. by the
pentose phosphate pathway) purposes. In addition to the typical glycolytic phenotype
exhibited in many cancers, there is also a developing story of a co-operative relationship
existing between aerobic and anaerobic cancer cells. The lactate necessarily produced
by glycolytic cells is being pushed back into the respiratory cycle by being converted
into pyruvate (summarized in [142, 143]); this spatial relationship is shown in Figure 5.1.
Lactate consumption has been observed in vitro in various models [144, 145] as well as in
vivo as early as the early 80s [26]. However, a renewed interest in the topic was piqued when
Sonveaux et al. [27] showed that reducing lactate uptake by cancer cells led to hypoxic cell
death, a particularly difficult subpopulation to target using traditional methods.
Metabolic phenomena have been studied in great detail by mathematical models, but
models of tumour metabolism rarely include the interaction of the transport mechanisms
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of microvessels with the localized metabolic behaviour of cells. In the section to follow,
we will develop a mathematical model that describes the concentrations of molecules that
are important to cellular metabolism in the tissue around a single three-dimensional vessel
that exhibits diffusion-dominated interstitial transport. We will then use this model to
demonstrate how the properties of the tumour cell population, such as glucose, lactate
and oxygen consumption rates, affect hypoxia and ATP production around a single vessel.
The effects of metabolic inhibitors will be investigated by parameter changes that could be
elicited by the application of glycolysis inhibitors, lactate dehydrogenase (LDH) inhibitors
or respiratory inhibitors. We are interested in those metabolic inhibitors that could cripple
the cells’ ability to produce ATP. Furthermore, these micrometer scale predictions give an
indication of local shifts in cell metabolism, which could aid in developing combination
treatments that can simultaneously hinder multiple metabolic pathways in tumours. Our
simulations show that treatments targeting glycolysis via glycolytic enzyme inhibition or
LDH inhibition, which have been thoroughly investigated [146, 147, 148], could be the
most successful metabolic suppression strategy.
5.2 Mathematical model
A model to describe the concentrations of the major players in the metabolic pathways
of respiration and glycolysis, will be outlined here. Its origins lie in a metabolic model
developed by Casciari et al. [3] that was subsequently applied on the microscale by [25].
The functional forms for the production rates are similar to those proposed by Mendoza
et al. [90].
In hypoxic and anoxic conditions, cells must partially or exclusively rely on metabolic
pathways, such as glycolysis, that do not require oxygen for ATP production. In glycolysis,
the preliminary stage of respiration, a single glucose molecule (C6H12O6) yields 2 ATP,
which we will denote under the reaction arrow with a boxed ATP yield number, with the
byproducts of lactate and a proton. Denoting glucose by G and lactate by L−(C3H5O−3 ),
the net reaction is
G
kG
GGGGGGA
2
2L− + 2H+, (5.1)
where kG (mM/s) is the rate of glucose consumption by glycolysis that results in lac-
tate formation. The accumulation of these hydrogen ions in a solid tumour is a primary
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contributor to tumour acidosis.
In the presence of oxygen (O2), glycolysis is typically followed by the rest of the respi-
ratory process with an ideal energy yield of approximately 29 ATP molecules with carbon
dioxide (CO2) and water (H2O) as the only byproducts. The constituent reactions can be
found in C.4 and the simplified summary reaction is
G + 6O2
kO
GGGGGGA
29
6CO2 + 6H2O, (5.2)
where kO is the rate of glucose consumption that results in cellular respiration.
To represent the metabolic symbiosis between cells primarily producing energy via
glycolysis and those consuming lactate in well-oxygenated areas, we will link the above
two reactions with the lactate-consuming net reaction
L− + H+ + 3O2
kL
GGGGGGA
13.5
3CO2 + 3H2O, (5.3)
where kL is the rate of lactate consumption. This summarizes the re-entry of lactate, via
conversion to pyruvate, into aerobic respiration that yields 13.5 ATP per lactate molecule.
The relationships between the summary reactions included in the model are given in Figure
5.2. For details on the omitted intermediary steps and derivations of these summary
reactions and ATP yields, see C.4.
Under the strictest assumptions, the only chemical species required for a mathematical
model are the three substrates required for the metabolic pathways in (5.1), (5.2) and (5.3).
We denote the concentrations of oxygen, lactate− and glucose in the extracellular space
by X = O, L, G, respectively, and their consumption rates per unit volume are denoted
by QX . These extracellular concentrations are modelled by conservation equations of the
form
∂X
∂t
+∇ · JX +QX = 0,
where JX is the flux of species X. In general, the flux can be given as a sum of convective,
migratory and diffusive elements. Due to the small molecular sizes of the molecules consid-
ered here, their transvascular and interstitial transport are diffusion-dominated. On larger
spatial scales, convection becomes an important transport mechanism for large molecules
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Figure 5.2: The summary reactions included in the metabolism model.
but since we are dealing only with the interstitial fluid pressure generated by a single mi-
crovessel, and the molecules are sufficiently small, convection is excluded here (as it was
in [25]). The migration of charged particles due to the presence of an electric field will
also be omitted since its contribution to the flux of lactate is minimal and requires the
addition of other charged molecules (e.g. protons, sodium, chlorine, etc.) to the model
in order to ensure electroneutrality. Assuming the simplified flux is given by Fick’s law
JX = −DX∇X, where DX is an effective diffusion coefficient in the tissue and that all
species have reached steady state, gives
DX∇2X = QX . (5.4)
In cylindrical coordinates, corresponding to the tissue outside of a vessel, the system of
equations is
DX
1
r
d
dr
(
r
dX
dr
)
= QX , X = G,L,O, (5.5)
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where the consumption rates will be discussed below.
The appropriate boundary condition at the vessel wall must ensure that the diffusive
flux in the interstitial space outside of the vessel is equal to the fluid flux across the
vessel wall, however, a simplified version of this boundary condition can be used which
corresponds to high vascular permeability, where the perivascular concentration and vessel
concentration are assumed equal: X(ω+) = VX . The far-field boundary condition at the
penetration depth (r=Ω)
dX
dr
∣∣∣∣
r=Ω
= 0, (5.6)
assumes that there is zero flux of the molecular concentrations far from the vessel. See C.1
for further information on the boundary conditions.
The consumption rates of glucose, lactate and oxygen are empirically formulated func-
tions of their concentrations that are capable of capturing the behaviour of multiple
metabolic behaviour regimes. Many have been proposed in the literature, those provided
in [65, 89] form a sample. The production rates given below are motivated by taking a
minimalist approach to the choice of functional forms with fewer parameters than previ-
ous propositions [25] that encompass previous models ([90]) yet capture many metabolic
regimes. Assuming that oxygen, glucose and lactate are present only in metabolic path-
ways, their consumption rates can be expressed in terms of the rates of the metabolic
reactions (5.1), (5.2) and (5.3): kO, kG and kL. Indeed, we have
QO =6kO + 3kL,
QL =kL − 2kG,
QG =kO + kG.
These three observations together yield the equation,
QG =
1
6
QO − 12QL, (5.7)
a strict relationship between the three consumption rates. We will now proceed with
formalizing these rates by formulating expressions for kO, kG and kL in order to obtain the
consumption rates. Note that an alternate approach could formulate expressions for only
two of QO, QG and QL and then use (5.7) for the remaining consumption rate. The latter
method is not plausible unless additional molecules are added to the model, specifically
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pyruvate, the molecular hub of these rates.
To establish kG, the rate of glycolysis that results in lactate production, above and
beyond the rate required as the pyruvate-producing preliminary step of respiration, we
must consider encompassing both normal cell behaviour and cancer cell behaviour. One
of the noted key differences between these cell types is the well-known Warburg effect
whereby cancer cells consume much more glucose, and preferentially utilize glycolysis even
in the presence of sufficient oxygen for respiration, a process dubbed aerobic glycolysis.
We propose the form
kG = BG
G
G+ ΛOO +KG
,
where BG is the maximal rate, KG is the half-maximal concentration (in the absence of
oxygen) and ΛO is a novel parameter that can inhibit superfluous glycolysis in the pres-
ence of sufficient oxygen to produce ATP. In cancer cells exhibiting the Warburg effect
this parameter would be relatively small, as the glycolytic flux would be highly elevated
regardless of oxygen concentration, while in normal cells or cancer cells that do not prefer-
entially utilize aerobic glycolysis this parameter value would be relatively large, effectively
inhibiting glycolysis until hypoxic conditions are encountered.
For glucose and lactate-fuelled respiration we use a basic Michaelis-Menten expression
to express the dependence on oxygen concentration and a competitive expression to include
the proportion that is glucose-fuelled and lactate-fuelled. These rates are
kO = BO
(
ΛGG
ΛGG+ ΛLL+ ΓG
)
O
O +KO
, (5.8)
kL = BL
(
ΛLL
ΛGG+ ΛLL+ ΓL
)
O
O +KO
, (5.9)
respectively. The Michaelis-Menten half-maximal concentration for oxygen is KO, the
maximal rates for glucose and lactate consuming cells are BO and BL respectively, the
preference of cells to utilize glucose or lactate in respiration is parameterized by ΛG and
ΛL, and to ensure that these expression are defined near (L,G) = (0, 0), ΓG and ΓL are
constants that correspond to half-maximal rates in the absence of the other fuel (these will
be set to zero later but for generality are included here).
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In summary, the consumption rates of the species in the model are:
QO =
(
6BO
ΛGG
ΛGG+ ΛLL+ ΓG
+ 3BL
ΛLL
ΛGG+ ΛLL+ ΓL
)
O
O +KO
, (5.10)
QL = BL
(
ΛLL
ΛGG+ ΛLL+ ΓL
)
O
O +KO
− 2BG G
G+ ΛOO +KG
, (5.11)
QG = BO
(
ΛGG
ΛGG+ ΛLL+ ΓG
)
O
O +KO
+BG
G
G+ ΛOO +KG
. (5.12)
Clearly these rates satisfy the aforementioned relation (5.7): QG = QO/6−QL/2.
In order to utilize the model, we require estimates of the diffusion coefficients and
vessel concentrations of the aforementioned molecular species along with the parameter
values contained in the functional forms for oxygen consumption (respiration) and lactate
production (glycolysis). The sheer volume of necessary parameters can be dramatically
reduced by first nondimensionalizing the system. This is a useful process for computational
and analytical reasons.
We can also rewrite the system of equations in a way more conducive to gaining some
analytical traction and simpler parameter estimation. Since the production rates of oxygen,
glucose and lactate satisfy the relation QG = QO/6 − QL/2, we can replace one of the
equations for these individual species with this relation, which we will evolve into a simpler
formula below. For concreteness we will omit the diffusion-reaction equation for glucose
and retain the equations for oxygen and lactate in the nondimensionalization below.
Nondimensionalizing concentrations by their vessel concentration VX , i.e. setting X =
VXx, and nondimensionalizing space by dividing the spatial variable r by a characteristic
length of r˜ = 1 µm (but not changing its notation), gives the nondimensional system:
1
r
d
dr
(
r
do
dr
)
=
(
6βo
g
g + λ`+ γg
+ 3
β`α`
αo
`
g/λ+ `+ γ`
)
o
o+ κo
, (5.13)
1
r
d
dr
(
r
d`
dr
)
= β`
(
`
g/λ+ `+ γ`
)
o
o+ κo
− 2βg
α`
g
g + δo+ κg
, (5.14)
1
r
d
dr
(
r
dg
dr
)
=
αo
6
1
r
d
dr
(
r
do
dr
)
− α`
2
1
r
d
dr
(
r
d`
dr
)
, (5.15)
where αx = dxvx (dx = DX/DG, vx = VX/VG), βx = BX/(DXVX), λ = Λv` (Λ = ΛL/ΛG),
δ = ΛOvo, κx = KX/VX and γx = ΓX/(VXΛX). In addition to these equations, we also
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require the nondimensional version of the vessel boundary conditions, namely, x(ρ) = 1,
where ρ = ω/r˜; the far-field boundary condition is essentially the same:
dx
dr
∣∣∣∣
r=P
= 0, (5.16)
where P = Ω/r˜.
First, integrating (5.15) over (r, P ) and enforcing the far-field boundary condition (5.16)
gives
dg
dr
=
αo
6
do
dr
− α`
2
d`
dr
. (5.17)
Now integrating the equations once more, this time over (ρ, r), and using the vessel bound-
ary condition gives
g(r) = 1− αo
6
(
1− o(r))+ α`
2
(
1− `(r)). (5.18)
This expression for glucose enables a simpler system to solve numerically for `(r) and o(r).
These solutions also hold in a Cartesian geometry, as was considered by Molvian et al. [25]
to correspond to the geometry of window chambers used by Helm et al. [5]. See C.2 for
additional details.
To calculate the ATP turnover rate, an analysis of the stoichometry of all the involved
processes at physiological pH is required. For glycolysis, 2 ATP are produced while for the
full process of respiration including glycolysis, approximately 29 ATP are produced [20],
see C.4 for summary biochemical reactions. This ATP yield is less than the yield assumed
by previous models, e.g. [65] assumed the classical 38, [25] assumed an intermediary 36,
while [63] assumed 32; these are all more than the accepted ideal yield of approximately
29 [20]. While this accepted value will be used to generate the results that follow, I have
also calculated a novel estimate of 24.25 ATP/glucose based on the reactions contained in
C.4. The discrepancy arises from the uncertainty associated with the efficiency of ADP
phosphorylation and processes such as ATP and pyruvate transport that effect the elec-
trochemical gradient across the inner mitochondrial membrane. Most significantly, the
multiple protonated states of phosphate, which is critical to intercellular buffering is in-
cluded in the summary reaction for phosphate transport across the inner mitochondrial
wall. The results calculated below have all been recalculated using this novel estimate in
C.6.
In terms of the reaction rates for the processes considered here for glycolysis (kG),
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glucose-fuelled respiration (kO) and lactate-fuelled respiration (kL), the production rate of
ATP PATP is given by:
PATP = 2kG + 29kO + 13.5kL. (5.19)
The total production rate in the tissue space is characterized by the normalized value
Φ =
∫ P
ρ
PATP rdr. (5.20)
The total production rate is the triple integral over a unit of tissue defined by a uniform
cylindrical annulus of height ∆z with inner radius ρ and outer radius P , so the parameter
of interest is normalized by 2pi∆z. This value is used to indicate the relative contributions
of the metabolic pathways.
5.2.1 Parameter estimation
There is no single study that has measured the apparent diffusion coefficients of oxygen,
glucose and lactate in the same type of tissue. In general, these apparent diffusion coef-
ficients may exhibit spatial-dependence due to changes in temperature, tissue properties
and molecular concentrations but for simplicity, we have assumed that they are constant
in the tissue surrounding a blood vessel. The diffusion coefficients will remain fixed for
the simulations presented here and were chosen for consistency with previous modelling
attempts (e.g. [64, 3, 25, 65, 63, 89]); they are given in Table 5.1 along with the other
model parameters.
The base case for vessel concentrations considers a slightly hypoglycaemic condition of
2 mM since glucose consumption is highly upregulated in tumours. For reference, a normal
fasting concentration of glucose is approximately 5 mM. It would be reasonable to consider
hyperglycaemic conditions that could arise locally in a tumour but for simplicity we will
neglect this consideration in the present study. For lactate we consider an elevated level of
2mM since cancer cells are performing increased glycolysis. If it is being consumed as the
primary respiratory fuel, it could be lower. A normal resting level is 1 mM of lactate. The
oxygen concentration will be taken to be consistent with the hypoxic conditions measured
by Helmlinger et al. [5]. They found the average partial pressure of oxygen in the tumour
vessel to be 13.5 mmHg [5]. Henry’s Law relates this partial pressure to the molar concen-
tration via a proportionality constant, known as the solubility coefficient, denoted by SO
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Parameter Value Units Reference
ω 11.5 µm [149]
Ω 401.5 µm [25]a
VO 1.43×10−2 mM [5]
VL 2 mM [25]
VG 2 mM this work
DO 1820 µm
2/s [116]
DL 177 µm
2/s [3]
DG 105 µm
2/s [105]
KO 2×10−4 mM [25]
KG 5.0×10−2 mM [25]
BO 2.32×10−4 mM/s this workb
BL 4.63×10−4 mM/s this workb
BG 2.8×10−3 mM/s this workc
ΛO 4×103 - this work
Λ 1 - [90]
ΓL 0 mM this work
ΓG 0 mM this work
Table 5.1: Fixed parameter values for physiological, molecular and metabolic parameters
for the ‘base case’ simulation.
a 401.5 is chosen for numerical convenience (400 was used in [25]). Evidence for steady
state achieved at this distance is given in [5] where oxygen and pH have reached steady
state.
b Numerical fit based on data from [5]. Details in C.3. These values satisfy 6BO = 3BL =
pO.
c This maximum glucose consumption rate is assumed to be approximately 3 × pO, the
maximum oxygen consumption rate. This is similar to the relationship that exists between
consumption rates in [4].
(mM/mmHg). At 37◦ C the solubility of oxygen of DS-carcinosarcoma in the rat kidney
is SO = 1.05× 10−3 mM/mmHg [117]; this yields VO ≈ 1.43× 10−2 mM.
The consumption and production rate parameters are typically varied over large ranges
as is commonly done since these can vary widely depending on the tumour type, e.g. [90].
However, we will enforce one condition to remain consistent with the oxygen profiles in [5].
Performing a least squares fitting to this spatial data, the maximum oxygen consumption
rate is approximately pO = 1.39 × 10−3 mM/s, the details are outlined in C.3. We will
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utilize this value to fix BO and BL, the maximum consumption rates of glucose-fuelled and
lactate-fuelled respiration respectively. We will ensureQO ≤ pO by taking pO = 6BO = 3BL
which implies that the maximal oxygen consumption rate is the same regardless of whether
lactate or glucose is the respiratory fuel. There are cancer cell lines, namely SiHa cervix
cancer cells [27] and C6 glioma cells [150], which have been shown to temporally obey the
relation 2BO = BL [90]; there are others where BO ≈ BL (e.g. WiDr colon cancer cells
[27]) or 3BO ≈ BL (e.g. LN18 and LN229 glioblastoma cells [151]) [90].
While the system given above is widely applicable, it can be argued that in the interest
of further parameter reduction, the constants γg and γ` are superfluous in this scenario
where ` never approaches zero. Thus, we will take γg = γ` = 0. This reduces our nondi-
mensional parameters to a total of 10.
5.3 Results and discussion
5.3.1 Base case
We will first examine how our model captures the behaviour of metabolic symbiosis in tu-
mours. Using the parameters given in Table 5.1, we numerically solve the nondimensional
system given by (5.13) and (5.14). The corresponding glucose concentration is found by
using the explicit formula (5.18). The solutions for the nondimensional oxygen, lactate
and glucose concentrations are given in Figure 5.3. The oxygen concentration decreases
to anoxic values approximately 100 µm away from the vessel as expected. The glucose
concentration also decreases as it is consumed by respiratory cells near the vessel and then
predominantly consumed by glycolytic cells further from the vessel. The lactate concen-
tration increases over double its vessel concentration as it is produced by glycolytic cells
at a much higher rate than it is consumed by lactate-fuelled cells. These observations are
complemented by consideration of their consumption rates shown in Figure 5.4. Oxygen
is consumed for the first 150 µm outside of the vessel and as it decreases you can clearly
see the glucose consumption rate ramp up in response to increased glycolytic activity. The
lactate consumption rate is negative (implying production) everywhere except for directly
adjacent to the vessel where there is very little glycolysis occurring. The positive contribu-
tion of lactate consumption to the total consumption rate is washed out as the glycolytic
production rate is much higher. The energetic landscape of the base case considered here
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Figure 5.3: Solution to base case boundary value problem. Nondimensional oxygen and
glucose concentrations decrease due to consumption. Lactate increases to almost double its
vessel concentration since it is produced by glycolysis at a higher rate than it is consumed
by respiration due to a limiting oxygen concentration. This image has been spatially
truncated to 300 µm since the concentrations are approximately constant after this point.
are given in Figure 5.5 where the contributions of the three cell populations’ metabolic
pathways are given as areas under the total ATP turnover rate. Glycolysis dominates
the total ATP production in hypoxic and anoxic regions while glucose-fuelled respiration
occurs sparingly near the blood vessel. The lactate-fuelled cell population, sandwiched
between these glucose consuming cells are utilizing the byproduct of the glycolytic cells
while there is still sufficient oxygen. Before analyzing the effects of parameter changes we
will note that the ATP production profile just described is a function of radial distance.
When considering the total ATP turnover rate of the whole tissue, those regions further
away from the vessel contribute much more than those close to the vessel. This is reflected
in the first bar of the graph given in Figure 5.8 where the total amount of ATP turnover
by respiratory cells is more accurately represented after integrating over the whole tissue.
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Figure 5.4: Consumption rates of oxygen, lactate and glucose for the concentrations given
in Figure 5.3. The glucose and oxygen consumption rates are strictly positive while the
consumption rate of lactate is predominantly negative. This indicates that even in regions
where lactate is being consumed, it is being produced at a higher rate by glycolysis.
5.3.2 Warburg effect
In the base case considered above glycolysis is inhibited until the oxygen consumption
drops to values that prevent the production of sufficient ATP to maintain cell survival.
However, cancer cells will commonly utilize glycolysis as a primary energy source even
when there is enough oxygen to ensure cell survival. In the model we characterize the
cell’s ability to hold off on utilizing glycolysis in oxygenated areas by the parameter ΛO.
Reducing it 400-fold from the base case above (from 4000 to 100) results in spatial ATP
turnover rate as given in Figure 5.6. Cells near the vessel greedily consume the available
resources leaving cells further from the vessel to die from insufficient ATP supply. The
ATP production breakdown corresponds to the second bar in Figure 5.8 and is slightly
higher than the whole tissue considered in the base case above.
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Figure 5.5: The base case for ATP turnover (consumption/production) rates corresponding
to consumption rates given in Figure 5.4. The contributions of the pathways are bounded
by the total ATP turnover rate PATP . Glycolysis dominates in hypoxic/anoxic regions
while glucose-fuelled respiration occurs sparingly near the blood vessel. Lactate-fuelled
cells are consuming the byproduct of the glycolytic cells where there is oxygen present.
5.3.3 Optimal metabolic behaviour
Instead of fixing all of the parameters to the values given in Table 5.1, we could leave some of
the parameters free and optimize the amount of ATP generated from the given metabolites
by imposing a maximum constraint on ATP production. For instance, setting all of the
parameters initially to those given in Table 5.1, and then minimizing some function of
Z = PATP − θ where θ is the maximum allowed ATP turnover rate. Allowing cells to
alter their consumption rates βo, βg and β`, along with the glycolytic trigger parameter
δ gives the results shown in Figure 5.7. In this simulation θ was set to 7 × 10−3 mM/s
and the minimized function was f(Z) = Z2. While there was still enough constraint that
the system still exhibited a non-constant ATP turnover where it could, this reinforces the
suggested optimal strategy of glucose-fuelled respiration near the vessel, glycolysis far from
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Figure 5.6: ATP turnover (consumption/production) rates for cells exhibiting the Warburg
effect (differs from base case because ΛO = 100 instead of 4000). The contributions of the
pathways are bounded by the total ATP turnover rate PATP . Glycolysis is dominant in all
regions of the tumour. Glucose-fuelled respiration occurs sparingly near the blood vessel.
Lactate-fuelled cells are consuming the byproduct of the glycolytic cells where there is
oxygen present.
the vessel and a lactate-consuming population in between these two.
5.3.4 Cancer treatment effects
The mathematical model presented here can give insight into the effects of blocking various
metabolic pathways. The three metabolic pathways that we have considered, namely
(i) glucose-fuelled respiration, (ii) lactate-fuelled respiration and (iii) glycolysis, could be
inhibited by various agents, and the effects on ATP production will be outlined below.
Entirely knocking out lactate metabolism could be achieved by inhibiting lactate dehy-
drogenase (LDH) which is responsible for the reentry of lactate into respiratory pathways
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Figure 5.7: The optimal metabolic behaviour on the microscale given an ATP turnover
maximum of θ = 7 × 10−3 mM/s. This shows glucose-fuelled respiration near the vessel,
glycolysis far from the vessel and a lactate-consuming population in between these two.
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Figure 5.8: The ATP turnover contributions of the pathways are bounded by the total
ATP turnover rate Φ in a unit annulus of tissue. This more accurately represents the total
contribution of each cell population to metabolism. From left to right the bars denote
the following cell populations: 1. Base case: Tissue that exhibits lactate consumption
in hypoxic conditions with parameters in Table 5.1, see Figure 5.5. 2. Warburg effect:
Tissue utilizing aerobic glycolysis, see Figure 5.6. 3. Glycolytic knockdown: Tissue
experiencing complete glycolytic inhibition. 4. LDH inhibitor: Tissue experiencing com-
plete LDH inhibition. 5. Respiration knockdown: Tissue experiencing mitochondrial
inhibition with glycolysis repression by oxygen. 6. Respiration knockdown and War-
burg effect: Mitochondrial inhibition with aerobic glycolysis. If either of the reactions
which block glycolysis are knocked out, glycolysis (3) or LDH inhibitors (4), the total ATP
produced is diminished (Φ < 50). If on the other hand respiration is inhibited then either
(i) if oxygen represses glycolysis there is minimal ATP production (5), or (ii) if glycolysis
is independent of oxygen concentration there is an intermediary amount of ATP produced
(6).
by converting it into pyruvate, see (C.15) for the reaction. Successful inhibition would
concurrently prevent the conversion of pyruvate to lactate as well, a crucial step for re-
generating NAD+ in glycolytic cells. This has been shown to reduce ATP levels and
consequently induce cell death in tumours [152]. The complete inhibition of lactate de-
hydrogenase would eliminate two of the three pathways considered here: lactate-fuelled
respiration and glycolysis. Complete inhibition can be reflected in the model by setting
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BL = 0 and BG = 0, leaving only glucose-fuelled respiration to produce ATP, a physiolog-
ically normal condition. However, the hypoxic and hypoglycaemic conditions considered
here do not leave enough fuel for cell survival. This scenario corresponds to the third bar
in Figure 5.8.
We could also target glucose transport into the cell, an intermediary of glycolysis or
one of the critical enzymes responsible for converting glucose to pyruvate. This is distinct
from the strategy noted above of inhibiting LDH which prevents the conversion of lactate
to pyruvate and vice versa. This has also been noted as a prime target for cancer therapy
[146, 147] and there are currently many potential targets [148]. Here we will consider the
shutdown of glycolysis as preventing both glucose-fuelled respiration and glycolysis since
both of these require glucose to be converted into pyruvate. However, it leaves the lactate-
fuelled respiratory pathway intact. This could be considered in the model by taking BO = 0
and BG = 0. Similar to the case of LDH inhibition this leads to a significant decrease in
ATP production as shown in the fourth bar of Figure 5.8.
The final scenario that we consider corresponds to full inhibition of respiration some-
where along the chain between pyruvate transport into the mitochondria and the electron
transport chain. There are numerous potential targets in the mitochondria [153] and we
will consider the complete shutdown of respiration by setting BL = 0 and BO = 0. This
would result in negligible oxygen consumption and with our base case of ΛO = 400 this
would lead to repressed glycolysis in the tissue. This is likely a non-physiological scenario
since glycolysis would attempt to compensate for a lack of ATP production but it would
lead to heavily reduced ATP production. If glycolysis was able to compensate for the lack
of respiration, represented in the model by reducing ΛO to 100, then the tissue could still
produce a significant amount of ATP. This indicates that in a hypoxic microenvironment,
commonly found in tumour tissue, the complete inhibition of respiration would still allow
the tumour energy supply to be maintained by glycolysis alone.
We could also consider the effects of theoretical single knockdowns in the model by
setting one of the parameters to zero at a time (results not shown). Inhibiting just one
of the respiratory pathways had negligible effect on the total ATP production (in both
the base case and Warburg case) since the other fuel compensated. If glycolysis alone is
inhibited, the respiration is split between lactate and glucose-fuelled and the total ATP is
similar to the amount produced during LDH inhibition or glycolytic inhibition (bars 4 and
5 respectively).
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5.4 A model for metabolism and acidity
Here we will utilize the model for interstitial fluid pressure formulated for a single vessel
in [71] (see Section 3.1.1 for a summary) to add convective transport to a pH microvessel
model [25] (see Section 3.4.2). This model assumed a two-dimensional region in Cartesian
coordinates to correspond with the experimental setup in [5], namely transparent dorsal
window chambers implanted in mice that contained human colon adenocarcinmoa. Firstly,
we see if the predicted plateau is robust enough to occur in a more appropriate geometry
corresponding to an in vivo tissue: a three-dimensional cylindrical vessel with diffusive
and convective transvascular transport. We also want to consider effects that could be
induced by cancer treatments, such as decreased vessel permeability and increased oxygen
concentration by the application of antiangiogenic agents or increased ratio of respiration
to glycolysis caused by glycolysis inhibitors.
Before adding convection we will first consider the model with glucose-fuelled respiration
and glycolysis (production rates given in Table B.4) are the included metabolisms and they
are coupled to the bicarbonate buffering system [3]. A diagram of the model is provided
in Figure 5.9, showing the extracellular species included in the model and the direction of
their diffusive transport. Also shown are the intracellular metabolism reactions and ATP
yields.
Collecting the system of steady-state equations for the pertinent molecular species
derived in Section 3.4.1, we have
DO
d2O
dr2
= QO, (5.21)
DG
d2G
dr2
= QG, (5.22)
DL
d2L
dr2
= QL, (5.23)
DC
d2C
dr2
= −krBH + kfC, (5.24)
DB
d2B
dr2
= krBH − kfC −QO, (5.25)
DH
d2H
dr2
= krBH − kfC −QO +QL, (5.26)
where QL = QO/3− 2QG, and QG and QO are empirical formulas relating the concentra-
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Figure 5.9: The metabolism and pH model diagram showing extracellular species direction
of diffusive transport and buffering, along with the intracellular metabolism, ATP yields
and buffering.
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tions of glucose and oxygen (and possibly pH) to their consumption rates. The boundary
condition at the vessel wall (r = ω) is
−DX dX
dr
∣∣∣∣
r=ω
= µX(VX −X0), (5.27)
where X0 = X(ω) ensuring equality of fluxes at the interface between blood and tissue,
while at the penetration depth (r = Ω)
dX
dr
∣∣∣∣
r=Ω
= 0, (5.28)
which assumes that the concentrations have reached a steady state equilibrium concentra-
tion.
5.4.1 Parameters
We require estimates of the diffusion coefficients, vessel concentrations, vessel permeabili-
ties and buffering reaction rates of all the molecular species mentioned above along with
functional forms and parameter values for oxygen consumption (respiration) and lactate
production (glycolysis). The values for oxygen, glucose and lactate diffusion coefficients are
provided above in Table 5.1. Those for the molecules necessary for including bicarbonate
buffers along with vessel concentrations and permeabilities are found in Table B.5 and the
metabolic parameters are found in Table B.4.
For blood vessel concentrations, we assume that the concentrations of the molecules
involved in the primary buffering reaction (3.44) are in equilibrium and thus,
VBVH
VC
=
kf
kr
= K.
Based on a pK of 6.12 [154], this gives K ≈ 7.6 × 10−4 mM. In normal vessels pH typi-
cally ranges from 7.35–7.45 with the higher end of this range usually occurring in arteries
while the lower end is observed in veins. pH values above this range imply alkalosis has
set in while values below this indicate acidosis, a characteristic commonly observed in
tumour vessels, e.g. tumour pH near a microvessel of approximately 7.25 [5]. The vessel
measurement corresponds to VH ≈ 4 × 10−5 mM, so we must have VB/VC ≈ 20. Vessel
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concentrations of bicarbonate typically lie in the range of 18–23 mM , and thus carbon
dioxide lies in the range of 0.75–1.25 mM. As noted above these blood vessel observations
along with these species diffusion coefficients are given in Table B.5.
5.4.2 Analytical observations
Before considering the effects of altering geometries and molecular transport, I will consider
some analytical ramifications of the model in its present form.
I will know rewrite the system (5.21)-(5.26) in a way more conducive to eliminate one of
the diffusion-reaction equations in a similar fashion to the three species system above. Since
the consumption rates of oxygen, glucose and lactate satisfy the relation QL = QO/3−2QG,
we can replace one of (5.21)-(5.23) with this relation; for simplicity we omit (5.22) since
QL and/or QO are present in (5.25) and (5.26). Assuming that we know O(r) and thus
QO, along with L(r) and thus QL, allows us to derive some useful relations in terms of
these concentrations.
Adding (5.24) and (5.25) gives
DC
d2C
dr2
+DB
d2B
dr2
+DO
d2O
dr2
= 0,
while subtracting (5.25) and (5.26) gives
DB
d2B
dr2
−DH d
2H
dr2
+DL
d2L
dr2
= 0,
both useful relations since we can simply integrate over the spatial variable twice to elim-
inate derivatives in this equation. Finally, we retain (5.26) to close the system for reasons
that will become evident in what follows. Nondimensionalizing concentrations by their
vessel concentration VX , i.e. setting X = VXx and formally nondimensionalizing space by
dividing the spatial variable r by a characteristic length of 1 µm (but not changing its
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notation), gives the non dimensional system:
d2o
dr2
= Qo, (5.29)
d2`
dr2
= Q`, (5.30)
d2`
dr2
=
αo`
3
d2o
dr2
− 2αg`
d2g
dr2
, (5.31)
d2b
dr2
= αhb
d2h
dr2
− α`b
d2`
dr2
, (5.32)
d2c
dr2
= −αbc
d2b
dr2
− αoc
d2o
dr2
, (5.33)
d2h
dr2
=
krVB
DH
bh− kfVC
DHVH
c− αohQo + α`hQ`, (5.34)
where αyx = d
y
xv
y
x, d
y
x = DY /DX , v
y
x = VY /VX and Qx = QX/(DXVX). In addition to
this system, we also require the non dimensional version of the vessel boundary condition
(5.27), namely,
−dx
dr
∣∣∣∣
r=ω
= µx(1− x0), (5.35)
where x0 = x(ρ) and µx = µX/DX ; the far-field boundary condition is essentially the same:
dx
dr
∣∣∣∣
r=Ω
= 0. (5.36)
First, integrating (5.31)-(5.33) over (r,Ω) and enforcing the far-field boundary condition
(5.36) gives
d`
dr
=
αo`
3
do
dr
− 2αg`
dg
dr
, (5.37)
db
dr
= αhb
dh
dr
− α`b
d`
dr
, (5.38)
dc
dr
= αbc
db
dr
− αoc
do
dr
. (5.39)
Before integrating again, it is worth noting that by applying (5.35) and rearranging the
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previous equalities at r = ω yields
`0 =1− β
o
`
3
(1− o0) + 2βg` (1− g0), (5.40)
b0 =1− βhb (1− h0) + β`b(1− `0), (5.41)
c0 =1 + β
b
c(1− b0) + βoc (1− o0). (5.42)
where βyx = µ
y
xV
y
x and µ
y
x = µY /µX . Now integrating the equations once more, this time
over (ω, r), gives
`(r) = `0 − α
o
`
3
(
o0 − o(r)
)
+ 2αg`
(
g0 − g(r)
)
, (5.43)
b(r) = b0 + α
h
b (h(r)− h0)− α`b(`(r)− `0), (5.44)
c(r) = c0 + α
b
c
(
b0 − b(r)
)
+ αoc
(
o0 − o(r)
)
(5.45)
= c0 − αhc (h(r)− h0) + α`c(`(r)− `0) + αoc
(
o0 − o(r)
)
.
As a consequence of (5.36), the steady state concentrations satisfy h(Ω)b(Ω)/c(Ω) = 1.
Thus in order to achieve a steady state concentration of h(Ω) = h∞ we must have,
h∞ =
c0 − αhc (h∞ − h0) + α`c(`∞ − `0) + αoco0
b0 + αhb (h∞ − h0)− α`b(`∞ − `0)
,
where `∞ = `0 − αo`o0/3 + 2αg`g0. This expression gives the far-field acidity for the system
as a function of vessel concentrations and diffusion coefficients .
5.5 Convective transport in a metabolism model
Adding convective transport to (3.56) gives the equation
∂X
∂t
=
DX
r
∂
∂r
(
r
∂X
∂r
)
− ri1
r
∂
∂r
(ruX) + PX . (5.46)
where ri is the retardation coefficient of species i. Typically, we assume that each solute
travels at the same velocity as the fluid and thus take ri = 1 [75]. Again, the production
rates PX are given in Table B.4 while the diffusion coefficients DX are given in Table B.5.
The analytical solution for IFV u is given in 3.9. Expanding the convection term and
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noting that du/dr = −u/r yields
DX
r
d
dr
(
r
dX
dr
)
− riudX
dr
+ PX = 0.
The boundary condition at the blood vessel wall ensures the equality of the flux of
solute through the vessel wall (3.28) with the flux through the interstitial space (3.21)
giving
rfuX −DX dX
dr
= µ(VX −X) PeX
ePeX − 1 +
Jf
S
(1− σi)VX at r = ω. (5.47)
We also require the concentrations to reach a steady state as we move away from the vessel
and take
dX
dr
= 0 at r = Ω, (5.48)
where Ω is the penetration depth [71], a distance far enough from the microvessel to
justify the assumption that the system has reached steady state but close enough to ensure
minimal contributions from other nearby vessels. This is more practical than the ‘far field’
boundary condition in (3.60) [25] since numerically we will be forced to consider a finite
spatial domain
Given the fluid flux Jf (determining the solute flux (3.5)), we can solve the coupled
system of oxygen and glucose. Using these we can then solve for the system governing
bicarbonate, carbon dioxide and hydrogen ions. Finally we determine the acidity using the
relation pH=− log10(H).
First, we notice that the plateau is still observed in this three-dimensional geometry
and as presented in Figure 5.10a the addition of convection has some effect on the pH but
does not exhibit a drastic change due to the relatively low magnitude of the interstitial
fluid velocity of a single blood vessel (see the inset of Figure 5.10a) indicating that diffusion
is the dominant form of transport for such small molecules on the microscale.
As mentioned in Chapter 2, the acidic microenvironment is caused by upregulated
glycolysis. In this model the ratio of oxygen to glucose consumption is determined by the
parameter R where R = 6 corresponds to purely respiration (where 6 oxygen are consumed
and 1 glucose molecule) or all the way down to 1 which indicates that far more glycolysis is
occurring than respiration. If cells performed only respiration, the plateau in pH would be
even more pronounced since all of the oxygen is being consumed close to the vessel leading
to a sudden switch to glycolysis close to the vessel (see Figure 5.10b). As R decreases
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Figure 5.10: pH profiles.
the transition is less pronounced as cells near the vessel do not consume all of the limited
oxygen supply leaving some for cells at intermediary distances.
Vessel permeability varies drastically from normal vessels to tumour vessels and as it
increases the convective and diffusive transport of molecules are enhanced. As shown in
Figure 5.11a, high permeabilities (the tumour base case µ0) have enough oxygen crossing
the vessel wall to ensure that glycolysis does not have to take over close to the vessel while
for low values (e.g. µ0/50), there is no plateau observed since the anoxic environment
causes glycolysis to take over immediately outside the vessel. Note, that despite this latter
case corresponding to a permeability closer to a normal vessel than a tumour vessel, we are
still dealing with a tumour vessel with a very limited oxygen supply. This is reflected by
the consumption rates that decrease to the repressed metabolic phase due to intermediate
oxygen concentrations right outside the vessel wall.
Finally, we observe the effects of hypoxia and anoxia by varying the vessel concentration
of oxygen. For very low values of oxygen (e.g. VO/10), we observe the same phenomenon
as when we considered low permeability. The switch to glycolysis happens very near the
vessel whereas for our base case oxygen concentration we observe the plateau; this is shown
in Figure 5.11b. For a high oxygen concentration found in a normal tissue (e.g. 3VO) we
notice the smooth pH curve expected from a sufficient oxygen supply since the switch to a
glycolysis-dominated metabolism occurs after the steady state of pH is reached.
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5.6 Conclusions
The mathematical models formulated and analyzed above can give insight into the metabolic
behaviours of cancer cells on the microscale. The tumour microenvironment characterized
by hypoxia and nutrient depravation leads to the utilization of highly unregulated gly-
colytic pathways and the consumption by respiring cells of the lactate produced by these
cells. These metabolic scenarios are encompassed by the functional forms proposed for
glucose, lactate and oxygen consumption.
To consider the effect of altering parameters in the model to the efficiency of energy
production we must also consider the rate of ATP turnover in the tissue. To this end
a detailed biochemical summary was performed in order to calculate novel estimates for
ATP yields. These energetic landscapes were considered in tissues that utilize anaerobic
glycolysis, thus keeping more cells alive, and those that experience the Warburg effect,
performing glycolysis in oxygenated areas. The analysis shows that the latter does confer
a proliferative advantage by producing more ATP.
The effects of metabolic inhibition was taken into account by knocking out the path-
ways considered in our model. Glycolytic inhibition blocked glycolysis and glucose-fuelled
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respiration, LDH inhibition blocked glycolysis and lactate-fuelled respiration while respi-
ration inhibition blocked both forms of respiration. Both strategies that block glycolysis
lead to significant decreases in total ATP production while those that block respiration
still allow sufficient ATP for cell survival.
Of the many biochemical reactions stated above, some are tissue-dependent, pH-dependent
or are not well established in the literature. Tissue-dependency of these models has been
considered in [90], while the coupling of buffering and reactions has been considered on the
microscale and temporal models [25, 155]. The uncertainty with the reactions above is pri-
marily associated with the transmembrane transport of glucose across the cell membrane
of glucose (C.12), pyruvate and phosphate transport into the mitochondria (C.18) and
other processes that consume the electrochemical gradient in the mitochondrion. These
transport processes may be very important to accurately modelling the efficiency of tumour
metabolism.
Model extensions, including the addition of acidity and buffering mechanisms along
with convective transport in the interstitial space and across the blood vessel wall have
also been indicated. The work presented here should lead to a reconsideration of the bio-
chemical reactions that constitute metabolic mathematical models and provide a minimally
parameterized and straightforward basis for future metabolite consumption models.
113
Chapter 6
Mathematical Model for the
Sequential Application of a Cytotoxic
Nanoparticle and a PI3K Inhibitor
The previous two chapters detailed models of a solid tumour’s macroscale angiogenic re-
sponse to hypoxia and the subsequent microscale metabolism that a tumour performs.
Treatment effects were analyzed by parameter variations that corresponded to treatments.
Here, we address treatment concentrations and combinations in a specific type of solid
tumour, breast cancer. This chapter details a mathematical model that describes drug
concentrations, subsequent effects on protein expression and finally cell viability. The
model was formulated based on data obtained via close collaboration with experimental-
ists at Dr. S. Sengupta’s Laboratory for Nanomedicine at Havard Medical School. This
experimental work was the first time that the combination of nanomedicine and a molec-
ular targeted therapy was tested in vivo. The primarily goal of the mathematical model
was to establish the optimal schedule of these two therapies which was determined by min-
imizing cell viability. The majority of the results contained in this chapter were published
in Cancer Research [8].
Before launching into the layers of the mathematical models, we will summarize the
necessary medical background and specifics of the study that were not already addressed
in Chapter 2.
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6.1 Medical motivation
Paralleling the question of optimal scheduling of chemotherapy and antiangiogenic agents
to optimize treatment effects [35, 59] is the problem of optimal scheduling chemotherapy
and molecular inhibitors. In both cases the complementary therapy is attempting to max-
imize the cytotoxic effects of chemotherapy. In the work considered here, a mathematical
model was developed for a novel combination of anticancer treatments: a chemotherapy
drug encapsulated in a nanoparticle delivery vehicle and a molecular inhibitor. Combi-
nations of cytotoxic agents and molecular inhibitors have been previously considered in
leukaemia and breast cancer [156, 157] but never with the effective delivery rendered by
a nanodelivery device. These nanomedicines have many advantages over traditional deliv-
ery including preferential accumulation in the tumour via the enhanced permeability and
retention (EPR) effect [46] and their ability to spatially and temporally control their drug
release [53].
In this study, the impact of sequencing of a cisplatin-based supramolecular nanopar-
ticle with an inhibitor of phosphoinositide 3-kinase (PI3K) was studied in a cell model
that is particularly difficult to treat: triple negative breast cancer (TNBC). TNBC is
characterized by the absence of estrogen receptors, progesterone receptors and Her2/neu.
These entities are typical targets for hormonal and chemotherapy treatments. Cisplatin
has shown some success in treating TNBC [32] but the dosage is highly limited due to
toxicity, particularly of the kidneys. To counteract this the group of our collaborators
engineered a polymeric cisplatinum (II) nanoparticle, which displayed preferential tumour
accumulation, bypassed the kidney, and exhibited an enhanced antitumour efficacy com-
pared to free cisplatin [158]. However, cisplatin has another drawback, it can upregulate
PI3K signalling, which reduces the apoptotic response of cells [43]. This outcome suggests
that a rational combination of PI3K inhibitor and cisplatin nanoparticles could further
improve treatment efficacy. Indeed, experiments showed that treatment with a novel (self-
assembling) cisplatin nanoparticle (SACN) results in activation of PI3K signalling. The
motivation now is to use a mathematical model to predict the optimal treatment schedul-
ing of SACNs combined with a PI3K inhibitor called PI8282. The model will be outlined
below before showing and the validation of the results were obtained both in vitro and in
vivo. Our results reveal the treatment with SACNs followed by the administration of PI828
results in better results than pre-treatment with PI8282 or simultaneous administration.
These results indicate the appropriate sequencing of this cytotoxic nanomedicine and a
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Figure 6.1: A detailed pathway of cell apoptosis showing the interactions between the
major players in this process. Image courtesy of Dr. M. Kohandel.
molecular targeted therapeutic to achieve optimal therapeutic efficiency.
6.2 Mathematical model
The mathematical model developed here is broken up into three parts. The first part
will describe the protein expression levels of pAkt, caspase-3 and XIAP. The next will
include the treatment effects of cisplatin-NP and PI828 on protein expression. Then a
nanoparticle release model will be used to describe the release profile of the nanoparticles
measured in this study. Finally, we will propose a simple model for predicting cell viability.
The consideration of parameter estimation will come in the next section.
In addition to the three proteins mentioned above, there are many more proteins and cell
signalling pathways that encourage cell survival or cell apoptosis, summarized succinctly
in Figure 6.1. Among all of them, we only consider a select few that are critical indicators
of cell viability: pAkt, caspase-3 and XIAP. pAkt and XIAP are key cell survival factor
while caspase-3 is widely considered to be the primary indicator of imminent cell apoptosis.
The expression of these proteins can be determined experimentally by Western blotting
techniques.
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Figure 6.2: A diagram summary of the protein expression and cell viability model. (A)
The simplified apoptosis pathway including the interactions of pAkt, XIAP and caspase-
3. (B) The cell viability model where tumour cells proliferate at a rate proportional to
pAkt concentration and the death rate is proportional to caspase-3 concentration. Image
courtesy of Dr. M. Kohandel.
6.2.1 Protein expression model
Several mathematical models of varying complexity have been developed to study intrinsic
and extrinsic apoptosis [159, 160, 161]; see [162] for a review. Here, we consider a simple
model containing three critical proteins: pAkt, XIAP, and capsase-3. The effects of com-
binations of liposomal cisplatin and PI828 treatments are investigated. The basic reaction
pathways are shown in Figure 6.2.
Akt phosphorylation is induced by activated PI3K. Once activated, Akt negatively reg-
ulates apoptotic pathways at a pre-mitochondrial level by blocking the actions of proteins
such as Bad and Bax, which in turn inhibits the release of cytochrome c into the cytosol. It
has also been reported that Akt directly phosphorylates and inactivates cell death protease
caspase-9 [163]. For simplicity and to keep the number of parameters manageable, these
multiple pro-survival initiatives are considered to have the net effect of inhibiting capsase-3
production, see (1) in Figure 6.2.
It has been also reported that active caspase-3 cleaves Akt in vitro, and inhibiting
caspase-3 can block this effect [164]. Thus, a negative feedback is assumed to represent the
cleavage of Akt by caspase-3, (2) in Figure 6.2. In addition, activated Akt interacts with
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and phosphorylates XIAP, protecting it from autoubiquitination [165], (3) in Figure 6.2.
XIAP inhibits caspase-3 by the degradation of caspase-3 ((4) in Figure 6.2), and
caspase-3 inhibits XIAP through ubiquitination and degradation [166, 159, 160, 167], (5) in
Figure 6.2(A). Caspase-3 can also inhibit XIAP by inactivating XIAP through formation
of a complex [159].
To include the effect of treatment, we first note that based on our experimental data
and other studies [164, 168], cisplatin increases the production of pAkt. This activation
might be mediated through EGFR and PI3K. Similar to previous studies [164], our data
shows an increase in caspase-3 due to cisplatin. This increase could be due to activation
of FasL, which in turn activates caspase-8 and subsequently caspase-3 [169, 170]. Another
possible pathway is the release of cytochrome c, which subsequently activates caspase-9
and caspase-3 [171, 170].
In addition, phosphorylation of XIAP by Akt protects ubiquitination and degradation
of XIAP in response to cisplatin. Since we have only considered the active form of XIAP in
our model, we assume that cisplatin reduces XIAP, as observed in the experimental data.
The reduction in XIAP could be also due to increase in caspase-3. Finally, we assume that
PI828 inhibits phosphorylation of Akt by binding to P13K.
Here, we will consider the effects of the chemotherapy agent cisplatin in nanoparticles in
combination with the P13K inhibitor PI828. Cisplatin is known to increase concentrations
of caspase-3 triggering cell death but unfortunately, it simultaneously increases pAkt which
commonly leads to anti-apoptotic effects and thus lowered efficacy of cisplatin treatment
and overall chemoresistance. To counter this resistance, PI828 can be administered which
inhibits PI3K, rapidly preventing the production of pAkt. The primary goal of this mod-
elling is to determine the optimal combination of these two drugs to minimize cell viability
for appropriate ranges of treatment dosages.
We consider the effects of the aforementioned treatments, liposomal cisplatin and PI828
along with their combinations, on the select group of proteins critical to apoptosis described
above: pAkt, caspase-3 and XIAP. Denoting the dimensionless concentrations of the pro-
teins by P=[pAkt]/P0, C=[caspase-3]/C0 and X=[XIAP]/X0, where P0, C0 and X0 are
experiment-dependent scaling factors. The system of equations for the protein expression
that we will use includes the indirect mutual inhibition of pAkt and caspase-3, the di-
rect mutual inhibition of caspase-3 and XIAP, along with production, natural decay and
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treatment effects, and is given by:
dP
dt
=
kp + λpfp(t)
1 + αpC + γpgi(t)
− δpP (6.1)
dC
dt
=
kc + λcfc(t)
1 + αcP
− βcXC − δcC (6.2)
dX
dt
= kx + λxPX − βcCX − δxX, (6.3)
where the concentration of PI828 is denoted by g(t) and the effects of cisplatin on pAkt
and caspase-3 production are denoted by fp(t) and fc(t) respectively. The models for these
treatment effects will be addressed below.
6.2.2 Treatment effects
We will first consider the effect of PI828, a potent inhibitor of Akt phosphorylation. It
performs this inhibition by blocking the activity of the enzyme P13K which is responsible
for phosphorylating Akt, creating pAkt. There are no release kinetics to consider for this
treatment. A reasonable approach would be to consider extracellular and intracellular con-
centrations, denoted by ge and gi respectively, that follow mass transport and exponential
decay of the effect giving
dge
dt
= −rgge
dgi
dt
= rgge − dggi.
However, even this simplistic approach introduces an unnecessary parameter and variable
since the effect of PI828 is very rapid (compared to the time scale of the experiments:
hours). Thus, it is sufficient to simply take
dg
dt
= −dgg. (6.4)
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The treatment effects of cisplatin on pAkt and caspase-3 are modeled by
dfp
dt
= rcci(t− Ti)− dpfp(t), (6.5)
dfc
dt
= rcci(t− Ti)− dcfc(t), (6.6)
where ci(t) is the intracellular cisplatin concentration which will be modelled below. Since
protein expression increase occurs on a similar time scale, and in the interest of parameter
reduction, we assume that the effect of the drug has the same activation constant rc and
time delay Ti, after the release of cisplatin nanoparticles, that accounts for intracellular
diffusion to active sites and the delayed impact of cisplatin on the apoptosis pathway.
This delay is attributed to the translational and transcriptional events that occur prior to
changes in the expression of the proteins of interest. However, to facilitate the fitting to
follow this model development, the delay in the equations above is not a strict time delay.
Instead, a linear chain of reactions is used where the delay of a signal is approximated by
N steps with equal reaction rates k [172]. Thus, the value of Ti is not explicitly included
in parameter fitting and can be shown to have mean T¯ = N/k and standard deviation
σT = T¯ /
√
N [173]. The number of intermediary reactions, N , which is suggested to be
set somewhere between 5 and 15, is set to 10 here since anything larger would promote
stiffness in the system and impede the proficiency of the fitting algorithms. The treatment
effects do exhibit different decay rates dp and dc since the cisplatin-induced production of
pAkt is sustained longer than the increased production of caspase (i.e. dp < dc).
6.2.3 Nanoparticle release
For nanoparticle release, many models were investigated. Preliminary data suggested that
out of all the candidates, a biexponential (or a biexponential with decay) release profile
was appropriate while a monoexponential yielded an unsatisfactory fit. Subsequent exper-
iments showed a simple erosion model fit well while even the simplest monoexponential
model was sufficient. Here we will only present the final published results utilizing the
monoexponential decay model while unpublished release profile results are found in D.
To determine the rate of cisplatin release from the liposome nanoparticles, release ex-
periments were performed over 120 hours in acidic and neutral conditions. In an acidic
environment these release profiles can be accurately determined by a one-parameter ex-
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ponential release profile. We can motivate the functional form by considering a simple
ordinary differential equation (ODE) that includes both the constant and sustained re-
lease of drug due to encapsulation in the liposome. To facilitate this, we assume that
the administered liposomes initially consists of a fixed fraction of cisplatin, θu, that will
be subsequently released upon administration at rate ru and a fixed fraction of cisplatin,
θi = 1−θu, that remains inert and is omitted from the modelling that follows. The fraction
of the total amount of contained cisplatin that is released depends primarily on the acidity
of the environment. In an acidic environment, just over 60% of the cisplatin is eventually
released from the liposome, as opposed to the approximately 40% that is released in a
neutral environment (this can be seen in Figure 6.5). This helps to preferentially target
tissues exhibiting an acidic microenvironment as found in solid tumours. The concentra-
tion of the cisplatin that is released from the nanoparticle is denoted by c(t) while the
unreleased cisplatin concentration remains to be released is denoted by u(t). The initial
conditions are u(t0) = θucT and c(t0) = 0 where t0 is the time of administration and cT is
the administered dosage (µM). The system of ODEs is then:
du
dt
= −ruu(t), (6.7)
dc
dt
= ruu(t), (6.8)
with the solution of interest being c(t).
6.2.4 Cellular chemotherapy concentrations
The model given above for the release profile experiments must be extended for the in
vitro experiments where expression of proteins are measured. The previous model will
now correspond to extracellular concentrations of cisplatin (denoted with subscript e) that
will now be transported inside the cell where the intracellular concentration (denoted with
subscript i) can then have an effect on the protein pathways. To facilitate this we add a
term to these extracellular concentrations to include the mass transport of cisplatin into
the cells, a process with some rate constant rc and time delay Te. This time delay accounts
for the effects of extracellular diffusion and transmembrane transport. In the interest
of avoiding extraneous parameters, and since the computational process to include delay
parameters introduces significant stiffness, we will make the assumption that this transport
delay (and the rate constant) is the same for nanoparticles and free cisplatin. Similar to
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Figure 6.3: Depiction of the drug model in Equations (6.9)–(6.12) for nanoparticle re-
lease and delayed transmembrane transport of self-assembling cis-platinum nanoparticles
(SACNs) and free cisplatin in an acidic environment.
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the time delay Ti in the treatment effects equations, we assume a linear chain of reactions
to obtain a distributed delay for the data fitting procedure. These drug-related reactions
are shown schematically in Figure 6.3. This leads to the extended system:
due
dt
= −ruue(t)− φcue(t), (6.9)
dce
dt
= ruue(t)− φcce(t), (6.10)
dui
dt
= −ruui(t) + φcue(t− Te), (6.11)
dci
dt
= ruui(t) + φcce(t− Te). (6.12)
6.2.5 Cell viability
With the model for protein expression and therapeutic concentrations established, we
now propose a model to predict cell viability. Making the simple assumptions that cell
survival is proportional to pAkt expression and cell death is proportional to caspase-3
expression proves to be a sufficient model for this prediction (see Figure 6.9a). The resulting
differential equation for cell viability is then given by
dN
dt
= (λNP − δNC)N. (6.13)
6.3 Parameter estimation
All of the parameter estimation to follow was performed using the MATLAB toolbox
PottersWheel (http://www.potterswheel.de) [139, 173]. This toolbox is capable of loading
multiple experimental data files and then estimating local and global parameters in the
ODE model. The parameter values were not determined simultaneously. The data fitting
process was done step-by-step as shown schematically in Figure 6.4. While the best fit
for release parameters is likely the unique global minimum of the chi-square error, those
determined for protein expression are not guaranteed to be a global minimum due to the
lack of experimental estimates of most of the parameters (aside from the decay rates) and
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Figure 6.4: Flowchart showing the computational algorithm used to fit parameters in the
mathematical model.
the sheer number of parameters to be estimated. The cell viability parameters are likely
the best estimate based on the given set of protein expression parameters.
6.4 Results
6.4.1 Cisplatin nanoparticle release
Fitting the parameters of the nanoparticle release model in Equations (6.7)–(6.8) to the
release profile data yields a suitable fit for the acidic environment (χ2red = 0.54, N = 15,
p = 2) and a mediocre one for the neutral environment (χ2red = 1.66, N = 15, p = 2),
see Figure 6.5 for these profiles and D for discussion of the reduced chi-squared statistic
χ2red. The release parameters for these fits are given in Table 6.1. Only those determined
for acidic environments are utilized in the calculations to follow so we will not present
a detailed model for neutral release properties; however, the release profile for a neutral
environment could be suitably fit by the addition of a single parameter that accounts for
liposomal erosion (χ2red = 0.61, N = 15, p = 3); this would have negligible effect on the
acidic release (χ2red = 0.58, N = 15, p = 3).
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Figure 6.5: (Data points) The release profile of cisplatin liposomes was evaluated at 37◦C
in neutral and acidic (tumour-like) pH in triplicates. 500 mwco dialysis bags packed with
16198665 ng liposome were stirred in 30 mL of acidic and neutral pH. 500 µL samples were
taken out at predetermined time points from the outer chamber and analyzed by AAS by
serial dilution. (Solid lines) Release profiles of cisplatin nanoparticles in acidic (χ2red=0.54,
N=15, p=2) and neutral (χ2red=1.66, N=15, p=2) microenvironments determined by fitting
solutions of Equations (6.7)–(6.8).
Parameter Neutral Acidic
ru 0.0471 [1/h] 0.0171 [1/h]
θu 0.499 0.614
Table 6.1: Nanoparticle release parameters in (6.7)–(6.8).
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6.4.2 Protein expression
The data from the in vitro protein expression experiments in 4T1 breast cancer cells are
used to determine the parameters in the model above; these parameters are given in Table
6.2. The only parameters present in the literature are those that determine decay rates
of the proteins [159]. Each experiment is considered to have a scaling factor for each
protein which are given in Table 6.3. This takes into account that the value used to
non-dimensionalize the protein concentrations is different for each experiment.
Parameter Value Parameter Value Parameter Value
kp 1.86 [1/h] αp 0.13 dg 0.001* [1/h]
kc 11.56 [1/h] αc 0.56 γp 6.42 [1/µM]
kx 0.29 [1/h] λx 0.01 [1/h] φc 0.26 [1/h]
δp 0.36 [1/h] βc 2.30 [1/h] rc 0.47 [1/h]
δc 0.48 [1/h] βx 0.040 [1/h] dp 0.030 [1/h]
δx 0.57 [1/h] λp 0.34 [1/h·nM] dc 0.28 [1/h]
λc 11.9 [1/h·nM]
Table 6.2: Protein expression parameters in (6.1)–(6.3).
*Parameter reached minimum allowable value. Indicates PI828 decay is not detected in
experiments on this time scale. This is evident from the continued inhibition exhibited in
Figure 6.7b.
Figure(s) P0 C0 X0
Figure 6.6a–6.6c (3 µM) 0.514 1.18 1.06
Figure 6.6a–6.6c (5 M) 0.381 1.36 0.770
Figure 6.7b 0.812 1.32 0.1*
Figure 6.8a-6.8b (Post) 0.510 0.834 1.29
Figure 6.8a-6.8b (Control) 0.511 0.529 1.29
Table 6.3: Experimental scaling factors for protein expression in (6.7)–(6.8).
6.4.3 Cell viability
Finally, with the release parameters and protein expression parameters approximated from
the data, we can introduce two parameters that predict cell viability. For this step of the fit-
ting we must have the same scaling parameters for each experiment. Fitting to the existing
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Figure 6.6: Mathematical predicted expression of caspase 6.6a, pAkt 6.6b and XIAP 6.6c
in the presence of different concentrations of SACN alone.
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Figure 6.7: The inhibition of pAkt and increase of caspase by PI828 alone 6.7b.
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Figure 6.8: The inhibition of pAkt by PI828 post treatment with SACN 6.8b and the
synergistic increase in caspase expression as compared to SACN alone-treated controls
6.8a.
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Figure 6.9: (a) Mathematical model-based prediction of cell viability using different dosing
schedules of SACNs and PI828. (Data points) In vitro measurements where the effect of
different drug combinations on 4T1 cell viability was quantified using MTS assay. SACN-
treated: cells were incubated with SACN containing media in an increasing concentration
gradient (0.5–50 µM) for 36 hours, after which it was replaced with control media for
12 hours. PI828 pretreatment: cells were pretreated with 5 µM PI828 for 12 hours, after
which the culture media were removed and cells were incubated with SACN in an increasing
concentration gradient (0.5–50 µM) for 36 hours. PI828 posttreatment: cells were incu-
bated with SACN-containing media in increasing concentration gradient (0.5–50 µM) for
36 hours, after which it was replaced with PI828-containing media at 5 µM concentration
for 12 hours. All readings were taken at 48 hours (data shown are mean ± SEM, n = 3).
(Lines) The cell viability data was used to fit (6.13) for increasing SACN concentrations
yielding the parameters in Table 6.4. For the purpose of plotting, the model predictions
at each SACN concentration were interpolated using cubic splines. (b) The mathemati-
cal model solution for cell viability for various post-SACN PI828 treatments: 36 hours of
SACN followed by 12 hours of PI828, 24 hours of SACN followed by 12 hours of PI828,
and 12 hours of SACN followed by 12 hours of PI828. Minimal cell viability was exhibited
in the case where PI828 was administered 24 hours after SACN. Once again each cell vi-
ability prediction was taken at 48 hours and the prediction for each SACN concentration
was interpolated with a cubic spline.
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cell viability data at the 48 hour time point, (data points in Figure 6.9a) gives the param-
eters in Table 6.4 and the model fit at the 48 hour time point shown in Figure 6.9a. Using
these parameters in the model, the cell viability associated with other treatment combina-
tions can now be determined. Since the data already displays that PI828 posttreatment
outperforming pretreatment, we will only investigate the posttreatment scenario. The cell
viability associated with administering PI828 12, 24 and 36 hours after SACN treatment
is shown in Figure 6.9b where once again the cell viability prediction is after 48 hours have
elapsed since the start of treatment. The 24 hour mark represents a superior treatment
option to both the earlier and later dosing regimens of molecular inhibitor, as in the early
administration (12 hours) the cisplatin has not had enough time to take effect whilst in
the later administration (36 hours) the treatment effects have begun to wear off by the
time PI828 is administered. This reinforces the importance of precise timing, on the or-
der of hours, in order to maximize the synergistic effects of these drugs and minimize cell
viability.
Parameter Value
λN 2.7×10−3 [1/h]
δN 1.5×10−3 [1/h]
Table 6.4: Cell viability parameters in (6.13).
6.5 Conclusions
Our mathematical model captured the rising cleaved caspase-3 and p-Akt levels, as can
be seen by the accurate fits in Figures 6.6a and 6.6b along with decreasing XIAP levels
after treatment with cisplatin nanoparticle (Figure 6.6c). The potent inhibition of pAkt
after PI828 administration was also facilitated by the model (Figure 6.7b). On the basis
of our assumptions and the above data, the model predicted the desired synergistic effects
of the combination treatments. Relative to the control case, the mathematical model
predicted synergistic increase in caspase-3 due to treatment with SACNs along with the
p-Akt inhibition provided by PI828 (Figures 6.8a and 4H respectively). In addition, as
shown in Figure 6.9a, PI828 administered after SACN treatment was predicted to result in
lower cell viability compared with pretreatment with PI828 followed by SACNs treatment
or with SACNs alone. We then sought to find the most efficient time for the administration
130
of PI828 after cisplatin nanoparticle treatment. It was determined that administration of
PI828 approximately 24 hours after cisplatin would yield lower cell viability as compared
to 36 hours or earlier times (Figure 6.9b).
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Chapter 7
Contributions and Future Work
In this concluding chapter, I will first outline the minor contributions to research that I
have made during my Ph.D., which do not comprise the bulk of my thesis in Chapters 4–6.
These include collaborative projects and unpublished results. This will be followed by brief
summaries of the major contributions made to the field of mathematical oncology including
evidence of scientific impact in the literature. Finally, a selection of future directions that
these mathematicals could take will be suggested.
7.1 Minor contributions
I will briefly outline a couple minor contributions that pertain to the material disseminated
in Chapter 5 along with a collaborative research project on antioxidant systems that has
led to a number of co-authored manuscripts.
A minor contribution that has some potential of evolving into substantially more is a
reconsideration of phosphate transport’s effect on ATP yield. The effects of this prelim-
inary parameter alteration was included in the supplementary material of the metabolic
symbiosis study in C.6. Phosphate transport, among other mitochondrial transport pro-
cesses, remains relatively unestablished in the literature. The role of the pH differences
between the cytosol, intermembrane space and mitochondrial matrix could be significant
to modelling the proton gradient across the mitochondrial membrane. In fact, if one makes
strong simplifying assumptions, the ATP yield from a single glucose molecule may be re-
duced from approximately 29 [20], to approximately 24. The truth may lie somewhere
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in between these two values, or even below that threshold, if pyruvate transport or other
molecular transport reduces the proton gradient further. Regardless, it remains pertinent
that these transport processes, along with ATP transport and subsequent utilization should
be compensated for in any model that makes steady state, or flux balance, assumptions.
An incremental generalization of the single vessel results in Chapter 5 is the two vessel
model equivalent that is a more appropriate simplified model of tissue and has been used
in previous models e.g. [83]. This introduces a well-defined parameter of intercapillary
distance and can be used to analyze asymmetrical situations as well. This still represents a
highly constrained geometry but represents the first generalization to a multi-vessel system.
Another project, which relates to the metabolism models is the development of mod-
els for antioxidant systems including the glutathione peroxide system. These counteract
reactive oxygen species (ROS) that are produced by cellular respiration and by growth
factors in tumours, among other processes. While essential to cell metabolism, at high
concentrations ROS become detrimental to normal cell function and in extreme conditions
can trigger apoptosis (cell death). To safeguard cells from ROS, there are various antiox-
idant enzymes that remove ROS or render them harmless. The ROS that is produced at
the highest rate is typically hydrogen peroxide (H2O2), a molecule that can be reduced by
various enzymes including catalase and those in the glutathione peroxides (GPx) family.
A mathematical model that considers the effects of these antioxidants in detoxifying hy-
drogen peroxidase is summarized in E. Interestingly we discovered that there is a synergy
between catalase and glutathione-peroxidase-1 which amplifies the detoxification power of
glutathione peroxidase-1. Hence any change (upregulation or downregulation) in the cata-
lase concentration has a direct affect on the glutathione peroxidase-1 activity and has to
be included in understanding any related phenomena. Also we propose that the activity
of glutathione peroxidase-1 could be regulated by changing the concentration of catalase.
The synergistic relationship between these antioxidants is reported in [174]. This work
was expanded to include the effects of cell permeability, especially the role of aquaporin
expression. This has important consequences for the efficacy of ascorbic acid for cancer
treatment and has also been submitted [175].
7.2 Major contributions
The major contributions to the field of mathematical oncology include the following:
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(i) Establishing the role of convective transport in angiogenesis signalling:
This model could be used in tumour growth models or to predict the effects of various
treatments. The alteration of biochemical signalling by convection could be generalizable
to other cell signalling pathways in tumours, and has been investigated in the context of
tumour invasion [176].This model has been used in the literature as inspiration for including
convective transport of AGFs in a tumour growth model [177] and has been quoted in [178]
for the observation that, “Angiogenic behaviours were suppressed when closer to the core of
the tumour and maximal angiogenic stimulation was detected towards the [outer] rim of the
tumor.” It has also been cited as an example of convection-based models [179, 180]. The
angiogenic effect of altering physiological parameters in tumours is the focus of Chapter 4.
(ii) Mathematical model for metabolic symbiosis in solid tumours: This
metabolism model includes lactate-fuelled and glucose-fuelled respiration along with oxygen-
repressible glycolysis. This was the first model to spatially consider the optimal ATP pro-
duction strategy in a tumour on the microscale and could be used to analyze metabolic
inhibitors. This may lead to a significant contribution to the study of metabolism in
biochemistry. This forms the majority of Chapter 5.
(iii) The link between metabolism and acidity: Using acidity models in tumours,
the effects of blood vessel permeability (antiangiogenic agents), hypoxia and metabolic
behaviour on acidosis are investigated. This research is contained in the latter half of
Chapter 5.
(iv) The optimal sequence of chemotherapy nanoparticles and molecular in-
hibitors: Utilizing nanoparticle release models in conjunction with protein expression
models can yield cell viability estimates for treatment optimization. The experimentally
confirmed prediction of inhibitor application after chemotherapy nanoparticles could guide
optimal scheduling models in this context. This contribution has the most medical and
clinical relevance and is outlined in Chapter 6.
7.3 Future work
Each of these aforementioned models could be extended or utilized in alternate systems. I
will indicate a sample of what I estimate to be the most fruitful endeavours.
For Chapter 4, the most obvious extension is to a non-symmetrical geometry that
could model more complex tumour shapes than the spherical one considered. However,
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this extension only warrants consideration if relevant experimental data is generated that
confirms the role of convection in angiogenic signalling. In terms of qualitative modelling
of angiogenesis, the distinct roles of various AGFs could be included by introducing sep-
arate equations for the different factors and explicitly including the inhibitory effects of
antiangiogenic factors and the stimulatory effects of proangiogenic factors via appropriate
terms in differential equations. The appeal of the model considered here is the utilization
of effective parameters for the two groups of AGFs that dramatically reduce the number
of parameters. By expanding the model to include multiple factors, diffusion coefficients,
degradation and production rates must also be estimated. A less dramatic model improve-
ment would be including continuous parameter values over the spatial domain of interest,
rather than the piecewise constant parameters considered, i.e. instead of of having one value
inside the tumour and one value outside the tumour (for diffusion, production and decay)
these values could be smoothly interpolated. The same could be said for the pressure
parameters as well, since the effective pressures, hydraulic conductivities, vessel perme-
abilities, etc. are all considered to be piecewise constant as well. This model also holds
promise for inclusion in more complicated models, including tumour growth models (I have
some preliminary results in this area), and more directly, models of tumour angiogenesis.
In Chapter 5 there are many possible areas for expansion include radially-dependent
parameters (diffusion coefficients, cell densities that modify metabolic parameters), axially-
dependent parameters (vessel concentrations, vessel permeability) and more generalized
functional forms for the consumption rates (e.g. ATP-dependent or pH-dependent). Ad-
ditional details of cellular metabolic pathways including other glycolytic and respiratory
intermediaries within the pathways or alternative metabolic pathways such as glutaminol-
ysis, could be adapted on a tumour-dependent basis. The most significant extension would
be to include non-symmetrical three-dimensional geometries. While relatively straightfor-
ward to formalize and even solve numerically, a complicated spatial domain would only be
clinically relevant once pertinent clinical data is generated. The details of the metabolic
reactions that are used to derive the summary metabolic reactions given by (5.1), (5.2)
and (5.3) are contained in C.4. An inherent assumption of these reactions is that all
ATP produced in these processes are subsequently consumed at the same rate. While
not tightly coupled, in steady state this is not an overly strict simplifying assumption.
However if there is significant overcompensation or underconsumption of ATP, it may be
worth adding ATP (and therefore ADP, phosphate and possible AMP) concentrations to
a time-dependent model.
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The model developed in Chapter 6 has multiple layers including nanoparticle release,
protein expression and cell viability. The most rudimentary of the three is the cell via-
bility model, which was proposed to be as simple as possible, in an attempt to predict
cell viability from only the expression of two proteins. Since this endeavour achieved the
research purpose, it was deemed inappropriate to propose a more complicated model for
this application, however a more comprehensive protein expression model could lead to
a more accurate cell viability model. The protein expression model could also be signifi-
cantly extended to include more of the apoptotic signalling pathways, however, we limited
ourselves to the inclusion of only those proteins for which expression was measured by our
experimental collaborators. There are many nanoparticle release models that exist in the
literature, and model selection here was motivated primarily by parameter minimization
and satisfactory fit to data.
These models could also be coalesced into a single entity that includes many microen-
vironmental features including IFP, AGFs, metabolites, acidity and multiple treatments
(and ROS). Certainly each of these processes are connected, as demonstrated in Chapter 2
and graphically summarized in Figure 2.8. While mathematically and computationally at-
tractive this would rely heavily on experimental verification that simultaneously measures
many different quantities. Mathematical modelling of the many interconnected processes
and phenomena in solid tumours will continue to progress in terms of biological, chemical
and physical relevance but most importantly in clinical and medical impact. This field is a
rich area for collaboration between multiple disciplines and I hope that this thesis can serve
as a launching point for others who want to investigate these fertile areas of mathematical
oncology.
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Appendix A
Mixture Theory
The derivation of the equations for IFP and IFV in Section 3.1 consider a highly simplified
derivation of a tissue treated as a fluid. However, the resulting equations are identical to
those obtained through more rigorous and complicated formulations. As an example, we
will present a brief argument for a biphasic tissue, adapted from [71] that considers the
tissue as a mixture of solid and fluid phases. The preliminary details of mixture theory,
not contained in [71], are adapted from unpublished notes from Dr. G. Tenti (provided in
personal communication) whose origins lie in the work of Biot [181].
Considering a biphasic material, for concreteness assume that there is a fluid phase and
a solid phase, which comprise volumes ∆Vf and ∆Vs respectively, in the volume element
∆V , where we assume saturation, so ∆Vf+∆Vs = ∆V . Within ∆Vf there is only fluid with
mass ∆Mf and within ∆Vs there is only solid with mass ∆Ms. We have two notions of mass
density that we could use, the apparent (partial, or bulk) mass density ρ˜i = ∆Mi/∆V ,
i = f,m or the true (realistic, or material) mass density ρi = ∆Mi/∆Vi, i = f,m. The
proportionality between these two mass densities is the volume fraction φi = ∆Vi/∆V ,
i = f,m, so that ρ˜i = ρiφi, i = f,m. Since φf + φs = 1 due to the saturation condition,
we will take φf = , and thus φs = 1− .
By considering the conservation of mass, with no sources or sinks, we have the continuity
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equations
∂ρ˜f
∂t
+∇ · (ρ˜fvf ) = 0,
∂ρ˜s
∂t
+∇ · (ρ˜svs) = 0,
where vf and vs are the velocities of the fluid and solid phases respectively. These equations
can be rewritten in terms of their true mass densities by using the relations ρ˜f = ρf and
ρ˜s = (1− )ρs to give
∂ρf
∂t
+∇ · (ρfvf ) = 0,
∂(1− )ρs
∂t
+∇ · ((1− )ρsvs) = 0.
Expanding these expressions give

Dρf
Dt
+ ρf
(
∇ · (vf ) + ∂
∂t
)
= 0,
(1− )Dρs
Dt
+ ρs
(
∇ · ((1− )vs) + ∂(1− )
∂t
)
= 0,
where the material derivative Dρi/Dt is given by
Dρi
Dt
=
∂ρi
∂t
+∇ρi · vi, i = f,m.
Assuming the fluid and solid phases are undergoing incompressible flow (or even stronger
that the solid, and possibly the fluid, is incompressible) sets this material derivative to
zero and gives
∇ · (vf ) + ∂
∂t
= 0,
∇ · ((1− )vs) + ∂(1− )
∂t
= 0.
Adding these two equations gives
∇ · (vf + (1− )vs) = 0. (A.1)
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The expression that relates these velocities to the interstitial fluid pressure p is given
by a generalized Darcy’s Law
(vf − vs) = −K∇p,
where K is the average tissue hydraulic conductivity; the derivation will be omitted, see
[182] for a clear generalized derivation of this equation in soft tissues. Substituting this
into (A.1) gives
∇ · (−K∇p+ vs) = 0.
Here we will simply assume that ∇ · vs = 0, equivalent to assuming that the matrix
dilatation of the elastic solid is in steady state. This finally gives
∇2p = 0,
which in cylindrical coordinates is simply (3.4).
A similar derivation for the macroscopic case with a distributed vessel source, mirroring
that given in Section 3.1.2, also leads to the same result in (3.12).
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Appendix B
Parameter values for mathematical
models
B.1 Homogeneous AGFs parameters
The angiogenic growth factor parameters given in [1] and used in Section 3.3 to plot the
AGFs in Figure 3.2 and the angiogenic activity in Figure 3.3 are given here in Table B.1.
These form the basis for the host and tumour parameters used in Chapter 4 and presented
in Table 4.2 for adding convection to an angiogenic factor model [81].
Parameter Units Host Tumour
Dp mm
2/s 4.0×10−5 5.5×10−5
Da mm
2/s 3.25×10−5 4.0×10−5
kp s
−1 2.0×10−4 1.99×10−4
ka s
−1 1.5×10−4 1.1×10−4
gp µ/mm
3/s 2.0×10−4 12.0×10−4
ga µ/mm
3/s 1.5×10−4 7.0×10−4
Table B.1: Angiogenic growth factor parameters from [1]. They use a tumour radius of 2.5
mm.
141
B.2 Interstitial fluid pressure parameters
The pressure parameters given in [2] and used in Section 3.1.2 to plot the nondimension-
alized IFP and IFV are given in Table B.2. These form the basis for host, tumour and
normalized tumour parameters used in Chapter 4 and presented in Table 4.2.
Parameter Units Host Tumour
Lp mm/s/mmHg 3.6×10−7 1.86×10−5
K mm2/s/mmHg 2.5×10−5 2.5×10−5
S/V mm2/mm3 17.4 16.5
pv mmHg 20 20
σv - 0.91 8.7×10−5
piv mmHg 20 19.8
pii mmHg 10 17.3
pe mmHg 10.9 20
α – 2 14
Table B.2: Pressure parameters from [2].
B.3 Microvessel model for pH
To convert between the notation used by Casciari et al. in their papers [3, 4] to the notation
used in this thesis, please consult Table B.3.
The production rates and parameters used in Section 3.4.2 are given in Tables B.4 and
B.5 respectively.
i a b c d e f g h
X O G L C B Cl− H Na+
Table B.3: Conversion of concentration notation Ci from [3, 4] to notation standardized
in this thesis X. Note that the ions Cl− and Na+ are omitted in [25] since they are
extraneous charge-maintaining variables when a model does not include charge migration.
If these concentrations exhibited interesting spatial patterns outside tumour vessels, then
they would be worth including in a simple model.
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Compound X QX (10
−2mM/s)
Cl− Cl 0
Na+ Na -
Glucose G pG
G
G+ kG
f1(O)
O2 O RPG
O
O + kO
f2(O)
Lactate− L −2QG + 13QO
CO2 C −krHB + kfC
Bicarbonate− B −kfC + krHB −QO
H+ H −kfC + krHB −QO +QL
Table B.4: Consumption rates and parameters for acidity-metabolism model from [25],
where fi(O) = 1 − aiO0.02 exp(−100(O − 0.01)4), i = 1, 2 where a1 = 2/3 and a2 = 1/2.
Other reaction parameters are pG = 1.8 × 10−3 mM/s, kO = 2 × 10−4mM, kG = 5 × 10−2
mM, kr = 58 /mM/s and kf = 7.4× 10−7 /s.
X DX (cm
2/s) µX (cm/s) VX (mM) σX
Cl 2.26×10−7 1.20×10−4 1.05×102 0.99
Na 3.14×10−7 1.20×10−4 1.22×102 0.99
G 1.10×10−6 3.0×10−5 2 0.95
O 1.82×10−5 3.0×10−5 1.43×10−2 0.99
L 1.8×10−6 1.20×10−4 2 0.99
C 8.9×10−7 3.0×10−5 1 0.99
B 2.2×10−7 1.7×10−5 20 0.99
H 1.9×10−6 1.20×10−4 4×10−5 0.99
Table B.5: Molecular parameters for metabolism model from [25]: diffusion coefficients
DX , vessel permeability µX , vessel concentration VX and osmotic reflection coefficient σX
estimated from [62].
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Appendix C
Metabolism model details
This appendix serves as supplementary material for Chapter 5.
C.1 Boundary conditions
The interstitial flux in the interstitial space of the tissue is assumed to be given by Fick’s
Law JX = −DX∇X, where DX is an effective diffusion coefficient in the tissue. This form
assumes that diffusion is the dominant transport mechanism for oxygen, glucose and lactate
on the microscale. This expression could be generalized to include convective transport
and charge migration effects.
In this case the transvascular transport is also assumed to be diffusion-dominated and
is given by Js = µXS(VX −X), where µX is the vessel permeability to solute X, VX is the
blood vessel concentration and X1 = X(ω
+) is the perivascular concentration; the super-
script ‘+’ denotes the exterior surface of the vessel. Once again this diffusive expression
could be extended to include convective transport (e.g. the Patlak equation [80]).
At the vessel wall the solute flux in the interstitium should be equal to the solute flux
across the vessel wall. Equating the above expressions for JX and Js gives the appropriate
boundary condition:
−DX dX
dr
∣∣∣∣
r=ω+
= µX(VX −X1). (C.1)
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This would me appropriate for any blood vessel that exhibits a difference in concentration
between the blood inside and the tissue outside. In many tumour blood vessels, the vessel
walls are poorly constructed, exhibiting large fenestrations and thus highly elevated perme-
ability. In the limit of large µX , we obtain the simplified version of the boundary condition
X(ω+) = VX , which assumes that the perivascular concentration and vessel concentration
are equal. This is the one we have used in our analysis.
We also require the concentrations to reach a steady state as we move away from the
vessel and take
dX
dr
= 0 at r = Ω, (C.2)
where Ω is the penetration depth [71], a distance far enough from the microvessel to
justify the assumption that the system has reached steady state but close enough to ensure
minimal contributions from other nearby vessels.
C.2 Generalized analytical derivation
In this paper the system was integrated twice in cylindrical co-ordinates to replace one of
the differential equations with a formula. Here we will generalize that result by showing the
calculation in Cartesian coordinates with the more widely applicable boundary condition
given in (C.1). The dimensional system is given by:
DX
d2X
dr2
= QX , X = O,L,G, (C.3)
where QX are the consumption rates of species X (given by (5.10)–(5.12)) and they satisfy
the relation QG = QO/6−QL/2.
The nondimensional system is given by
d2o
dr2
= Qo, (C.4)
d2`
dr2
= Q`, (C.5)
d2g
dr2
− αo
6
d2o
dr2
+
α`
2
d2`
dr2
= 0, (C.6)
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where αx = dxvx (dx = DX/DG, vx = VX/VG), and Qx = QX/(DXVX). These are subject
to the nondimensional boundary conditions
−dx
dr
∣∣∣∣
r=ρ
= µx(1− x1), (C.7)
where x1 = x(ρ) and µx = µX/DX ; the far-field boundary condition is
dx
dr
∣∣∣∣
r=P
= 0. (C.8)
First, integrating (C.6) over (r, P ) and enforcing the far-field boundary condition (C.8)
gives
dg
dr
− αo
6
do
dr
+
α`
2
d`
dr
= 0, (C.9)
the identical expression to that found in cylindrical coordinates (5.17). Before integrating
again, it is worth noting that by applying the more general vessel boundary condition (C.7)
and rearranging the previous equality at r = ρ yields
g1 = 1− βo
6
(1− o1) + β`
2
(1− `1), (C.10)
where βx = µxvx (µx = µX/µG). Now integrating the equation (C.9) once more, this time
over (ρ, r), gives
g(r) = g1 − αo
6
(
o1 − o(r)
)
+
α`
2
(
`1 − `(r)
)
, (C.11)
an analogous expression to (5.18) with modified perivascular concentrations.
C.3 Numerical methods
For estimation of the maximum consumption rate of oxygen pO (mM/s), we use parame-
ter fitting and boundary value problem (BVP) solving functions in MATLAB[139]. This
algorithm imposes a constraint on the system that limits the rate of ATP production by
lactate or glucose fuelled respiration, proportional to the rate of oxygen consumption. The
data we use to fit the model are from experiments performed by [5] that represent the first
micrometer scale measurements of the partial pressure of oxygen (pO2) and interstitial
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pH adjacent to tumour blood vessels. We will utilize their measurements of average pO2
provided as a function of distance from a single blood vessel to estimate this oxygen con-
sumption rate in the model. In their experiment the individual measurements were taken
from multiple blood vessels in 7 tumours. When averaged, these measurements were only
considered up to a distance D/3 from the vessel, where D is the distance to the nearest
neighbouring vessel, in order to ensure that the contribution was predominantly from the
local effects of a single vessel. These tumours were grown in window chambers, and so are
appropriately modelled in Cartesian coordinates [25, 83].
To reduce the number of parameters and to discourage overfitting the problem, we
will fix the half-maximal concentration KO = 2 × 10−4, a value previously estimated on
the microscale [25]; this is lower than 4.640 × 10−3 mM measured in EMT6/Ro tumour
spheroid [105] and commonly used for macroscopic models (e.g. [64, 65, 63, 89]). The
simplified boundary value problem is given by the Cartesian equation (C.3) (X = O), with
QO = pO
O
O +KO
,
or in nondimensional terms by (C.4) with
Qo = po
o
o+ κo
,
where po = pO/(DOVO), along with boundary conditions o(ρ) = 1 and dx/dr|r=P = 0.
To solve the BVP the MATLAB function ‘bvp5c’ was used; this function utilizes the
four-stage Lobatto Illa formula (implemented as an implicit Runge-Kutta formula) and
ensures fifth-order accuracy. Analytical Jacobian matrices were specified for the boundary
conditions and the BVP once it was converted to a first order differential equation system.
The absolute and relative residual tolerances are set to 10−7. Starting at po = 1 × 10−5,
the function ‘fminsearch’, which utilizes the Nelder-Mead algorithm, was used to find the
minimum residual sum of squares, i.e. RSS =
∑N
i=1(yi − o(xi))2, where the points (xi, yi)
are the spatial variable and the oxygen concentration data means from [5] and o(xi) are
the solutions to the BVP interpolated at the same points as the observations. After 11
iterations, the algorithm converges to a value of RSS = 0.0184 with po = 5.35×10−5. The
algorithm terminates since the difference between the estimated parameter value (pO) and
other points in the simplex is less than a tolerance of 10−4 and the corresponding function
values (RSS) are also less than this tolerance. This solution for o(r) with corresponding
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Figure C.1: Solution to oxygen boundary value problem fit to radial oxygen profile data
from [5]. Inset: scaled oxygen consumption rate.
scaled consumption rate Q˜o = Qo/po is shown in Figure C.1. In dimensional terms, using
the values for DO and VO in Table 5.1, this corresponds to pO = 1.39× 10−3 mM/s. This
value is one order of magnitude lower than the value used in [64], which was based off [4].
This sets a maximum value for the total oxygen consumption rate of both lactate-fuelled
and glucose-fuelled respiration, i.e. pO = 6BO = 3BL. This can be justified by noting that
QO ≤ max(6BO, 3BL).
To show the effect of changing geometries, from the Cartesian system used in [25] to the
cylindrical one used here, we have found the solution to the simple oxygen BVP in Cartesian
and cylindrical coordinates using the parameters determined above. The solutions and
the corresponding consumption rates are shown in Figure C.2. This demonstrates the
significant difference between modelling the experimental setup of a window chamber, e.g.
the pO2 and pH measurements by Helmlinger et al. [5], using a flat vessel wall [25, 83], and
using a rounded wall which corresponds to the in vivo situation of an isolated microvessel
[183].
For the full system we fix all parameters at specified values and use the MATLAB
solver ‘bvp5c’ to numerically solve the couple ODE system given by (5.13)–(5.14). Once
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Figure C.2: The Cartesian solution to oxygen boundary value problem fit to radial oxygen
profile data from [5] is the same as that in Figure C.1. The cylindrical solution utilizes
the same parameters as the Cartesian solution. This visualizes the effect of changing
geometries (Cartesian: flat wall; cylindrical: rounded wall). Inset: Corresponding scaled
oxygen consumption rate.
again the Jacobian matrices for the boundary conditions and the corresponding first order
system are specified and the absolute and relative residual tolerances are set to 10−7. The
formula 5.15 is used to determine the resulting glucose concentration. The ATP production
is then determined by the formula (5.19).
C.4 Biochemical Summary
Preliminaries
The direction of the arrows in the reactions to follow are taken to be in the direction
that is predominantly exhibited in the environment that is being considered; they do not
imply irreversibility of the reaction. The reactions presented below are sometimes the
sum of many reactions in which case the Enzyme Commission (EC) number(s) will be
149
stated. These reactions are protonated to a physiological pH of 7.3, to remain consistent
with the pathways in the HumanCyc database [184]. The reactions presented below hold
at physiological pH 6.9 ≤ pH ≤ 7.4. In many cases, the nomenclature is simplified to
promote readability (e.g. the name D-glucopyranose which encompasses both α−D and
β−D glucose will be referred to simply as ‘glucose’). Molecular formulae are given in
Tables C.1. The primary purpose of the following biochemical summary is to determine the
relation between oxygen consumption, glucose consumption and ATP turnover in various
simplified metabolic regimes. The ATP yield will be emphasized by boxing the number of
ATP produced (and subsequently consumed) under a reaction and in summary equations.
This is the key to translating the biochemical reactions into ATP yields that will be used
in the mathematical model.
Transport across cell membrane
Glucose transport: We will simply write glucose transport across the cell membrane as
one molecule transported from extracellular space (subscript e) to the cytosol (subscript c).
The stoichiometry of this transmembrane transport is tissue-dependent and humans express
sodium-dependent transporters [185] and glucose/H+ symporters but predominantly utilize
uniporters [186]:
Ge → Gc. (C.12)
Cystolic processes: Glycolysis
The molecules involved in the reactions presented in this section all occur in the cytosol;
the subscript c on the molecules will be omitted in this subsection for simplicity.
Glycolysis: The conversion of glucose to pyruvate is the first step of cellular respi-
ration that will be used for the glucose-fuelled summary reactions to follow. The process
of glycolysis includes ten reactions catalyzed by the following enzymes in the given or-
der: (i) glucokinase/hexokinase (EC 2.7.1.1/2.7.1.2), (ii) glucose-6-phosphate isomerase
(EC 5.3.1.9), (iii) 6-phosphofructokinase (EC 2.7.1.11), (iv) fructose-biphosphate aldolase
(EC 4.1.2.13), (v) triosephosphate isomerase (EC 5.3.1.1), (vi) glyceraldehyde-3-phosphate
dehydrogenase (EC 1.2.1.12), (vii) phosphoglycerate kinase (EC 2.7.2.3), (viii) phospho-
glycerate mutase (EC 5.4.2.11/5.4.2.12), (ix) phosphoglycerate enolase (EC 4.2.1.11), and
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(x) pyruvate kinase (EC 2.7.1.40). The summary reaction for glycolysis is:
G + 2ADP + 2Pi + 2NAD
+ → 2P + 2ATP + 2NADH + 2H+ + 2H2O (C.13)
ATP hydrolysis: We assume ATP is consumed at the same rate that it is produced.
Reactions that have utilized this reaction will have the number of ATP consumed in a
box underneath the reaction arrow. This cellular energy consumption is given below and
is the stoichiometric proton source [187]. Due to the pKa of phosphate, it may buffer a
significant proportion of these protons, or other buffers may diminish this effect. They will
appear in summary equations as cytosolic protons H+c .
ATP + H2O→ ADP + Pi + H+ (C.14)
Lactate dehydrogenase (LDH): This enzyme (EC 1.1.1.27) facilitates the conver-
sion between pyruvate and lactate. This is necessary for NADH regeneration (oxidation)
without oxygen.
P + NADH + H+ GGGBFGG L
− + NAD+ (C.15)
Glucose to Lactate:=(C.13)+ 2×(C.14)+2×(C.15). This is the net fermentation
reaction given in (5.1) that characterizes glycolytic cell population.
G
kG
GGGGGGA
2
2L− + 2H+. (C.16)
Note: Cytosolic H+ production during conversion of glucose to lactate is a result of
ATP consumption, not the release of H+ from the neutral lactic acid.
Transport into mitochondria
The subscript m denotes molecules inside the mitochondrial matrix. We will omit con-
sideration of transport across the outer mitochondrial membrane since the molecules that
must subsequently cross the inner mitochondrial matrix can easily traverse the large porins
of the outer membrane, expect in the case of phosphate transport due to the necessity of
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protonation. We will differentiate the intermembrane space (with the subscript i) when
considering the proton gradient across the inner mitochondrial matrix.
A key consideration for these reactions that involve molecules passing from one cell
compartment to another is that any charge differences induced by transport must be com-
pensated for with the corresponding cost to the proton gradient. While the reactions are
all charge balanced with respect to the total reaction, if they are not electroneutral with
respect to each cell compartment (each subscript) on both sides of the reaction, then the
equivalent proton transport must be included. This ensures the critical maintenance of the
electrochemical gradient across the inner mitochondrial membrane.
Malate-aspartate shuttle: This shuttle effectively delivers NADH from the cytosol
into the matrix to be utilized by ETC. We will take this to be the dominant shuttle
mechanism and thus consider the glycerol phosphate shuttle to be negligible (it is less
efficient). Sum of reactions/transport: (i) malate dehydrogenase (cytosol, EC 1.1.1.37),
(ii) malate import (iii) malate oxoglutarate antiporter, (iv) malate dehydrogenase (matrix),
(v) aspartate aminotransferase (matrix, EC 2.6.1.1), (vi) glutamate-aspartate antiporter,
(vii) aspartate aminotransferase (intermembrane space), (viii) oxaloacetate export. This
shuttle is electroneutral but does diminish the proton gradient:
NADHc + H
+
c + NAD
+
m → NAD+c + NADHm + H+m (C.17)
Pyruvate transport: The mitochondrial pyruvate carrier has been identified [188,
189] but the exact stoichiometry remains unclear. Here we will assume the transport is
symport with H+. If this is not the case it would have minimal effect on the system since
it only accounts for a one proton reduction in the gradient per pyruvate.
Pc + H
+
i → Pm + H+m (C.18)
Glycolysis + Transport:=(C.12)+(C.13)+2×(C.17)+2×(C.18)
Ge + 2ADP + 2Pi + 2NAD
+
m + 2H
+
i → 2Pm + 2ATP + 2NADHm + 4H+m + 2H2O (C.19)
The subscript on extracellular glucose will be omitted in what follows.
ATP-ADP translocase: This is required for ATP produced in mitochondria to reach
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the cytosol and ADP in cytosol to be recycled into mitochondria.
ADPc + ATPm → ADPm + ATPc (C.20)
This diminishes the electrochemical gradient by one charge and must be compensated for
with the opposite and equal charge transfer.
Phosphate carrier: The transport of phosphate is taken to be antiport with OH−
[190]. However the net reaction is complicated by the multiple protonations of phosphate
at physiological pH. The pKa of phosphate in cells is 6.82, lower than the typical pH of the
cytosol and mitochondrial matrix and approximately equal to the intermembrane space pH
[191]. To fully model this process a multi compartment intracellular buffering model would
have to be constructed. Under the restriction that Pi exists predominantly as a hydrogen
phosphate ion (HPO2−4 ) in the cytosol and mitochondrial matrix, and can be sufficiently
converted to dihydrogen phosphate ion (H2PO
−
4 ) in the intermembrane space, the form
required for transport [190]. The neutral summary reaction is:
Pi,c + 2H
+
i → Pi,m + 2H+m. (C.21)
To derive this we will briefly distinguish between P2−i :=HPO
2−
4 and P
−
i :=H2PO
−
4 . It is
the sum of the following processes:
1. outer membrane transport: P2−i,c → P2−i,i ,
2. intermembrane protonation: P2−i,i + H
+
i → P−i,i,
3. hydroxide antiport: P−i,i + OH
−
m → P−i,m + OH−i ,
4. mitochondrial disassociation: P−i,m → P2−i,m + H+m,
5. hydroxide balance: H+i + OH
−
i → H2Oi, H+m + OH−m → H2Om,
6. water exchange: H2Oi → H2Om.
ATP transport:=(C.20)+(C.21). The transport of ATP into the cytosol, and reimport
of phosphate and ADP is summarized by:
ADPc + Pi,c + 2H
+
i + ATPm → ADPm + Pi,m + 2H+m + ATPc (C.22)
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Mitochondrial matrix processes
The molecules in this section without subscripts are all present in the mitochondrial matrix
(typically denoted with subscript m).
Pyruvate dehydrogenase complex: The link between glycolysis and the citric acid
cycle.
P + CoA + NAD+ → Ac-CoA + NADH + CO2 (C.23)
Citric acid cycle: The summary of reactions catalyzed by: (i) citrate synthase (EC
2.3.3.1), (ii) aconitase hydratase (EC 4.2.1.3), (iii) isocitrate dehydrogenase (EC 1.1.1.41),
(iv) oxoglutarate dehydrogenase (EC 1.2.4.2), (v) succinyl-CoA synthetase (EC 6.2.1.4),
(vi) succinate dehydrogenase (EC 1.3.5.1), (vii) fumarase (EC 4.2.1.2), (viii) malate de-
hydrogenase (EC 1.1.1.37). We also include phosphate exchange for conversion of energy
output of pathways from GTP to ATP yield alone via nucleoside-diphosphate kinase (EC
2.7.4.6).
Ac-CoA + 3NAD+ + Q + ADP + Pi + 2H2O→
CoA + 3NADH + QH2 + ATP + 2H
+
m + 2CO2 (C.24)
Pyruvate cofactor yield:=(C.23)+(C.24)+(C.22)
P+4NAD++Q+ADPc+Pi,c+2H
+
i +2H2O→ 4NADH+QH2+ATPc+4H+m+3CO2 (C.25)
Electron transport chain (ETC)
NADH oxidation: The complete ETC is the sum of Complex I, Complex III and Complex
IV. Used to calculate the number of intermembrane protons generated per NADH.
NADH +
1
2
O2 + 11H
+
m → NAD+ + 10H+i + H2O (C.26)
QH2 oxidation: Partial ETC (from Q) is the sum of Complex III and Complex IV.
Used to calculate the number of intermembrane protons generated per QH2.
QH2 +
1
2
O2 + 6H
+
m → Q + 6H+i + H2O (C.27)
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ATP synthase: It requires the transport of ten protons from the intermembrane space
across the inner membrane into the mitochondrial matrix to drive a single revolution of
the 10 subunits of ATP synthase [21]. This enables the production of 3 ATP molecules.
3ADP + 3Pi + 10H
+
i → 3ATP + 7H+m + 3H2O (C.28)
ATP production by ETC:=(C.28)+3×(C.22). The net movement of 16 protons
results in 3 ATP in the cytosol.
3ADPc + 3Pi,c + 16H
+
i → 3ATPc + 3H2O + 13H+m (C.29)
Respiration summaries
Pyruvate and ETC:=(C.25)+4×(C.26)+(C.27)
P + 2.5O2 + ADPc + Pi,c + 46H
+
m → ATPc + 3CO2 + 44H+i + 3H2O (C.30)
Glucose and ETC:=(C.19)+2×(C.30)+2×(C.26)
G + 6O2 + 4ADPc + 4Pi,c + 110H
+
m → 4ATPc + 6CO2 + 106H+i + 10H2O (C.31)
Glucose-fuelled ATP yield:=(C.31)+106/16=6.625×(C.29). A total of 6.625× 3 =
19.875 ATP are generated by the ETC per glucose molecule bringing the total to φg =
19.875 + 4 = 23.875 ATP per glucose.
G + 6O2 + φgADPc + φgPi,c + φgH
+
m → 6CO2 + (φg + 6)H2O + φgATPc (C.32)
Glucose-fuelled respiration:=(C.32)+ φg ×(C.14)
G + 6O2 + φgH
+
mGGGGGGA
23.875
6CO2 + 6H2O + φgH
+
c (C.33)
In order for this summary reaction to balance we must assume that the proton load
induced by ATP consumption in the cytosol is then transferred to the intermembrane
space. We can then dismiss these protons by assuming they are lost to proton leak, i.e.
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H+i → H+m, or we could have them be used as fuel for sustained ATP production. For
simplicity, to remain consistent in this respect to previous ATP yield estimates and since
proton leak is a significant factor in loss of energy metabolism efficiency, we will assume
the former approach yielding:
G + 6O2
kO
GGGGGGA
23.875
6CO2 + 6H2O (C.34)
Lactate and ETC:=Reverse reaction of (C.15)+(C.18)+(C.17)+(C.26)+(C.30)
L− + 3O2 + ADPc + Pi,c + 55H+m → 3CO2 + 53H+i + 4H2O (C.35)
Lactate-fuelled ATP yield:=(C.35)+53/16=3.3125×(C.29). A total of φ` = 3.3125×
3 + 1 = 10.9375 ≈ 11 ATP are generated per lactate molecule.
L− + 3O2 + φ`ADPc + φ`Pi,c + (φ` + 1)H+m → 3CO2 + (φell + 3)H2O + φ`ATPc (C.36)
Lactate-fuelled respiration:=(C.36)+φ`×(C.14).
L− + 3O2 + (φ` + 1)H+mGGGA
11
3CO2 + 3H2O + φ`H
+
c (C.37)
Once again, if we desire to eliminate protons, we will assume H+c → H+i → H+m. Thus
ending at:
Lactate-fuelled respiration:=(C.36)+ φ`×(C.14).
L− + 3O2 + H+m
kL
GGGGGGA
11
3CO2 + 3H2O (C.38)
C.5 Metabolism reaction details
Presented below are the constituent steps of metabolic processes including glycolysis,
malate-aspartate shuttle, citric acid cycle and electron transport chain. In some cases the
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Molecule Symbol Formula
Metabolites in mathematical model
oxgen O2 O2
lactate L− C3H5O−3
glucose G C6H12O6
Coenzymes
adenosine monophosphate AMP C10H12N5O4-PO
2−
3
adenosine diphosphate ADP AMP-PO3−3
adenosine triphosphate ATP ADP-PO4−3
nicotinamide adenine dinucleotide NAD+ C21H26N7O14P
−
2
reduced NAD+ NADH NAD+-H2−
coenzyme Q10 Q C59H90O4
ubiquinol QH2 C59H92O4
coenzyme A CoA C21H32N7O16P3S
4−
acetyl CoA Ac-CoA CoA-C2H2O
4−
Other molecules
protona H+ H+
water H2O H2O
carbon dioxide CO2 CO2
phosphateb Pi HPO
2−
4
pyruvate P C3H3O
−
3
Table C.1: Molecular formulae for the central molecules presented in metabolic reactions
considered in (C.12)–(C.38). The formulae presented are those that predominantly exist
at physiological pH 6.9 ≤ pH ≤ 7.4 and in this range the reactions are balanced in mass
and charge.
a The proton typically exists as hydronium H3O
+ in water.
b A pKa value for phosphate is 6.82 so H2PO
−
4 exists at significant concentrations, especially
in acidic environments found in cancer cells and in the intermembrane space of most cells,
where pH values are low.
157
reactions have been simplified, especially those that comprise the ETC. It should be noted
that all reactions are balanced in mass and charge at physiological pH, 6.6 ≤ pH ≤ 7.4,
based on the pKa values of the molecules.
Glycolysis
These are the ten enzyme-catalysed steps of glycolysis including enzyme commission (EC)
numbers. Glycolytic intermediary formulae at physiological pH are given in Table C.2
while other molecules are given in Table C.4.
1. Glucokinase/hexokinase (EC 2.7.1.1/2.7.1.2)
G + ATP→ G6P + ADP + H+ (C.39)
2. glucose-6-phosphate isomerase (EC 5.3.1.9)
G6P→ F6P (C.40)
3. 6-phosphofructokinase (EC 2.7.1.11)
F6P + ATP→ FBP + ADP + H+ (C.41)
4. fructose-biphosphate aldolase (EC 4.1.2.13)
FBP→ G3P + DHAP (C.42)
5. triosephosphate isomerase (EC 5.3.1.1)
DHAP→ G3P (C.43)
6. glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12)
G3P + NAD+ + Pi → BPG + NADH + H+ (C.44)
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Molecule Symbol Formula Reactions
glucose G C6H12O6 (C.39)
glucose 6-phosphate G6P C6H11O9P
2− (C.39),(C.40)
fructose 6-phosphate F6P C6H11O9P
2− (C.40),(C.41)
fructose-1, 6-biphosphate FBP C6H10O12P
4−
2 (C.41),(C.42)
glyceraldehyde 3- phosphate G3P C3H5O6P
2− (C.42),(C.43),(C.44)
dihydroxyacetone phosphate DHAP C3H5O6P
2− (C.42),(C.43)
1,3-biphosphoglycerate BPG C3H4O10P
4−
2 (C.44),(C.45)
3-phosphoglycerate PG3 C3H4O7P
3− (C.45),(C.46)
2-phosphoglycerate PG2 C3H4O7P
3− (C.46),(C.47)
phosphoenolpyruvate PEP C3H2O6P
3− (C.47),(C.48)
pyruvate P C3H3O
−
3 (C.48)
Table C.2: Molecular formulae for glycolytic intermediaries involved in the metabolic re-
actions (C.39)–(C.48). Chemical formulas presented are those that predominantly exist at
physiological pH 6.6 ≤ pH ≤ 7.4 based on the pKa values of the molecules, and in this
range the reactions are balanced in mass and charge.
7. phosphoglycerate kinase (EC 2.7.2.3)
BPG + ADP→ PG3 + ATP (C.45)
8. phosphoglycerate mutase (EC 5.4.2.11/5.4.2.12)
PG3→ PG2 (C.46)
9. phosphoglycerate enolase (EC 4.2.1.11)
PG2→ PEP + H2O (C.47)
10. pyruvate kinase (EC 2.7.1.40)
PEP + ADP + H+ → P + ATP (C.48)
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Malate-aspartate shuttle
Most treatments of this shuttle present it as a two-compartment system, but here we will
explicitly consider the cytosol, inter membrane space and mitochondrial matrix. While
always occurring in the mitochondrial matrix, depending on the source, malate dehydro-
genase and aspartate aminotransferase are presented as occurring in either the cytosol or
intermembrane space. We will assume malate dehydrogenase is predominantly cytosolic
and that aspartate aminotransferase predominantly occurs in the intermembrance space.
The former is justified because if this occurred in the intermembrane space it would re-
quire the transport of the relatively large coenzyme NADH across the outer mitochondrial
membrane rather than import of malate and export oxaloacetate. The latter is less con-
sequential since if aspartate aminotransferase was cystolic it would require the export of
two molecules and import of one molecule, however these molecules would all cancel out in
either case. Below are the six steps of the malate-aspartate shuttle, responsible for effec-
tively transferring a reduced NADH from the cytosol into the mitochondrion. The formulae
for molecules that are also CAC intermediaries are provided in Table C.3, namely, malate
(M), oxaloacetate (OAA) and 2-oxoglutarate (α), while those that are not are provided in
Table C.4.
1. malate dehydrogenase (cytosol, EC 1.1.1.37)
OAAc + NADHc + H
+
c → Mc + NAD+c (C.49)
2. outer mitochondrial membrane transport of malate
Mc → Mi (C.50)
3. malate-oxoglutarate antiporter
Mi + αm → Mm + αi (C.51)
4. malate dehydrogenase (matrix, EC 1.1.1.37)
Mm + NAD
+
m → OAAm + NADHm + H+m (C.52)
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5. aspartate aminotransferase (matrix, EC 2.6.1.1)
OAAm + Glut
−
m → Aspm + αm (C.53)
6. glutamate-aspartate antiporter
Aspm + Glut
−
i → Aspi + Glut−m (C.54)
7. aspartate aminotransferase (intermembrane space, EC 2.6.1.1)
Aspi + αi → OAAi + Glut−i (C.55)
8. OAA export
OAAi → OAAc (C.56)
Citric acid cycle
The ten constituent reactions of the CAC are provided below. The formulae for CAC
intermediaries are given in Table C.3 while all others are given in Table C.4.
1. Citrate synthase (EC 2.3.3.1)
OAA + Ac-CoA + H2O→ Cit + CoA + H+ (C.57)
2. Aconitase hydratase (EC 4.2.1.3)
Cit→ cis-Acon + H2O (C.58)
cis-Acon + H2O→ Iso (C.59)
3. Isocitrate dehydrogenase (EC 1.1.1.41)
Iso + NAD+ → OAS + NADH + H+ (C.60)
OAS + H+ → α + CO2 (C.61)
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Molecule Symbol Formula Reactions
oxaloacetate OAA C4H2O
2−
5 (C.49),(C.52),(C.53),(C.55),
(C.56),(C.57),(C.66)
citrate Cit C6H5O
3−
7 (C.57),(C.58)
cis-aconitate cis-Acon C6H3O
3−
6 (C.58),(C.59)
isocitrate Iso C6H5O
3−
7 (C.59),(C.60)
oxalosuccinate OAS C6H3O
3−
7 (C.60),(C.61)
2-oxoglutarate α C5H4O
2−
5 (C.51),(C.53),(C.55),(C.61),(C.62)
succinyl-CoA s-CoA CoA-C4H3O
5−
3 (C.62),(C.63)
succinate Suc C4H4O
2−
4 (C.63),(C.64)
fumarate F C4H2O
2−
4 (C.64),(C.65)
malate M C4H4O
2−
5 (C.49),(C.51),(C.52),(C.65),(C.66)
Table C.3: Molecular formulae for citric acid cycle intermediates involved in the metabolic
reactions (C.57)–(C.66). Chemical formulas presented are those that predominantly exist
at physiological pH 6.6 ≤ pH ≤ 7.4 based on the pKa values of the molecules, and in this
range the reactions are balanced in mass and charge.
4. oxoglutarate dehydrogenase (EC 1.2.4.2)
α + NAD+ + CoA→ S-CoA + NADH + CO2 (C.62)
5. succinyl-CoA synthetase (EC 6.2.1.4)
S-CoA + GDP + Pi → Suc + CoA + GTP (C.63)
6. succinate dehydrogenase (EC 1.3.5.1)
Suc + Q→ F + QH2 (C.64)
7. fumarase (EC 4.2.1.2)
F + H2O→ M (C.65)
8. malate dehydrogenase (EC 1.1.1.37)
M + NAD+ → OAA + NADH + H+ (C.66)
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Nucleoside-diphosphate kinase (NDK, EC 2.7.4.6): Phosphate exchange for conversion
of energy output of pathways to ATP yield alone.
GTP + ADP→ GDP + ATP (C.67)
Electron transport chain
The net reactions of the complexes that make up the electron transport chain (ETC) are
presented below in a simplified form.
Complex I:
NADH + Q + 5H+m → NAD+ + QH2 + 4H+i (C.68)
Complex III:
QH2 + 2H
+
m + 2Cytc
3+ → Q + 4H+i + 2Cytc2+ (C.69)
Complex IV:
2Cytc2+ + 4H+m +
1
2
O2 → H2O + 2Cytc3+ + 2H+i (C.70)
Liver functions
Processes that maintain vessel concentrations:
Alanine deamination (alanine to pyruvate): Consumes 4 ATP.
Gluconeogenesis (pyruvate to glucose): Consumes 6 ATP.
C.6 The effect of respiratory ATP yield on the results
The calculations contained in Chapter 5 consider a respiratory ATP yield of 28.9 [20]. This
corresponds to the traditional system where ATP yield does not include the costs associ-
ated with ATP consumption and phosphate transport. Preliminary considerations, that
admittedly use strong assumptions, suggest that the ATP yield may be as low as 24 ATP
per glucose molecules. The recalibrated results, using this lower ATP yield, are presented
in Figures C.3, C.4, C.5 are analogous to Figures 5.5, 5.6, 5.8. The difference in results
is that the contribution of respiratory processes is diminished relative to glycolytic ATP
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Molecule Symbol Formula Reactions
Coenzymes
adenosine monophosphate AMP C10H12N5O7P
2−
adenosine diphosphate ADP AMP-PO3−3 (C.39),(C.41),(C.45),
(C.48),(C.67)
adenosine triphosphate ATP ADP-PO4−3 (C.39),(C.41),(C.45),
(C.48),(C.67)
nicotinamide adenine NAD+ C21H26N7O14P
−
2 (C.44),(C.49),(C.52),
dinucleotide (C.60),(C.62),(C.68)
reduced NAD+ NADH NAD+-H2− (C.44),(C.49),(C.52),
(C.60),(C.62),(C.68)
coenzyme Q10 Q C59H90O4 (C.68),(C.69)
ubiquinol QH2 C59H92O4 (C.68),(C.69)
coenzyme A CoA C21H32N7O16P3S
4− (C.57),(C.62),(C.63)
acetyl CoA Ac-CoA CoA-C2H2O
4− (C.57)
guanosine monophosphate GMP C10H12N5O8P
2−
guanosine diphosphate GDP GMP-PO3−3 (C.63),(C.67)
guanosine triphosphate GTP GDP-PO4−3 (C.63),(C.67)
Other molecules
protona H+ H+ (C.39),(C.41),(C.44),
(C.48),(C.49),(C.52),
(C.57),(C.60)–(C.61),
(C.68)–(C.70)
oxgen O2 O2 (C.70)
water H2O H2O (C.47),(C.57),(C.58),
(C.59),(C.70)
carbon dioxide CO2 CO2 (C.61),(C.62)
phosphate Pi H2PO
−
4 /HPO
2−
4 (C.44),(C.63)
glutamine Glut C5H10N2O3
glutamate Glut− C5H8NO−4 (C.53),(C.54),(C.55)
aspartate Asp C4H6NO
−
4 (C.53),(C.54),(C.55)
Table C.4: Molecular formulae for other molecules involved in the metabolic reactions
(C.39)–(C.70). Chemical formulas presented are those that predominantly exist at phys-
iological pH 6.6 ≤ pH ≤ 7.4 based on the pKa values of the molecules, and in this range
the reactions are balanced in mass and charge.
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Figure C.3: The base case for ATP turnover (consumption/production) rates corresponding
to consumption rates given in Figure 5.4 with altered respiratory ATP parameters. The
contributions of the pathways are bounded by the total ATP turnover rate PATP . Glycolysis
dominates in hypoxic/anoxic regions while glucose-fuelled respiration occurs sparingly near
the blood vessel. Lactate-fuelled cells are consuming the byproduct of the glycolytic cells
where there is oxygen present.
production, and thus the share of the total ATP yield due to oxygen-fuelled metabolism is
lessened.
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Figure C.4: ATP turnover (consumption/production) rates for cells exhibiting the Warburg
effect with altered respiratory ATP parameters (differs from base case because ΛO decreased
from 4000 to 100). The contributions of the pathways are bounded by the total ATP
turnover rate PATP . Glycolysis is dominant in all regions of the tumour. Glucose-fuelled
respiration occurs sparingly near the blood vessel. Lactate-fuelled cells are consuming the
byproduct of the glycolytic cells where there is oxygen present.
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Figure C.5: The contributions of the pathways are bounded by the total ATP turnover
rate Φ in a unit annulus of tissue. This more accurately represents the total contribution
of each cell population to metabolism. From left to right the bars denote the follow-
ing cell populations: 1. Base case: Tissue that exhibits lactate consumption in hypoxic
conditions with parameters in Table 5.1. 2. Warburg effect: Tissue utilizing aerobic
glycolysis. 3. Glycolytic knockdown: Tissue experiencing complete glycolytic inhibi-
tion. 4. LDH inhibitor: Tissue experiencing complete LDH inhibition. 5. Respiration
knockdown: Tissue experiencing mitochondrial inhibition with glycolysis repression by
oxygen. 6. Respiration knockdown and Warburg effect: Mitochondrial inhibition
with aerobic glycolysis. The dashed red line shows a threshold of Φ = 100. If either of the
reactions which block glycolysis are knocked out (glycolysis or LDH inhibitors) the total
ATP produced is less than half the threshold. If on the other hand respiration is inhibited
then either (i) if oxygen represses glycolysis there is minimal ATP production, or (ii) if
glycolysis is independent of oxygen concentration there is more ATP produced than the
threshold.
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Appendix D
Additional nanoparticle release and
protein expression work
This appendix serves as supplementary material for Chapter 6. The preliminary nanopar-
ticle release profile fitting with definitions for the goodness of fit measure χ2 and additional
protein expression experiments that went unpublished is outlined here.
D.1 Preliminary nanoparticle models
Preliminary nanoparticle release experiments suggested a biexponential release with decay
was an appropriate model. Here we will outline this result while noting that a simpler
decay equation was sufficient for fitting in Chapter 6.
For cisplatin released from liposomes, a biexponential release is assumed. Biexponen-
tial processes are common in pharmocokinetics to describe various phenomenon (e.g. the
clearance of doxorubicin from plasma [192]) where two similar yet separate processes occur
with differing rate constants. This biexponential release profile is characterized by an ini-
tial burst followed by a slower sustained release. We can motivate the functional form by
considering a simple system of ordinary differential equations (ODEs) that includes both
the initial rapid release of some cisplatin and the sustained release due to encapsulation in
the liposome. To facilitate this, we assume that the administered liposomes consists of cis-
platin that is rapidly released at rate rb and slowly released at rate rs. The concentrations
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of rapidly and slowly released cisplatin are denoted by cb and cs respectively, and the lipo-
somes are initially comprised of a fixed amount of quick release and prolonged release given
by cb0 and cs0 respectively (see Figure D.1). For both release processes, only a fraction, φ,
of the total amount of contained cisplatin is released, an amount that depends primarily
on the acidity of the environment. Even in an acidic environment, our data shows that
55% of the cisplatin is never released from the liposome. The total amount of administered
cisplatin, denoted cT , satisfies the relation cT = cb0 +cs0 where the total amount of released
cisplatin is given by φcT . In addition to the two types of release, we must also consider
the natural decay of released cisplatin at a rate dL. The system of ODEs is then:
dcb
dt
= −rbcb (D.1)
dcs
dt
= −rscs (D.2)
dce
dt
= rbcb + rscs − dLce (D.3)
with the solution of interest being the released cisplatin
ce(t) = Ab exp(−rbt) + Af exp(−rf t)− (Ab + Af )exp(−dLt),
where
Ab =
φcb0rb
dL − rb , Af =
φcf0rf
dL − rf .
We use equations (D.1)–(D.3) to obtain parameters to describe the release profile data
in neutral and acidic environments. The pH-dependent parameters that differ between
environments will be the fraction of released cisplatin φ and the decay rate of the cisplatin
dL; the release parameters remain constant between both environments. We will quantify
the goodness of fit for a model f with p parameters to N observations yi with the reduced
chi-squared statistic χ2red = χ
2/ν, where ν is the degrees of freedom, typically set to
ν = N − p− 1 and
χ2 =
N∑
i=1
yi − f(xi)
σ2i
,
where σ2i is the variance of the ith observation. It is typically assumed that χ
2
red < 1 is
overfitting and χ2red > 1 is an inadequate model with the goal being to get χ
2
red as close as
possible to one. Fitting the parameters to the release profile data yields a very accurate
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Parameter Units Fit Value
rb h
−1 0.5737
rs h
−1 0.05352
d
(n)
L h
−1 0.0009932
d
(a)
L h
−1 0.001703
cb0 µM 0.4099
cf0 µM 0.5901
φ(n) - 0.2300
φ(a) - 0.3790
Table D.1: Parameters for the preliminary release profile experiments.
(over)fit as can be seen in Figure D.2 (χ2red = 0.1032, N = 18, p = 8). The parameters are
given in Table D.1.
It is worth noting that a single exponential fit does not provide an accurate prediction
for liposome release in these experiments, although monoexponential fits are commonly
sufficient. The model in this case would be (D.1) and dce
dt
= rbcb − dLce. Attempting to
fit our release profiles with this model leads to fits that overestimate the release at times
immediately following the initial burst (e. g. t=6, 7 hours) and then underestimates values
for later times, as can be seen in Figure D.3. The reason for this is that the relatively small
standard deviations for early times are causing the rate of release to be large enough to fit
the burst while driving the decay rate dL to zero in an attempt to fit the underestimated
later time points with larger standard deviations. In fact, setting the value dL = 0 improves
the fit slightly with χ2red = 3.799 (N = 18, p = 5); this is the result shown in Figure D.3.
Allowing the release rate rb to be locally fitted to each experiment does not improve the
fitting statistic (χ2red = 4.1102, N = 18, p = 6; results not shown).
D.1.1 Liposomal model
As mentioned in Chapter 6, the unsatisfactory fit in the neutral microenvironment to the
final nanoparticle release experiments could be fit by the addition of a single additional
parameter accounting for liposomal erosion. The fit to this model is given in Figure D.4
(χ2red = 0.61, N = 15, p = 3); this would have negligible effect on the acidic release
(χ2red = 0.58, N = 15, p = 3).
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Figure D.1: Depiction of biexponential drug model corresponding to the extension of (D.1)–
(D.3) to cellular concentrations for nanoparticle release and delayed transmembrane trans-
port of self-assembling cis-platinum nanoparticles (SACNs) and free cisplatin in an acidic
environment.
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(a) Release profile of cisplatin from liposomes
in acidic and neutral environments. For this
project, we use the acidic release profile that is
typical in the tumour microenvironment.
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liposomal release.
Figure D.2: Release profile kinetics.
D.2 Additional protein expression experiments
Initially, the PI828 post-treatment experiment was performed without a control. This
data was used in the parameter fitting algorithm but remained unpublished since this
experiment with controls is contained in Figure 6.8. The model fit to this data is shown
in Figure D.5.
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Figure D.3: Attempting to fit the release profile of cisplatin from liposomes in acidic and
neutral environments using a single exponential.
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Figure D.4: Fitting the release profile of cisplatin from liposomes in acidic and neutral
environments using a liposomal release model.
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Figure D.5: The inhibition of pAkt by PI828 post treatment with SACN D.5b and the
synergistic increase in caspase expression as compared to SACN alone-treated controls
D.5a.
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Appendix E
Reactive oxygen species and
antioxidant model
A collaborative work that I made both analytical and numerical contributions to, is briefly
outlined below with a focus on those aspects which I was directly involved in.
E.1 Introduction
H2O2 is produced in eukaryotes during metabolic processes [193, 194] and by other external
and internal sources such as growth factors [195, 196]. The concentration level of H2O2
plays a role in the initiation progression and treatment efficacy of major diseases such as
cancer, diabetes, Alzheimers disease and Parkinsons disease [197, 198, 199, 200, 201, 202,
203]. H2O2 is also involved in critical cell signalling processes such as cell growth and
apoptosis [204, 205, 206, 207].
H2O2 is highly reactive and can directly and indirectly damage cell compartments, hence
cells must employ detoxifying mechanisms to remove excess H2O2 [208, 209, 210]. One of
the principal mechanisms for detoxification is glutathione peroxidase, which along with
other detoxifying agents such as catalase remove H2O2 [211, 212]. Whether or not these
antioxidants work independently or they have evolved symbiotically to assist each other
with H2O2 detoxification is not clear. To unravel this we derive a relationship between the
concentration of H2O2, the production rate of H2O2 and the concentrations of antioxidants
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based on the kinetic equations which govern the detoxification of H2O2 by glutathione
peroxidase-1 and catalase. We use this relationship to show that catalase and glutathione
peroxide-1 behaves in a synergetic way. This synergy could help in understanding many
pathological cases, the efficacy of therapies and the design of new drugs or therapies.
E.2 Mathematical model
The three major families of antioxidants that exist in cells, which help to regulate and
detoxify H2O2, are the glutathione peroxidase family, the peroxiredoxin family and cata-
lase. In our model we assume that catalase and glutathione peroxidases are the major
antioxidants in the system to avoid the extraneous complexity of the full problem. We
also utilize the fact that glutathione peroxidase-1 is the predominant member of the glu-
tathione peroxidase family in removing H2O2 and thus only consider its effect in our model
[213]. We also assume that catalase, which is sequestered in the peroxisomes, is exposed to
the same concentration levels of H2O2. We will discuss the affect of these assumptions in
the discussion section and argue that these assumptions do not affect the main conclusion
of this paper. We use chemical reaction equations to derive corresponding kinetic equa-
tions for the concentrations of involved species and thus obtain a relationship between the
concentrations of these species at steady state.
The detoxification of H2O2 by catalase is given by the chemical reaction
H2O2
kcat
GGGGGGGAO2 + 2H2O. (E.1)
In this process H2O2 is converted to harmless oxygen and water in the presence of catalase.
GPx has been the subject of previous mathematical models [214] and its mechanism is
well established [215, 216]. The action of these enzymes rely on the presence of a specific
cofactor: glutathione (GSH) which is responsible for converting GPx0 to [GS-GPx] and
then [GS-GPx] back to its reduced form GPxr. These reduced forms can now once again
eliminate H2O2 from the environment. The generally accepted molecular reactions that
occur in the conversion of H2O2 to H2O, in dilute solutions, is represented by the following
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three reactions [216]:
GPxr + H2O2 + H
+
k1
GGGGGAGPx0 + H2O, (E.2)
GPx0 + GSH
k2
GGGGGA[GS-GPx] + H2O, (E.3)
[GS-GPx] + GSH
k3
GGGGGAGPxr + GSSG + H
+, (E.4)
where k1, k2 and k3 are the reaction rates calculated by Antunes et al. [215] and given in
Table E.1. These reactions are commonly summarized as
H2O2 + 2GSH
GPx
GGGGGGGGAGSSG + 2H2O. (E.5)
Table E.1: Rate constants for the GPx system from [215].
Rate (µM−1s−1)
k1 21
k2 0.04
k3 10
We will now write down a system of equations that correspond to the reactions (E.1)–
(E.4). An equation that tracks H+ and H2O concentrations are not included, under the
assumption that reactions are independent of pH and water content. The two major as-
sumptions are: (i) spatial independence, this leads to a system of ODEs, and (ii) the
concentration of catalase remains constant. We will denote this constant catalase concen-
tration by C. Letting x1 = [GPxr], x2 = [GPx0], x3 = [[GS-GPx]] denote the concentra-
tions of GPx and its intermediate forms during recycling, x4 = [H2O2] the concentration
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of hydrogen peroxide, and x5 = [GSH] gives the following system of ODEs:
x˙1 = k3x3x5 − k1x1x4, (E.6)
x˙2 = k1x1x4 − k2x2x5, (E.7)
x˙3 = k2x2x5 − k3x3x5, (E.8)
x˙4 = −k1x1x4 − kcatCx4 + p4, (E.9)
x˙5 = −k3x3x5 − k2x2x5 + p5, (E.10)
(E.11)
where p4 and p5 are the constant production rates of H2O2 and GSH respectively. Note
than an equation for GSSG is omitted since it only plays the role of a waste product.
We are interested in finding the steady state solution to (E.6)–(E.10) and will now
derive the concentration of H2O2 as a function of x1, x2, x5 and C. Equations (E.6)–(E.8)
sum to zero, so the total concentration of GPx is fixed at some total value eT satisfying
x1 + x2 + x3 = eT . This relationship is only valid because there are no sources or sinks
more any of these species. Furthermore, the concentration of [GS-GPx] is negligible since
k2  k1 and k2  k3, so we will use the approximation x1 + x2 = eT . Using these
assumptions, the steady state concentrations can be found, or we could look at temporal
behaviour.
E.3 Results
I have analyzed the aforementioned system in multiple scenarios. Along with performing
numerical analytical analysis of this system, I have also proven stability results. We have
also used the model to quantify the synergy between catalase and glutathione-peroxidase-1
which amplifies the detoxification power of glutathione peroxidase-1. Hence any change
(upregulation or downregulation) in the catalase concentration has a direct affect on the
glutathione peroxidase-1 activity and has to be included in understanding any related
phenomena. Also we propose that the activity of glutathione peroxidase-1 could be regu-
lated by changing the concentration of catalase. The synergistic relationship between these
antioxidants is reported in [174]. This work was expanded to include the effects of cell per-
meability, especially the role of aquaporin expression. This has important consequences
for the efficacy of ascorbic acid for cancer treatment [175]. While I was involved in model
178
development and calculating system solutions, I am not the first author of these results,
so they are omitted.
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